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Abstract  
 
Background: It is unknown whether in malaria-endemic areas, cotrimoxazole (CTX) 
prophylaxis can be stopped in HIV-infected patients on antiretroviral therapy (ART) who 
have regained immune competence. The aims of this thesis were to: review the 
literature on the effect of CTX on malaria; investigate the effect of stopping CTX on 
malaria incidence in a randomised trial; and assess the effect of CD4 count and ART 
regimen on malaria.  
 
Methods: (i) The literature was systematically searched for relevant papers. (ii) Data 
from the recently completed COSTOP trial were used to examine the effect of stopping 
CTX on malaria incidence among HIV-infected Ugandan adults on ART. Participants 
with CD4 count ≥250 cells/µl were randomised (1:1) to continued CTX or placebo. CD4 
counts were determined at ART initiation, enrolment and during follow-up. Malaria was 
defined as fever with parasitaemia. Incidence and rate ratios (RR) were estimated using 
random effects Poisson regression, accounting for multiple episodes. 
 
Results: (i) Six studies were identified. All reported an increase in malaria following 
CTX discontinuation. However, all studies were subject to bias and/or confounding. (ii) 
In COSTOP, 2180 participants were followed for a median of 2.5 years. They 
experienced 453 malaria episodes. Malaria incidence was 3.5 (95%CI=2.7-4.4) times 
higher on placebo than CTX. Few cases of severe malaria occurred, and no increase in 
malaria mortality. CD4 count had no effect on incidence. Partcipants on a protease 
inhibitor-based regimen experienced malaria significantly less often than those on other 
regimens.  
 
Conclusion: Among participants with CD4 of ≥250 cells/µl, malaria incidence increased 
when CTX was stopped. This effect was lower than shown in previous (unblinded) trials. 
Malaria mortality did not increase. CD4 count had no effect on malaria incidence. These 
results support current WHO guidelines on CTX use in malaria-endemic areas, but 
there may be subgroups who benefit from CTX discontinuation. 
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Chapter 1: General introduction  
 
1.1 Malaria 
Malaria is a disease of humans that is caused by 5 species of protozoa. All these 
species belong to the genus plasmodium: P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi. Two of these pose the greatest threat: P. falciparum, being the most 
virulent, is responsible for most deaths, and is the most common in Africa. P. vivax has 
a wider geographic distribution than P. falciparum because it can develop and survive in 
cooler climates and also develops a dormant liver stage that can reactivate months and 
even years after an infection leading to recurrence of symptoms (1).   
 
Malaria is transmitted from person to person by the bite of an infected female anopheles 
mosquito which bites between dusk and dawn. The life cycle of the malaria parasite is 
similar for all the 5 species. Part of the cycle takes place in the human host and part in 
the mosquito, as follows: 
 
The mosquito stage: The female Anopheles mosquito takes up male 
(microgametocytes) and female (macrogametocytes) gametocytes when it feeds on a 
person infected with malaria. While in the mosquito’s gut, the microgametes penetrate 
the macrogametes generating zygotes. The zygotes develop into motile and elongated 
ookinetes which invade the mid-gut wall of the mosquito where they develop into 
oocysts. The oocysts grow, rupture and release sporozoites (the infectious form of the 
parasite) which migrate to the mosquito’s salivary glands. The sporozoites are then 
inoculated into humans when the mosquito takes a blood meal (2-5). 
 
The human stage: During the blood meal sporozoites enter the human blood stream. 
Subsequently they enter liver cells and mature into schizonts which rupture and release 
merozoites that burst out of the liver cells. P. vivax, and P. ovale have a dormant stage 
(hypnozoites (6, 7)) which persists in the liver and causes relapses by invading the 
blood stream weeks or even years later. Merozoites enter the red blood cells and 
multiply forming new merozoites or develop into gametocytes (reproductive form). 
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During the liver stage the patient remains well; blood stage parasites are responsible for 
the clinical manifestations of the disease. The cycle continues once the gametocytes 
are ingested by the female anopheles mosquito.(2-5).  
 
Malaria infection in human beings presents with non-specific symptoms which include 
fever, headache, malaise, joint pains, nausea and vomiting. Identification of plasmodium 
in blood is usually based on microscopic examination of a peripheral blood smear or 
reading an immunochromatographic rapid diagnostic test (RDT) (8). For microscopic 
examination, a drop of the patient’s blood is used to make a blood smear on a slide 
which is then stained with Giemsa or Leishman’s stain to give the parasite a distinct 
appearance.  A thick smear is used to quantify the number of parasites relative to the 
number of white blood cells, expressed as number of parasites per microliter of blood, 
and a thin smear to identify the species (9, 10). RDTs detect parasite-specific antigens 
or enzymes in blood (8). Polymerase chain reaction (PCR) tests which detect parasite 
nucleic acids tests in blood can also be used to identify plasmodium. These tests are 
more sensitive and specific than microscopy or RDTs; however they require specialised 
and costly equipment and reagents. Finally, serological tests which detect anti-
plasmodium antibodies can also be applied, but these detect past rather than current 
infection, and are usually used for screening purposes (8, 11).  
 
Malaria is classified as acute uncomplicated if in addition to the above-mentioned 
symptoms and a positive parasitological test, there are no signs of severity. 
Convulsions, mental confusion, severe anaemia and other signs of end-organ failure 
are indicative of severe malaria (8, 12). 
 
In areas of high malaria endemicity, children are exposed to repeat infections which 
leads to development of partial immunity. Therefore, malaria infection among adults 
usually occurs as asyptomatic parasitaemia or presents as a mild disease. Severe 
malaria in high endemicity areas is mainly seen in children. In areas of low malaria 
endemicity, immunity to malaria may not be acquired and even adults may acquire 
severe malaria (13).  
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 Artemesinin based combination therapies (ACTs) are recommended for the treatment of 
acute uncomplicated malaria.  Treatment of severe malaria requires intravenous or 
intramuscular artesunate until a patient can tolerate oral medication and then treatment 
with 3 days of an ACT. Parenteral quinine is indicated for treatment of severe malaria 
when, an effective ACT (based on resistance patterns in the region) is not promptly 
available. Oral quinine is used in the treatment of uncomplicated malaria, particularly in 
the first trimester of pregnancy, or also  as alternative when an effective ACT is not 
available (8). 
  
For prophylaxis, sulfadoxine–pyrimethamine is used for pregnant women, doxycycline, 
mefloquine, and primaquin for travellers from non-endemic areas, and cotrimoxazole  
(CTX) for HIV-infected individuals (8, 14). The use of CTX is discussed in more detail in 
section 1.5 below.  Other measures used for prevention of malaria include sleeping 
under an insecticide-treated bednet (ITN), indoor residual spraying (IRS) of houses or 
dwellings with insecticides, and spraying of breeding places for vector control (8).  
 
1.2 HIV/AIDS 
The human immunodeficiency virus (HIV) that causes the acquired immunodeficiency 
syndrome (AIDS) is a lentivirus, a subgroup of retroviruses. There are two types; HIV 1 
and HIV 2 (15). Both are transmitted through contact with body fluids of an infected 
person. This can occur through sex, sharing needles, breastfeeding or from mother to 
child during pregnancy. Once acquired, the virus multiplies rapidly and destroys the 
body’s defence mechanisms, mainly the CD4 cells, resulting in opportunistic infections 
(OI) and increased occurrence of diseases like malaria and malignancies (16-20). HIV 
infection is identified by use of tests that detect antibodies to the virus, or using PCR to 
detect viral ribonucleic acid (RNA). There are 6 classes of antiretroviral (ARV) drugs 
used to treat HIV: non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside 
reverse transcriptase inhibitors (NRTI), protease inhibitors (PI), fusion inhibitors, CCR5 
antagonists (CCR5), and integrase strand transfer inhibitors (INSTI) (21). For 
antiretroviral therapy (ART), these drugs are used in combinations of 3 to 4 drugs (ART 
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regimens) to maximally suppress virus replication and reduce the risk of the virus 
developing resistance to individual drugs (22). These drug regimens are used in a 
sequential way; initially patients start on first-line therapy, then second line, and then 
third-line/salvage therapy. A patient’s regimen is switched due to poor response to 
treatment either due to occurrence of opportunistic infections, declining CD4 count or 
viral load >1000 copies/µl (23). In Uganda, the Ministry of Health recommends 2 NRTIs 
and an NNRTI for first-line, 2 NRTIs and a PI for second-line, and 2 NRTIs, raltegravir 
(INSTI) and darunavir/ritonavir (PI) for third-line therapy (24). Individual drugs within a 
regimen may be substituted due to toxicity (23). 
 
These drugs suppress viral replication which allows the immune system, including CD4 
cells, to recover (25-27).  Some studies suggest that NNRTIs (28) and PIs (29) might 
also have an antimalarial effect although the evidence for this and for the mechanisms 
involved is inconclusive .   
 
 
1.3 Interaction between malaria and HIV infection 
HIV impairs T-cell immunity, which is an important component of the antimalarial 
immune response (30, 31). In areas of stable malaria transmission, HIV infection is 
associated with more cases of clinical malaria and increased prevalence and density of 
parasitaemia in non-pregnant adults (32-34). In areas of unstable transmission, HIV is 
associated with increased risk of severe malaria and death (35, 36). HIV infection has 
also been associated with impaired response to malaria treatment leading to 
recrudescence and re-infection; however, with the introduction of the highly efficacious 
artemesinin combination therapies (ACT) there is less recurrence of malaria (32). 
Malaria infection is associated with CD4 cell activation and activation of proinflammatory 
cytokines which facilitates the spread of the virus among CD4 cells and rapid viral 
replication (37). Following infection with malaria, there is a temporary rise in HIV viral 
load which can last up to 10 days (38) and it has been suggested that this elevated viral 
load might lead to faster HIV disease progression and higher risk of HIV transmission 
(39). Some studies have also reported higher mortality from malaria in HIV-infected 
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patients (40). As mentioned above (section 1.2), some ART drugs are thought to have 
antimalarial properties, particularly protease inhibitors (PIs) which should lead to a 
reduction in malaria incidence among patients taking these drugs. A study done in 
Uganda found less malaria in HIV-infected patients on ART and CTX compared to 
patients on CTX only (IRR 0.3 (95%CI=0.2-0.7). Additionally, with the recovery of the 
immune system on ART, a reduction in the incidence of malaria is expected, however 
evidence on this association is lacking.  
 
1.4 Public health importance of malaria and HIV disease  
There were an estimated 214 million cases of malaria worldwide in 2015 resulting in 
438,000 deaths; 88% of these cases and 90% of the deaths occurred in Africa (16).  
Overall, 36.9 million people worldwide were estimated to be living with HIV at the end of 
2014, with 2.0 million people becoming newly infected globally.  Sub-Saharan Africa is 
the most affected region, with 25.8 million people living with HIV in 2014 and accounts 
for almost 70% of the global total of new HIV infections. About 1.2 million children and 
adults were reported to have died from AIDS-related illnesses globally in 2014  (22). 
 
Malaria and HIV are therefore important global health problems and together they are 
estimated to cause more than a million deaths per year (41). These diseases also have 
a wide geographical overlap particularly in sub-Saharan Africa, frequently resulting in 
co-infection and mutual enhancement as mentioned above.  
 
1.5 Chemoprophylaxis 
Chemoprophylaxis is used to prevent opportunistic infections in HIV-infected patients 
particularly those whose immune function has declined, as shown by low CD4 cell 
counts, but have not yet been started on ART. The highest risk of opportunistic 
infections has been associated with CD4 count <200 cells/µl (42). Prophylaxis can be 
either primary or secondary. Primary prophylaxis is to prevent occurrence of an 
infection, while secondary prophylaxis is given after an infection has occurred and  is 
aimed at preventing recurrence or malaria. Drugs recommended for prophylaxis include: 
CTX for bacterial, protozoal and fungal infection; isoniazid for TB; and fluconazole for 
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cryptococcal meningitis (43, 44). CTX has also been found to be effective for 
prophylaxis against malaria and is recommended for use in malaria endemic areas (14, 
45) (CTX use is discussed in detail in section 1.6). In HIV-infected patients whose 
immune function has been restored, the incidence of opportunistic infections is reduced 
(26) and prophylaxis may be stopped (except for CTX in malaria-endemic areas) (14, 
43). Increasingly HIV-infected adults are being started on ART at high CD4 counts and 
many countries are now using the WHO recommended test-and-treat approach 
whereby HIV-infected individuals are started on treatment as soon as they are 
diagnosed (46). The role of prophylaxis in HIV-infected adults with CD4 counts >350 
cells/µl is therefore not clear. 
 
1.6 Cotrimoxazole  
Among HIV-infected patients, the daily prophylactic use of CTX reduces mortality and 
morbidity from OIs (47-54) such as toxoplamosis, Pneumocystis jiroveci pneumonia, 
recurrent non-typhoidal salmonella bacteraemia and isosporiasis (Appendix 1). In 
addition CTX has been shown to reduce the incidence of malaria in HIV-infected 
patients (45, 50, 55) as well as among HIV-exposed uninfected children (56). 
 
CTX is a broad spectrum anti-microbial agent comprised of trimethoprim and 
sulfamethoxazole. It is active against a wide range of bacteria(57), fungi (58) and 
protozoa(59). Both drugs act by inhibiting the folate metabolism in these organisms 
(60). Resistance to CTX is usually caused by mutations in the folate pathway involving 
the dihydrofolate reductase and dihydropteroate synthetase enzymes and is common in 
areas with widespread CTX use for prophylaxis by HIV-infected patients (61, 62).  
 
In Uganda it is recommended that CTX prophylaxis should be given to all HIV-infected 
adults and children regardless of whether they are on ART or not (63).The 
recommended dose of CTX for adults is one double-strength tablet or two single-
strength tablets once daily: the total daily dose is 960 mg (800 mg sulfamethoxazole 
and 160mg trimethoprim) (64).  
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The World Health Organization (WHO) recommends CTX prophylaxis for anybody with 
a CD4 cell count <350 cells/µl or who is in clinical stages 3 or 4 of HIV infection, 
irrespective of their CD4 count. In settings where malaria and/or severe bacterial 
infections are highly prevalent, CTX prophylaxis should be initiated regardless of CD4 
cell count or WHO stage (14). The possible preventive effect on malaria was originally 
not part of the rationale for the use of CTX. Indeed fears about the possible 
development of cross-resistance against other anti-malarial drugs due to widespread 
CTX use were expressed by some authors (65-67).  
 
Although CTX is generally well tolerated, its possible side effects include headache, 
vomiting, diarrhoea and hypersensitivity-related skin reactions. When used for long term 
prophylaxis, as is the case in HIV-infected patients, it has been associated with 
neutropenia, thrombocytopenia and anaemia due to haematotoxicity (bone marrow 
suppression) (68-70) and it increases patients’ pill burden and cost of care (71). 
 
Once a patient is started on effective ART, viral replication is suppressed and immune 
function eventually recovers resulting in fewer OIs and reduced mortality, and therefore 
some authors recommend stopping CTX once CD4 count has risen to >200 cells/mm3. 
Stopping CTX has been shown to be safe in studies in industrialized countries (72, 73). 
Obviously, the epidemiological situation in these countries differs from that in sub-
Saharan Africa (SSA) where more bacterial OIs and malaria occur.  
 
In 2006, the Ministry of Health in Uganda noted that the benefit of CTX prophylaxis for 
adults and children on ART in Africa whose CD4 cell counts were >200 cells/µl or CD4 
percentage >15%, respectively, had not been evaluated. It recommended that until 
more information is available, the decision to discontinue CTX prophylaxis in this group 
should be made by the provider on an individual basis (74).  
 
In its previous guidelines of 2006, WHO recommended that in resource-limited countries 
CTX should be continued for life, but discontinuation could be considered among people 
with evidence of immune recovery (CD4 >350 after at least six months of ART) (64). 
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 At the time when the study underlying this PhD was initiated, it was therefore not clear 
whether CTX prophylaxis in HIV-infected patients from countries with high incidences of 
bacterial OIs and malaria could safely be stopped once their immunity has recovered 
due to ART. If found to be safe, stopping CTX would reduce pill burden and reduce the 
risk of CTX related side effects, in particular haematotoxic adverse effects. It was also 
not known whether the severity of malaria in immune competent patients on ART would 
differ between those taking CTX prophylaxis and those not taking CTX, and whether 
and in which way this may depend on CD4 levels at the time of CTX cessation.  
 
The aim of my PhD project was to address these questions, in HIV-infected adults using 
the opportunity of a randomised placebo controlled trial of CTX cessation in Uganda 
(COSTOP). COSTOP aimed to assess the efficacy and safety of stopping CTX 
prophylaxis in HIV-infected adults who were stable on ART. Enrolment into the trial 
started in January 2011 and ended in March 2013. Enrolment was stratified by site 
(Entebbe and Masaka) and enrolment CD4 count (<500, ≥500). Participants were 
followed up for up to 3.5 years. Main results of the trial were presented at the 
Conference on Retroviruses and Opportunistic Infections (CROI) in February 2015 (75). 
Analysis of the main trial outcomes was based on the per protocol population and 
showed that with respect to efficacy, the incidence of CTX preventable events (adjusted 
for site and CD4 stratum) in the placebo arm was 1.57 (90% CI=1.12-2.21) times higher 
than that in the CTX arm. With respect to safety, the incidence of grade 3 or 4 
haematological adverse events (adjusted for site and CD4 stratum) in the placebo arm 
was 0.70 (95% CI=0.59-0.82) times lower than that in the CTX arm. There was no 
difference in the number of deaths by trial arm.  In conclusion, discontinuing CTX 
prophylaxis was associated with a significant increase in CTX-preventable events but a 
reduction in grade 3 or 4 haematological adverse events. There was no statistically 
significant difference in mortality between those that stopped and those that continued 
CTX prophylaxis. 
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The incidence of malaria was a secondary outcome of the COSTOP trial. It was 3.47 
(95% CI 2.74 – 4.39) times higher in the placebo arm than in the CTX arm. The detailed 
investigation of the incidence of clinical and severe malaria were planned sub-studies of 
the COSTOP Trial and are the subject of this PhD thesis. 
 
Since this PhD research proposal was written, 3 open-label trials have contributed 
additional data on whether CTX prophylaxis may be safely stopped in HIV-infected 
patients who are stable on ART (76-78); these studies are also discussed in the 
systematic review (chapter 3). In December 2014, WHO also revised its guidelines and 
now recommends that CTX may be discontinued in patients who are clinically stable 
with evidence of immune recovery and/or viral suppression on ART, but should be 
continued in countries with high endemicity of malaria and bacterial infections 
(14).These guidelines were issued shortly before the COSTOP trial results were 
presented at CROI 2015 (appendix 2) (75). 
 
 
1.7 Research questions to be addressed by this PhD research 
1. What information is available in the current literature on the effect of CTX on 
malaria in HIV-infected patients on ART and are there other studies underway 
which aim to address this question? 
 
2. Does the occurrence of malaria increase in HIV-infected patients who are stable 
on ART when they stop CTX prophylaxis compared to those that continue and if 
so, is this increase sustained over time? 
 
3. Is there a difference in the severity of malaria between patients on ART who stop 
using CTX compared to those that continue? 
 
4. Is the occurrence of malaria in patients who stop CTX associated with the extent 
of their immune status, as indicated by CD4 count? 
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5. Does the kind of ART regimen used affect the incidence of malaria in HIV-
infected patients on ART? 
 
1.8 Overall aim  
To determine the effect of CTX on malaria incidence and severity in HIV-infected 
persons on ART.  
 
1.9 Overall objectives 
Using a systematic review;  
 To assess the available literature on this association. 
 
Using a randomised placebo controlled trial;  
 To describe malaria incidence and severity in adults who stop taking CTX 
prophylaxis compared to those that continue.  
 To describe the effect of the immune status on malaria incidence in patients 
stopping CTX versus those that continue.  
 To assess the effect of antiretroviral regimen on malaria.  
 
2.0 Role of the candidate 
2.0.1 COSTOP trial 
I am a co-investigator of the COSTOP trial and was the Trial Coordinator from its 
beginning in July 2010 to September 2012 (when I took up my PhD research at 
LSHTM). During this time I was responsible for or made substantial contributions to: 
 Obtaining approvals from the regulatory bodies (Uganda Virus Research Institute 
Science and Ethics Committee (SEC), National Drug Authority (NDA), and 
Uganda National Council of Science and Technology (UNCST)) and their 
subsequent (annual) renewals 
 Developing the manual of operations and protocol amendments 
 Developing the study questionnaires and data collection forms  
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 Creating standard operating procedures (SOPs) for data collection and 
processing 
 Staff recruitment and training 
 Setting up study clinics 
 Negotiating with ART providers, explaining the study to them and securing their 
collaboration 
 Overseeing screening and enrolment  
 Ensuring that the protocol was adhered to  
 Supervision of study teams 
 Reporting serious adverse events (SAE) to the regulatory bodies (SEC, NDA, 
and UNCST) 
 Reporting to the Trial Steering Committee (TSC) on the progress of the trial 
 Compiling case summaries for the Endpoints Review Committee (ERC) 
 Carrying out administrative duties related to the trial 
 
After September 2012 during my PhD studies I contributed to the following: 
 Data cleaning process 
 Developing the close-out manual of operations 
 Dissemination of the trial information and results which included the design paper 
(Anywaine et al, published in 2015) (appendix 3), the COSTOP main Results 
presentation (an oral presentation by Jonathan Levin in February 2015 at CROI, 
Munderi et al.) (appendix 2), and the malaria sub-study results (a poster 
presentation by the candidate in July 2015 at IAS, Kasirye et al.) (appendix 4) 
 
2.0.2 PhD work 
My role in the systematic review included: 
 Designing the review after discussions with Kathy Baisley (KB) and Heiner 
Grosskurth (HG).  
 Performing the search for the relevant studies.  
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 Independently screening the abstracts and extracting data from the identified 
studies; KB served as a second independent reviewer.  
 WrIting the first draft and revising it following comments from KB, HG and Paula 
Munderi (PM).  
 Submitting the final version of the paper for publication. Responding to reviewers’ 
comments. 
 
My role in the experimental part of my PhD research included: 
 Trial coordination and planning data collection until September 2012 as 
described above. 
 Identification of the malaria-related research topics at the design stage of the trial 
and obtaining approval from the TSC to investigate them as part of a PhD 
programme. 
 Preparation of the research proposal for the PhD. 
 Data analysis with respect to incidence of clinical and severe malaria by trial arm 
and effect of ART regimen on malaria under the supervision and guidance of a 
senior statistician (KB). 
 Contribution to the analysis of the effect of CD4 count on malaria incidence. The 
analysis itself was mainly performed by KB as it involved a more complicated 
statistical technique (the use of cubic splines to model the effect of CD4 on 
malaria incidence). 
 Writing the first drafts of all papers from the experimental work (listed below). 
Revision of drafts following comments from supervisors (KB) and (HG), further 
revision following comments from other COSTOP investigators (PM, Jonathan 
Levin, Zacchaeus Anywaine, Andrew Nunn and Anatoli Kamali) and submission 
of final versions for publication.  
 
Papers written as part of the PhD project: 
 Kasirye R., Baisley K, Munderi P, Grosskurth H. (2015). Effect of cotrimoxazole 
prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral 
therapy in sub-Saharan Africa. Trop Med Int Health 20(5): 569-580. 
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 Kasirye R, Baisley K, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, 
Grosskurth H. Incidence of malaria by cotrimoxazole use in HIV infected 
Ugandan adults on antiretroviral therapy: a randomized placebo controlled study. 
AIDS. 2015. Epub 2015/11/13. 
 Kasirye R, Grosskurth H, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, 
Baisley K: Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence 
among HIV-infected Ugandan adults on antiretroviral therapy: a randomized 
controlled study. Submitted to Malaria Journal (March 2016), accepted (July 
2016). 
 Kasirye R, Grosskurth H, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, 
Baisley K: Effect of antiretroviral therapy on malaria incidence in HIV-infected 
Ugandan adults: a prospective cohort study. Submitted to AIDS (March 2016). 
 
2.1 Funding 
My PhD research was supported by a PhD training grant from the MRC/UVRI Uganda 
Research Unit on AIDS. 
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Chapter 2: Methods 
 
2.1 Introduction  
This chapter provides an overview of the methods used for this PhD research. Two 
separate studies were conducted to achieve the objectives: 
A systematic review:  
 To assess the available literature on the effect of CTX on malaria in HIV infected 
patients on antiretroviral therapy ART. 
 
A randomised placebo controlled study (I conducted a sub-study within the COSTOP 
trial):  
 To describe malaria incidence and severity in adults who stop taking CTX 
prophylaxis compared to those that continue.  
 To describe the effect of the immune status on malaria incidence in patients 
stopping CTX versus those that continue.  
 To assess the effect of antiretroviral regimen on malaria and whether this effect 
differs by CTX use.  
 
In this chapter, the two studies are described in general. More detailed information on 
specific methods is presented in the research papers included in subsequent chapters. 
 
2.2 Systematic review 
Embase, Pubmed and Medline, Web of Science, Global Health and the Cochrane 
Library were searched up to 14 April 2014 for abstracts using terms for malaria, HIV and 
CTX. After screening the abstracts, full text copies of potentially relevant papers were 
obtained.  Studies that had original data on the effect of CTX on malaria in HIV infected 
patients on ART were included.  Data from papers identified by the search were 
extracted using a standard form. Guidelines on preferred reporting items for systematic 
reviews and meta-analyses (PRIMSA) (1) were used. Assessment of bias and 
confounding within studies and the quality of papers was based on PRISMA guidelines 
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and the Newcastle-Ottawa quality assessment of studies scale (2). A formal meta-
analysis was not done owing to the diversity in study methodologies, comparison 
groups and populations. The results of this work were published in Tropical Medicine 
and International Health in May 2015. 
 
2.3 The COSTOP Trial 
My research was embedded in the COSTOP trial (ISRCTN44723643). Details of the 
trial’s design have been published (appendix 3) (3). COSTOP was a randomised double 
blind placebo controlled non-inferiority trial to evaluate whether long-term prophylaxis 
with CTX could be safely discontinued among Ugandan adults on ART who have 
achieved sustained immune restoration (measured as a confirmed CD4 count ≥250 
cells/µl). The trial had two co-primary outcome measures: 
 
(i) The efficacy outcome measure was the time to the occurrence of the first 
clinical event (pre-defined CTX-preventable opportunistic clinical event 
(appendix 1) or death).  
(ii) The safety outcome measure was the time to the occurrence of the first grade 
3 or 4 haematological adverse event.  
 
Incidence, severity and treatments outcomes of malaria infection were among the 
secondary objectives of COSTOP. Other secondary outcomes of the trial included mean 
change in CD4 count after 12 months, mean change in haematological indices after 12 
months, and incidence of hospitalisation (all causes). 
 
2.3.1 Study setting 
The study was conducted by the MRC/UVRI Uganda Research Unit on AIDS at its 
research clinics located in Masaka district and Entebbe (located in Wakiso district) 
(Figure 1) which are both situated along the shores of Lake Victoria. The climate in 
Uganda allows stable, year round malaria transmission with relatively little seasonal 
variability in most areas. Malaria is highly endemic in 95% of the country, i.e. in areas 
where about 90% of the Ugandan population lives (4).  
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Figure 1: Map of Uganda showing location of study sites (Entebbe and Masaka) 
 
2.3.2 Study population  
Adult patients meeting the selection criteria listed below were randomised to receive 
either placebo (one tablet daily) or active CTX (one tablet of 960 mg daily) in place of 
their usual CTX (Figure 2). 
 
Selection criteria for patients 
Inclusion criteria   
a) HIV-infected patient with documented intake of CTX for at least 6 months 
b) Age 18 years and above 
c) Documented intake of ART for at least 6 months 
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d) Clinically asymptomatic 
e) Two CD4 counts (not more than 6 months apart) ≥250 cells/µl the most recent no 
more than 4 weeks prior to enrolment 
f) Able to attend study appointments and report to the study clinic in the event of  
     intercurrent illness  
 
Exclusion criteria 
a) Acute illness (OI or other co-morbidity). Patients were eligible for enrolment after 
resolution of the illness  
b) First trimester pregnancy. Pregnant women who reached their second trimester of 
pregnancy were subsequently eligible 
c) Known hypersensitivity to CTX 
d) Grade 3 or 4 anaemia (haemoglobin <7.5g/dL), neutropenia (count <0.75X109/L) or 
thrombocytopenia (count <50 x109/L) at time of enrolment 
 
2.3.3 Drug description 
Active CTX (960 mg tablets) and matching placebo tablets were supplied from CIPLA 
Limited in India. The tablets were similar in appearance but differed slightly in taste. 
They were supplied in 1000 tablet containers. They were later repacked in containers of 
31 tablets and labelled by independent staff of the MRC/UVRI Uganda Research Unit 
on AIDS under the supervision of an independent clinician and statistician. 
 
2.3.4 Research facilities and set up 
The study was based at two research clinics located at Entebbe and Masaka hospital 
respectively. Each clinic had consultation rooms, a registry for storage of patient files, a 
pharmacy, a room for phlebotomy and a meeting room (Figure 3).  Data entry and 
laboratory analyses were done at the offices of the MRC Unit in Masaka and Entebbe, 
both located within 3 km of the clinics. Each clinic had a team of 2 doctors, 2 
nurses/counsellors, 1 administrator, 1 study clerk, 1 field worker and 1 driver. The trial 
was managed by a full time Trial Coordinator under the supervision of the Principal 
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Investigator, and was overseen by a TSC. I was Trial Coordinator from the beginning in 
July 2010 until August 2012. 
 
2.3.5 Study procedures 
Randomisation 
Allocation to one of the two treatment arms was done by an MRC statistician using 
random permuted blocks of variable size with separate randomisations carried out in 
four strata. Strata were defined by the four combinations of the study site (Entebbe or 
Masaka) and baseline CD4 count category (250-499 vs. 500 or above). There were two 
randomisation registers at each trial site, one for each baseline CD4 category, 
containing trial numbers pre-allocated to either trial drug or placebo. Randomisation of 
patients was on individual basis. Three cases were identified of randomised participants 
belonging to the same household. They as well as all other trial participants they were 
encouraged to store their drugs individually and instructed not to share their drugs with 
anybody. 
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Figure 2: COSTOP trial profile  
Eligibility criteria: 
Patient stable on ART for at least 6 months + 
on daily CTX prophylaxis 
Confirmed sustained CD4 count ≥250 cells/µl 
No contraindication to discontinuing CTX 
prophylaxis 
(Screened n = 2933) 
Randomised 
n = 2180 
 
Study arm: Continue CTX (n = 1089)  
 
Take active CTX 960 mg daily 
Continue ART 
Haematology every 3 months 
CD4 after first 3 months, then 6 monthly 
 
Study arm: Discontinue CTX (n = 1091)  
 
Take placebo CTX once daily 
Continue ART 
Haematology every 3 months 
CD4 after first 3 months, then 6 monthly 
Cotrimoxazole preventable events, 
Grade 3 or 4 haematological adverse events or 
death 
 
Reasons for screen out (n = 753) 
Low CD4 count   382 (51%) 
Neutropenia        89 (12%) 
Never returned    93 (12%) 
Other                     189 (25%) 
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Screening 
The trial teams visited ART provision centres in Masaka (TASO Masaka, Kitovu Mobile, 
Uganda Cares) and Entebbe (TASO Entebbe, Entebbe Hospital, Kisubi Hospital) and 
provided information about the study to potential participants. These centres were run 
by non-governmental organisations or by public or private not-for-profit hospitals. 
Consent to participate in the screening procedure was obtained from potential 
participants by a doctor who also recorded their history of OIs, CTX prophylaxis and 
ART. The doctor also assessed their health and prescribed treatment for concurrent 
illnesses. Blood specimens were obtained for full blood count and CD4 count from all 
patients and a urine sample from women to conduct a pregnancy test. This information 
was recorded on the Screening questionnaire (appendix 5).  
Figure 3: COSTOP Trial site in Masaka  
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Enrolment 
Potential participants reported to the study clinics for enrolment within 2-4 weeks of 
having been screened. They were triaged by a nurse who also recorded information on 
previous adherence to CTX and ART and social economic details on the Nurse 
Enrolment questionnaire (appendix 6). A doctor then assessed the patient’s health and 
reviewed their medical history. Any additional or new information on chronic or current 
illnesses and medication was recorded on the Doctor Enrolment questionnaire 
(appendix 7). If the doctor then found the patient to be eligible for enrolment, they were 
asked to provide written informed consent; this information was captured on the 
Enrolment Consent form (appendix 8). They were then randomised by assigning them 
the next available number on the trial register based on their baseline CD4; this number 
was captured on the Randomization form (appendix 9). Blood was collected for plasma 
storage and for a malaria blood slide. Trial drug was dispensed. The COSTOP study did 
not provide ART; instead participants continued to receive ART from their ART 
providers as before. Each participant was issued with an insecticide-treated bed net 
(ITN) and the need to use it was emphasized.  
 
Follow up 
Participants were seen every month (28 days) for the first three months and three 
monthly thereafter (Table 1). Participants were followed up for a minimum of 12 and a 
maximum of 38 months depending on date of enrolment. 
 
At every visit the following was done: 
 Assessment of adherence to trial drug. Participants were encouraged to bring 
their drug containers at all visits. They were asked whether they missed any of 
their scheduled doses, the returned pills were counted and were compared to the 
expected number that should have been returned. The number of days on which 
trial drug was missed and the reasons were captured on the Adherence form 
(appendix 10).  
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 Assessment of adherence to ART. Participants were asked whether they had 
missed any ART doses since the previous visit. Information on the drug missed, 
number of days missed and reasons for missing drug was captured on the 
Adherence form.  
 
 Adherence to ITN use.  Participants were asked whether they had been sleeping 
under an ITN since the previous visit. The number of days the participant did not 
use the ITN and reasons were recorded. This information was captured on the 
Adherence form. 
 
 Physical check-up and recording of intercurrent illness. Participants had their 
blood pressure, temperature and weight taken by a nurse and were asked 
whether they had any illnesses or had taken any new medication since the 
previous visit. This information was captured on a Nurse form (appendix 11). 
 
 Further medical check-up. A doctor reviewed the nurse form, assessed the 
participant’s health and filled the Doctor Follow up form (appendix 12). 
Information was collected about history of fever, diarrhoea or cough. The 
participant was examined and any relevant diagnostic tests requested. Any 
diagnoses made and treatment prescribed were recorded. Information on 
changes in ART regimen was retrieved from the participant’s medical diaries 
provided by the ART provider and recorded on the Doctor Follow up form as well. 
If a participant was treated for malaria or had a positive malaria test, this 
information was captured on a Malaria form (appendix.13). Details of the malaria 
form are described later in this chapter. 
 
 Provision of trial drug. Trial drug was dispensed to participants in containers with 
31 tablets each (3 extra per month). 
 
Blood was drawn for the following laboratory procedures (Table 1); 
 Blood slide (thick and thin films), to assess for malaria. 
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 Full blood count, to detect possible drug related haematological toxicities.  
 CD4 count, to monitor immune response to ART. 
 Plasma storage, for future studies. 
 
If within two weeks of an appointment a participant had not attended the study clinic, a 
phone call or home visit was made to the participant by a field worker and/or counsellor. 
The reason for the missed appointment was established, and if the participant was still 
interested in participating in the trial, they were reminded about the importance of 
attending their scheduled visits and a new visit date was agreed. If the participant was 
no longer interested in taking trial drug or participating in the trial they were advised to 
sign a Consent Withdrawal form (appendix 14) indicating their choice and their follow up 
would be stopped or modified accordingly.  
 
Extra / sick visits 
Participants were encouraged to come to the study clinic whenever they were ill. 
Adherence forms, Nurse forms and Doctor follow up forms were filled as described 
above. The participant was investigated and treated based on their symptoms and 
signs.  
 
Discontinuation of trial drug 
In the event of adverse drug reactions considered to be possibly related to trial drug, 
medication was discontinued but the blinded allocation of trial drug was maintained, 
unless unblinding was required in the interest of the participant’s safety (for example in 
the case of a potential CTX related hypersensitivity reaction). Reasons for unblinding a 
participant were captured on the Unblinding form (appendix 15). The specific event was 
then managed accordingly. The decision to restart trial drug after resolution of the 
adverse event was based on the cause of the event. 
 
If a participant’s CD4 dropped below 250 cells/µl (and was confirmed by a repeat test), 
trial drug was discontinued permanently and the participant switched to open label CTX. 
Such participants continued to be followed until the end of the study. The participant 
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was investigated for ART treatment failure by ruling out other potential causes of the 
drop in CD4 count; this was done by assessing adherence to ART and screening for co-
infections, for example tuberculosis. This information was shared with the ART provider. 
Change of a participant’s ART regimen due to treatment failure was done by the ART 
provider and was commonly based on CD4 count for first line ART failure and viral load 
measurement for second line failure, as recommended by the national treatment 
guidelines (5). HIV viral load measurements were done when specifically requested by 
a doctor, mainly for suspected failure on second line ART and not as a routine 
investigation. Information on starting or stopping trial drug and change in ART regimen 
was recorded on the Doctor follow up form. 
 
Participants could also be withdrawn from trial drug for the following reasons: 
 Participant decision to withdraw consent for study participation 
 Intercurrent illness which prevented further treatment. 
 Any change in a participant’s health condition which justified the discontinuation 
of treatment in the clinician’s opinion. 
 
No additional participants were recruited to replace those who withdraw from the trial. 
Participants who were withdrawn from the study were still followed up and their clinical 
data were recorded, unless a participant explicitly also withdrew consent for follow-up 
 
2.3.6 Trial monitoring  
The trial was monitored by an Independent Data Safety and Monitoring Committee 
(IDMC). The IDMC met every 6-12 months. The IDMC reviewed the event rate and 
assessed whether the study was on schedule to meet its objectives and should continue 
as planned. The trial was also monitored by an internal (MRC unit) monitor.  
 
2.3.7 Data collection and management  
Participants were identified by unique trial and clinic numbers. Individual data was 
captured in duplicate on case record forms (CRFs). Data was checked at the clinic, 
double entered using Access into the COSTOP database at the central data and 
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statistics section in Entebbe. Range and consistency checks were routinely done.  
Original CRFs were stored centrally but copies were kept to participants’ files at the 
clinic.  
 
2.4 Malaria specific work within COSTOP 
2.4.1 Main outcomes  
Malaria diagnosis was defined as current fever or a recent history of fever combined 
with a positive malaria blood slide on microscopy, as is commonly used in studies 
clinical malaria (6-8).  Patients were assessed for parasitaemia at each scheduled visit 
and when they were ill.  If participants were suspected to have malaria, they were 
triaged by a nurse and assessed by a doctor. Results from routine tests were returned 
to the doctor within 24 hours and within one hour for a patient suspected to have 
malaria. 
 
The information captured during a malaria episode was recorded on the Malaria form 
(appendix 13), and included: 
 date of diagnosis, dates of the initial and follow up visits, and highest recorded 
temperature 
 symptoms and signs according to a check list   
 laboratory results (whether the blood slide was positive or negative). In the case 
of a positive slide; the plasmodium species found and the number of parasites 
per 200 white blood cells.  
 treatment given using a check list and source of treatment (options included 
study clinic, self-medication or other source, e.g. another clinic attended by 
patients who were unwell during a journey) 
 date of resolution of symptoms and results of the follow up blood slide. 
 
If hospitalisation was required, patients were admitted to Entebbe or Masaka hospital 
where they were followed up by the research team until discharge. A Hospital 
Admission form (appendix 16) was filled which captured reasons for admission, 
treatment given, and duration of admission.  
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2.4.2 Main exposures  
Trial drug 
The main exposure of interest was trial drug. As mentioned earlier trial arm allocation 
was by trial number given to a participant at enrolment. This information was recorded 
on a randomization form and was revealed after unblinding at the end of the trial. A 
provision was made for unblinding if it was necessary for patient management but no 
participant was unblinded during the trial. Adherence to trial drug was assessed using 
self-reports and pill counts and recorded on the Adherence form at all routine visits.  
 
ART regimen 
Information on participants’ initial and current ART regimens was obtained from records 
during screening at the ART provision centres and recorded on the Screening 
questionnaire. Changes in the ART regimen during follow up were recorded on the 
Doctor Follow up form. 
 
CD4 cell count 
CD4 counts for patients before joining the study were obtained from ART provision 
centres and recorded on the Screening questionnaire. CD4 counts during the study 
were measured at 3-months then 6 monthly (Table 1) by FACS-count (Becton-
Dickinson San Jose). Data were reviewed by a doctor, double-entered and stored as 
with other CRFs. CD4 count data were thus available for the time of ART initiation, time 
of enrolment into the trial and during follow-up. 
 
2.4.3 Sample size 
2180 patients were recruited into the COSTOP trial. Details of the sample size 
calculation for the COSTOP trial are covered in chapter 4.  
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I assessed the power that the sample size of COSTOP would provide to detect an 
increase in malaria incidence under a variety of assumptions (Table 2). For example, 
under the assumption that the incidence of  malaria in the control arm (with continued 
CTX prophylaxis) would be 1.4 malaria episodes /100 person years (pyrs) as observed 
in the study by Campbell et al (9), the COSTOP trial would provide >80% power to 
detect as significant (at the 5% significance level) a doubling of malaria incidence in 
those who stop CTX compared to those that continue,  assuming a 15% loss to follow up 
at the end of the study and an average follow up of 2 years.  
 
2.4.4 Analysis  
Data was analysed using Stata 12 and 13. For all comparisons by treatment arm, the 
analysis was by ‘Intention to treat’, with participants analysed according to the arm to 
which they were randomised. Detailed analysis methods used for specific study 
objectives are described in the subsequent chapters presenting papers addressing each 
objective.  
 
2.5 Ethical considerations and permissions 
The studies on malaria specific research questions were a sub- analysis of the main 
COSTOP trial. The trial was approved by the UVRI Science and Ethics Committee 
(SEC), the National Drug Authority (NDA) and the Uganda National Council of Science 
Technology (UNCST). Permission to conduct the malaria related work as PhD research 
was granted by the COSTOP TSC. Ethical clearance for the PhD project was obtained 
from the Ethics Committee of the London School of Hygiene and Tropical Medicine 
(LSHTM) (Appendix 17). 
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Table 1: Trial procedures 
 
  
 Trial time 
 
Trial Procedure  Screening  Enrolment  
(Wk 0) 
Wk 4 Wk 8 Wk 12 Wk 24 3 
mthly  
6 mthly  
Consent for screening x        
Consent for enrolment/ 
plasma storage  
 x       
History and physical exam x x x x x x x x 
CD4 
 
x    x x  x 
Full blood count  
 
x    x x x  
Pregnancy test  
 
x        
Malaria slide  
 
 x x x x x x  
Plasma storage  
 
 x    x  x 
Adherence assessment    x x x x x  
Study drug prescription/refill    x x x x x x  
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Table 2: Power calculations (at 5% level of significance) for a given sample size and different 
scenarios  
Sample size 
(n per arm) 
Malaria 
incidence in 
control arm 
(/100 pyrs) 
Loss to 
follow up (%) 
Minimum 
increase in 
malaria 
incidence 
that could be 
detected (%)  
Average follow 
up (yrs) 
Power (%) 
1090 1.0 15 50 2 27 
1090 1.4 15  50 2 36 
1090 5.0 15 50 2 86 
1090 1.0 15 100 2 70 
1090 1.4 15  100 2 84 
1090 5.0 15 100 2 100 
1090 1.0 20 50 2 26 
1090 1.4 20  50 2 35 
1090 5.0 20 50 2 84 
1090 1.0 20 100 2 67 
1090 1.4 20 100 2 81 
1090 5.0 20 100 2 100 
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Chapter 3: Effect of cotrimoxazole prophylaxis on malaria 
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Systematic Review
Effect of cotrimoxazole prophylaxis on malaria occurrence in
HIV-infected patients on antiretroviral therapy in sub-Saharan
Africa*
R. Kasirye1,2, K. Baisley1, P. Munderi2 and H. Grosskurth1
1 London School of Hygiene and Tropical Medicine, London, UK
2 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
Abstract objective To systematically review the evidence on the effect of cotrimoxazole (CTX) on malaria in
HIV-positive individuals on antiretroviral therapy (ART).
methods Web of Science, PubMed and MEDLINE, EMBASE, Global Health and Cochrane Library
databases were searched using terms for malaria, HIV and CTX. Studies meeting the inclusion
criteria were reviewed and assessed for bias and confounding.
results Six studies (in Uganda, Kenya, Malawi, Zambia and Zimbabwe) had relevant data on the
effect of CTX on malaria in patients on ART: four were observational cohort studies (OCS) and two
were randomised controlled trials (RCTs); two were in children and one in women only. Samples
sizes ranged from 265 to 2200 patients. Four studies compared patients on ART and CTX with
patients on ART alone; 2 (RCTs) found a significant increase in smear-positive malaria on ART
alone: (IRR 32.5 CI = 8.6–275.0 and HR 2.2 CI = 1.5–3.3) and 2 (OCS) reported fewer parasitaemia
episodes on CTX and ART (OR 0.85 CI = 0.65–1.11 and 3.6% vs. 2.4% of samples P = 0.14). One
OCS found a 76% (95% CI = 63–84%) vs. 83% (95% CI = 74–89%) reduction in malaria
incidence in children on CTX and ART vs. on CTX only, when both were compared with HIV-
negative children. The other reported a 64% reduction in malaria incidence after adding ART to
CTX (RR = 0.36, 95% CI = 0.18–0.74). The 2 RCTs were unblinded. Only one study reported
adherence to CTX and ART, and only two controlled for baseline CD4 count.
conclusion Few studies have investigated the effect of CTX on malaria in patients on ART. Their
findings suggest that CTX is protective against malaria even among patients on ART.
keywords malaria, cotrimoxazole, HIV, antiretroviral therapy
Introduction
Malaria and HIV infection are important global health
problems, and these diseases have a wide geographical
overlap resulting in frequent co-infection [1–4]. HIV
infection is associated with deterioration of the patient’s
immune system and an increased incidence of opportunis-
tic infections (OI) and of malaria [5–8]. Among HIV-
infected patients, the use of daily prophylaxis with
cotrimoxazole (CTX) reduces mortality and morbidity
from OI [9–15], and it reduces malaria incidence in HIV-
infected patients before [12, 16, 17] and after starting
antiretroviral therapy (ART)[18, 19], and in children
exposed to HIV infection[20].
WHO [21] recommends ART for HIV-infected adults
and adolescents with a CD4 count <500 cells/ll or if a
person has TB, is pregnant, is breastfeeding, HBV
co-infected with severe liver disease or in a sero-discordant
partnership. WHO also recommends CTX prophylaxis for
anybody with a CD4 count <350 cells/ll, or clinical stage
3 and 4 disease and irrespective of CD4 count or clinical
stage in areas of high malaria prevalence and/or severe
bacterial infections [22]. This policy aims to reduce OI
and all-cause mortality. The possible preventive effect on
malaria was not originally part of the rationale for CTX
prophylaxis. Indeed, fears about the possible development
of resistance against antimalarial drugs owing to*freely and fully available at www.tmih.com
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wide-spread CTX use were expressed by some authors
[23–25].
CTX use increases patients’ pill burden and cost of
care and is associated with haematological toxicity and
hypersensitivity skin reactions. However, adverse reac-
tions to CTX are rare (<2 per 100 person-years of CTX
use) and mainly mucocutaneous in nature; they resolve
with drug discontinuation [26–28]. With patients on
ART being able to regain near normal immune function,
some researchers recommend stopping CTX once patients
are stable on ART [29, 30]. However, these recommen-
dations are based on studies in industrialised countries
which have fewer malaria and bacterial infections than
sub-Saharan Africa (SSA). So although HIV-infected
patients on ART in SSA may not need CTX for preven-
tion of OI, they might still benefit from its antimalarial
effect [31]. A Guideline Development Group on Cotrim-
oxazole prophylaxis was convened by WHO in 2013.
This group recommended that in settings with high
malaria prevalence and/or severe bacterial infections,
even among patients that are stable on ART, CTX should
be continued [22].
Our objectives were (i) to systematically review
publications on the effect of CTX on malaria in
HIV-infected patients on ART in order to assist policy-
makers in SSA in taking informed decisions within the
context of the epidemiological situation in their area
and (ii) to provide background information for an
ongoing controlled trial of malaria incidence among
HIV-infected patients on ART with and without CTX
co-medication.
Methods
Search strategy
The following databases were searched for publications
to 14 April 2014: EMBASE, PubMed and MEDLINE,
Web of Science, Global Health and the Cochrane
Library. The search used terms for malaria, HIV and
CTX, without a term for ART, to reduce the chance of
missing relevant papers.
A combination of the following MESH terms and free
text was used:
• malaria, malaria incidence, malaria prevalence,
malaria severity, malaria outcomes, malaria treat-
ment, Plasmodium and parasitaemia for malaria.
• cotrimoxazole, trimethoprim/sulfamethoxazole,
septrin and bactrim for cotrimoxazole.
• HIV, human immunodeficiency virus, acquired
immunodeficiency syndrome, AIDS and immune
suppression for HIV infection.
An example of the search strategy as used in MEDLINE
• malaria OR malaria adj3 (occurrence OR incidence
OR prevalence OR treatment OR parasit?emia OR
outcomes OR sever*) OR Plasmodium.
• HIV OR human immunodeficiency virus OR
acquired immunodeficiency syndrome OR AIDS OR
Immune suppres*.
• 1 AND 2.
• cotrimoxazole OR trimethoprim sulfamethoxazole
OR septrin OR bactrim.
• 3 AND 4.
The search results were exported to Endnote reference
management software (Thomson Reuters, version 97)
and duplicates were removed. All titles and abstracts
were screened independently by two authors (RK and
KB); inconsistencies were discussed and consensus on
potential eligibility reached. Abstracts were checked for
studies reporting on a combination of malaria, HIV, co-
trimoxazole and antiretroviral therapy. Review articles
were excluded but their reference lists were checked for
possible additional relevant papers. Reference lists from
papers identified from the systematic search were also
checked. Full text copies of potentially relevant papers
were then obtained. Data requests were sent to authors
of studies for which relevant information might have
been collected but not reported in their publications.
Guidelines on preferred reporting items for systematic
reviews and meta-analyses (PRIMSA) were used.
Included studies
We included studies containing original data on the effect
of CTX on malaria in HIV-infected patients on ART. No
restrictions on area of the world, participant age, lan-
guage or the date of publication were used.
Data extraction
Data from papers identified by the search were indepen-
dently extracted by two authors (RK and KB) using a
standard form to collect the following information: first
author’s name, year of publication, type of study, study
population, study aim, sample size, follow-up time, study
results, how malaria diagnosis was made, number and
severity of malaria episodes and the association between
malaria and CTX.
Bias
Assessment of bias and confounding within studies and
quality of papers was based on PRISMA guidelines[32]
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and the Newcastle-Ottawa quality assessment of studies
scale[33]. Studies were assessed on selection bias, adher-
ence to CTX, objectivity of malaria diagnosis, cohort
retention, follow-up duration (for assessment of seasonal
variation), adjustment for confounding and outcome
reporting. A formal meta-analysis was not performed
owing to the diversity in study methodologies, compari-
son groups and populations.
Results
A total of 516 abstracts were retrieved, of which 492
were removed because they were duplicates, were not rel-
evant or did not meet the inclusion criteria (Figure 1).
Full text was reviewed for 24 abstracts; only 6 had data
on the effect of CTX on malaria in HIV-infected patients
on ART and were retained for the final qualitative syn-
thesis. 16 potentially eligible studies did not report on the
association of CTX and malaria in patients on ART;
authors of 14 papers were contacted where it was felt
that relevant data might have been collected but not
reported. However, none was able to provide information
relevant to this review so the studies were not included.
All six studies included in the final synthesis were con-
ducted in SSA; no relevant studies were found from
malarious areas in other continents. Of the six studies,
two were randomised controlled trials and four were
observational cohort studies; two studies were conducted
among children only and four among adults (one in
women only) (Table 1). Four studies were conducted in
Uganda only (or the analysis of malaria was restricted to
Ugandan sites); the other two were multisite studies con-
ducted in Kenya, Malawi, Uganda, Zambia or Zimba-
bwe. The diagnosis of malaria was based on a patient
having history of fever and a positive blood slide or rapid
diagnostic test (RDT) (4 studies); clinical features alone
or clinical features and a positive blood slide (1 study);
and a positive blood slide or positive RDT, or detection
6 Studies included in 
qualitative synthesis 
18 Papers excluded 
3-Papers covered same population (2 were 
excluded)
16-Papers did not have data on the association  
between CTX and malaria in patients on ART
(even after feedback following request to 
authors)
24 Abstracts subjected to full 
review
244 Abstracts excluded because  
the abstracts did not describe
original data on malaria in HIV  
patients on a combination of CTX  
and ART. 
268 Abstracts reviewed  
248 Duplicates removed 
516 Abstracts identified through database 
searches
Medline (19)
Pubmed (83)
Embase (191)
Global health (49)
Web of science (157)
Cochrane database (17)
Figure 1 Results of the systematic search.
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of Plasmodium falciparum histidine rich protein 2 in
plasma (1 study). Study samples sizes ranged from 265 to
2200 patients. Median length of follow-up was not speci-
fied for one study and was between 4 months and
4.9 years for the others. A summary of studies in the
final synthesis is shown in Table 1.
Summary of study objectives and populations
Bwakura-Dangarembizi et al. [34] conducted a rando-
mised, open-label, controlled trial in Uganda and Zimba-
bwe to assess the effect of stopping vs. continuing CTX
prophylaxis in HIV-infected children and adolescents on
long term ART. The trial enrolled 760 participants with
median age of 7.9 years; at enrolment, the median time
on ART was 2.1 years and median CD4 T-cell percent-
age was 33% (nadir-13%).
Campbell et al. [35] conducted a cluster randomised
(by household) controlled trial in Uganda to investigate
the effect of CTX discontinuation on the incidence of
malaria and diarrhoea among HIV-infected adults on
ART with CD4 > 200 cells/ll. The trial enrolled 836 par-
ticipants; at enrolment, the median time on ART was
3.7 years, median CD4 was 489 (nadir = 129) cells/ll,
and 94% had a viral load <100 copies/ll.
Gasasira et al. [12] assessed the protective efficacy of
CTX on the incidence of falciparum malaria and on the
prevalence of Plasmodium falciparum mutations confer-
ring antifolate resistance among children treated for
malaria in Uganda, comparing HIV-infected children on
daily CTX both on and off ART, and HIV-uninfected
children not taking CTX. The study enrolled 899 chil-
dren (300 HIV infected) with a median age of 7.4 (HIV-
uninfected) and 5.7 years (HIV infected) at enrolment.
The median CD4 T-cell percentage was 23% (HIV-
infected). HIV-infected children contributed 665 person-
years of follow-up, of whom 275 were on ART (292 par-
ticipants).
Mermin et al. [19] assessed the effect of ART on
malaria and the additive effects of CTX, ART and insecti-
cide-treated bed nets (ITNs) in HIV-infected adults attend-
ing clinics of The AIDS Support Organization (TASO) at
two sites in Uganda. Study participants had sequential
exposure to the intervention divided into four phases:
• Phase 1 – no intervention (466 participants; median
CD4 at enrolment = 75 cells/ll)
• Phase 2 – participants started on CTX prophylaxis
(399 participants; median CD4 at enrolment = 77
cells/ll)
• Phase 3 – participants continued CTX and started on
ART (1035 participants; median CD4 at enrol-
ment = 124 cells/ll)
• Phase 4 – participants continued CTX and ART, and
ITNs were provided (985 participants; median CD4
at enrolment = 175 cells/ll)
Skinner et al. [36] assessed the effect of a protease
inhibitor (PI)-based ART regimen on malaria compared
with a nevirapine-based regimen, stratified by CTX use.
Patients were part of the Optimal Combination Therapy
After Nevirapine Exposure study (OCTANE) [37], a mul-
ticentre trial comparing non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) and PI-based regimens for HIV-
infected women with a history of nevirapine prophylaxis
to prevent mother-to-child HIV transmission. The Skin-
ner et al. study evaluated 265 women from the OCTANE
trial who at baseline had a median age of 37 years, med-
ian CD4 of 121 cells/ll and HIV RNA of 5.2 log10 cop-
ies/ml.
Walker et al. [18] assessed the effect of CTX on sur-
vival, WHO stage, malaria, CD4 count, body mass index
(BMI) and haematological indices in HIV-infected
patients with CD4 count <200 cells/ll initiating ART in
Uganda and Zimbabwe in the Development of Antiretro-
viral Therapy (DART) trial for Africa which compared
ART monitoring strategies in resource limited settings.
The trial enrolled 3179 participants; the analysis of
malaria incidence was restricted to 2222 participants in
Uganda. At enrolment into the DART trial, median CD4
count was 83 cells/ll.
Effect of CTX on malaria in patients on ART
Two of the six studies evaluated the effect of CTX on
malaria in HIV-positive participants on ART as their
main study objective. The other four studies had different
objectives, but the data allowed assessment of the effect
of CTX on malaria.
The six studies used different comparison groups: CTX
and ART vs. ART alone (4 studies); CTX and ART vs.
HIV negative (1 study); CTX only vs. HIV negative (1
study); CTX only vs. HIV positive not on treatment (1
study); CTX and ART vs. HIV positive not on treatment
(1 study); CTX, ART and ITNs vs. HIV positive not on
treatment (1 study).
All four studies that examined the occurrence of
malaria in HIV-positive persons on CTX and ART com-
pared with those on ART alone found a beneficial effect
of CTX. Bwakura-Dangarembizi et al. [34] found that
children and adolescents who discontinued CTX had a
higher incidence of malaria (HR 2.21, 95% CI = 1.50–
3.25 P < 0.001) compared to those who continued CTX
prophylaxis. Campbell et al. [35] also found strong evi-
dence of a higher malaria incidence in patients on ART
572 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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who discontinued CTX compared to those who contin-
ued CTX prophylaxis (IRR 33; 95% CI = 9–275,
P < 0.001). Walker et al. [18] found strong evidence of a
reduction in the number of clinical malaria episodes
among patients on ART and CTX compared to those on
ART alone (OR = 0.74, 95% CI = 0.63–0.88,
P < 0.001); however, the reduction in the risk of para-
sitaemia was not statistically significant (OR 0.85; 95%
CI = 0.65–1.11, P = 0.23). Skinner et al. [36] found
weak evidence of decrease in detectable parasitaemia in
patients who were on CTX and ART compared to those
who were on ART alone (3.6% vs. 2.4%; P = 0.14).
Gasasira et al. [12] found a 76% (95% CI = 63–84%)
reduction in malaria incidence in children on CTX and
ART, and a similar 83% (95% CI = 74–89%) reduction
in children on CTX only, when both were compared with
HIV-negative children not on CTX.
Mermin et al. [19] found that CTX alone was associ-
ated with 76% reduction in malaria incidence
(RR = 0.24, 95% CI = 0.15–0.38; P < 0.001), and CTX
and ART reduced malaria incidence by 92% (RR = 0.08,
95% CI = 0.04–0.17; P < 0.001), when compared with
HIV-positive participants not on CTX or ART. In their
sequential comparisons of the additive effects of the inter-
ventions in each phase of the study, they found that add-
ing ART to CTX was associated with a 64%
(RR = 0.36, 95% CI = 0.18–0.74; P = 0.006) reduction
in malaria incidence compared to CTX alone.
Four studies reported parasite density. Bwakura-Dan-
garembizi et al. [34] found parasite density to be higher
in patients on ART who stopped CTX compared with
those who continued CTX (median parasite density per
200 white cells = 221/ll vs. 153/ll, P = 0.004). Campbell
et al. [35] found that 70% of the 55 malaria episodes in
patients on ART who stopped CTX had parasite densities
>1250/ll compared with 100% of the two episodes in
patients who continued CTX. Gasasira et al. [12] found
that geometric mean parasite density was lower for HIV-
infected children who were also on CTX (6462/ll) com-
pared to HIV-uninfected children (11 270/ll), although
the difference was not statistically significant (P = 0.40).
Mermin et al. [19] evaluated the cumulative and additive
effects of CTX, ART and ITNs on malaria parasitaemia
>1250/ll; their conclusions were similar to those when
malaria was defined as fever with a positive blood slide
(as described above).
Risk of bias and confounding
All studies reviewed were of good quality but subject to
sources of bias (Table 2). Three studies reported adher-
ence to CTX (Bwakura-Dangarembizi, Campbell and
Gasasira et al.), and 3 (Bwakura. Mermin and Walker
et al.) reported adherence to ART. Only the Bwakura
et al. study reported both CTX and ART adherence.
Campbell et al. and Bwakura-Dangarembizi et al. were
the only studies randomised by CTX use; however, these
studies were not blinded. Most of the studies used clinical
and/or laboratory based methods to diagnose malaria;
Walker et al. also used clinical diagnosis alone.
Multivariate analysis to control for potential confound-
ers was not used by Skinner et al. due to the small number
of malaria cases. Only the Mermin, Bwakura-Dan-
garembizi and Walker studies controlled for the potential
confounding effect of CD4 count at baseline. No study
explored the potential confounding effect of socio-eco-
nomic status. The Walker study was the only study to
control for potential time-dependent confounders such as
current CD4 count, haemoglobin and BMI levels.
Discussion
Most studies in this review were conducted after 2005,
when most developing countries had started to roll out
ART to patients, of whom most were on CTX. The
search was performed using terms for malaria, HIV and
CTX, without using the term for ART, to reduce the
chance of missing relevant papers. However, only six
studies were identified with data on the effect of CTX on
malaria in patients on ART.
Four of the six studies compared malaria occurrence in
patients on ART alone with that in patients on ART and
CTX, and all found a higher incidence of malaria in
patients on ART alone. This is expected given the anti-
malarial properties of CTX[38], even in areas where
malaria parasites have antifolate resistance[12]. The
strongest evidence for this beneficial effect was observed
in the Campbell (IRR = 32.5) and Bwakura-Dan-
garembizi (HR = 2.21) studies. The latter study was con-
ducted in children and adolescents and the former in
adults. With better immune memory to malaria in adults
[39], a smaller difference in malaria incidence between
those stopping CTX and those continuing CTX might be
expected in adults than in children, but the reverse was
observed. The Campbell study was stopped after just
4 months because of increased malaria incidence in the
discontinuation arm. As the authors point out, it is not
clear whether the increase in malaria after stopping CTX
may have been only temporary. It is possible that the lar-
ger beneficial effect of CTX on malaria in adults in this
study, compared with that in children and adolescents in
the Bwakura-Dangarembizi study, is because of the
shorter follow-up time (4 months vs. 2.1 years,
respectively).
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 575
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The other two studies showed strong evidence of a
decrease in episodes of clinical malaria (Walker et al.
OR = 0.74, 95% CI = 0.63–0.88; P < 0.001), and weak
evidence of a decrease in malaria prevalence (Skinner
et al. 3.6% vs. 2.4%, P = 0.14), in patients on ART and
CTX compared to patients on ART alone. One study
showed that HIV-infected children on CTX had 80%
(95% CI; 72–85%) lower malaria incidence than HIV-
negative children not on CTX.
Only the Bwakura-Dangarembizi and Campbell studies
were originally designed to look at the effect of CTX on
malaria in patients on ART. This may explain why most
studies did not report adherence to CTX and/or ART
and did not attempt to address potential bias and con-
founding related to malaria. Both the Bwakura-Dan-
garembizi and Campbell studies were randomised by
CTX use, but investigators and participants were not
blinded. These trials showed that patients stopping CTX
prophylaxis had a higher risk of malaria than those who
continue CTX. The Bwakura-Dangarembizi study
reported more hospitalisations in children stopping CTX
than in those who continued. The Campbell study
showed no significant difference in adult hospitalisation
rates or mortality between the trial arms, and none of the
four deaths recorded was related to malaria. Malaria in
this study was uncomplicated and the clinical relevance
of this malaria is therefore not clear.
Results of a trial ‘CTX Prophylaxis Discontinuation
Among ART-Treated Adults: A Randomized Non-Inferi-
ority Trial’ were presented at the Conference on Retrovi-
ruses and Opportunistic Infections in March 2014[40].
These results were not included in this synthesis because
some data relevant to the review were not provided and
the results are yet to be published in a peer-reviewed
journal. This trial was an open-label randomised con-
trolled trial comparing stopping vs. continuing CTX pro-
phylaxis among 500 HIV-infected adults in western
Kenya on ART >18 months and followed for a year. The
authors reported that patients stopping CTX had a 33.2
(95% CI = 4.5–241.0; P = 0.001) times higher malaria
incidence than those who continued CTX. They also
found that combined morbidity and mortality were
greater in the group stopping CTX (IRR 2.27; 95%
CI = 1.52–3.38, P < 0.001) but that this result was dri-
ven by malaria morbidity.
Publication of the full results of this trial is awaited
but like the Campbell study, this trial was not blinded
and therefore susceptible to reporting bias. However, the
results suggest that the higher incidence of malaria
seen in patients stopping CTX in the Campbell study
may be maintained even when patients are followed for
longer.
It is clear from this review that patients who are stable
on ART and stop taking CTX experience malaria epi-
sodes more frequently but a number of questions remain
unanswered:
• Given that none of the studies was blinded, how
much does reporting bias contribute to the observed
increased risk of malaria in patients who stop CTX
compared to that in those who continue?
• What is the clinical significance of malaria occurring
in HIV-infected adults on ART who do not take
CTX prophylaxis?
• Do patients who stop CTX have a higher incidence
of malaria than would be observed in HIV-unin-
fected people?
• How does CTX compare with other antimalaria pro-
phylactic drugs such as chloroquine (which may
imply a lower pill burden)?
• Does the background ecological exposure to malaria
have an effect on the relationship between malaria
and CTX?
• Is CTX prophylaxis still beneficial in patients recently
diagnosed with HIV who start ART early, that is with
high CD4 counts, for example 500 cells/ll?
Two ongoing randomised controlled trials, one in
Uganda (ISRCTN44723643) and one in Malawi
(NCT01650558), will help answer some of these ques-
tions. These studies investigate the effect of CTX on
malaria incidence in HIV-infected patients on ART. The
Ugandan trial is double-blind and placebo-controlled,
and compares continued CTX prophylaxis with stopping
CTX. The Malawian trial compares continued CTX with
stopping CTX, but is not placebo-controlled; instead
weekly chloroquine (CQ) prophylaxis is substituted for
CTX. Results are expected in 2015.
Conclusion
Few studies have investigated the effect of CTX on
malaria in patients on ART; these studies show a trend
towards a beneficial effect of CTX on malaria. Only 2 of
the reviewed studies were randomised and they were the
only ones specifically designed to investigate this associa-
tion. Most of the reviewed studies were subject to bias
and confounding, and the clinical relevance of malaria
experienced by patients stable on ART who are not on
CTX prophylaxis is unclear.
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Chapter 4: The COSTOP trial 
 
This chapter gives an overview of the COSTOP trial in which the experimental PhD 
work was embedded. 
 
4.1 Aim  
The aim of the COSTOP trial was to assess the safety of discontinuing cotrimoxazole 
(CTX) prophylaxis in HIV infected adults, whose immunity had been restored on ART. 
COSTOP was a randomised a placebo controlled trial. The trial had two co-primary 
outcome measures:  
(1) Time to first CTX-preventable event excluding malaria (efficacy outcome)  
(2) Time to the occurrence of the first grade 3 or 4 haematological adverse event (safety 
outcome) 
 
Secondary outcome measures included: 
 All-cause mortality 
 Incidence of all confirmed malaria episodes 
 Severity and outcome of all confirmed malaria episodes 
 Mean change in CD4 count after 12 months on the trial 
 Mean change in haematological indices after 12 months on the trial 
 Incidence of hospitalisation (all causes) 
 
The main COSTOP trial analysis did not include malaria related outcomes; these 
outcomes were my responsibility from the conception of the trial and were to part of my 
PhD project.   
 
Non-malarial clinical events occurring during follow up were adjudicated by an end-
points review committee (ERC) as to whether they were CTX preventable or not.  
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 4.2 Methods  
The study population and screening, enrolment and follow up procedures are described 
in detail in the Methods section of this thesis (chapter 2) and in the published COSTOP 
design paper (Appendix 3). 
 
Statistical methods 
Sample size 
The sample size calculation for the efficacy outcome was based on being able to 
conclude non-inferiority of placebo, whereas the calculation for the safety outcome was 
based on superiority of placebo.  Led by the trial statistician, Jonathan Levin, different 
scenarios were assessed at the planning stage of the trial. The trial was designed to 
have 80% power at the 5% level of significance to detect non-inferiority of placebo to 
CTX (upper limit of adjusted hazard ratio (aHR) 90% confidence interval (CI) <1.25) with 
respect to the incidence of CTX preventable effects. Assuming an incidence of CTX 
preventable effects of 10 per 100 pyrs in the CTX arm, it was calculated that a sample 
size of 2160 participants followed up for 18 months with a 4% loss to follow up per year 
would be required to achieve this. For the co-primary endpoint of the time to the first 
grade 3 or 4 haematological adverse event, a sample size of at least 1000 subjects per 
arm would have approximately 85% power to detect as statistically significant at the 5% 
level a true hazard ratio (HR) of 2 for those that continue CTX compared to those that 
stop, if overall 10% of those in the arm that continues CTX prophylaxis experience such 
an event. The above assumptions on the incidence of CTX preventable events were 
derived from other studies conducted in Uganda, in particular a trial that compared ART 
monitoring strategies (DART) (1, 2).  
 
Intention to treat and per protocol populations 
Intention to treat (ITT): This population comprised all participants who took at least one 
dose of study medication and who had at least one follow-up assessment. 
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Per protocol (PP): The PP population consisted of  all participants whose adherence 
assessed by pill count or self-report remained above 80% for each period between 
study visits. 
 
Analysis 
The trial statistician developed the analysis plan and performed the main trial analyses.  
For the time to first CTX-preventable event or death analysis, the statistical test for non-
inferiority was used; hence the main analysis was based on the PP population. This 
analysis is preferred for non-inferiority/equivalence studies because it is conservative 
i.e. it excludes data on participants who for example had protocol violations, dropped 
out or crossed over in treatment which would dilute the treatment effect and make it 
easier to conclude that there was no difference between arms. Time to event methods 
were applied (Kaplan Meier plots, stratified log rank test and Cox proportional hazards 
regression). Non-inferiority was tested by estimating the HR for the experimental arm 
versus the control arm and finding the two-sided 90% CI. The experimental arm was to 
be considered non-inferior to the control arm if the upper limit of the 90% CI was less 
than 1.25. 
  
For the time to first grade 3 or 4 haematological adverse event, an analysis based on 
the ITT population was carried out. This analysis that is preferred for testing for 
superiority because it is conservative i.e. it includes participants for example who did not 
take their drugs, had protocol violations or switched drug all of which will dilute the 
treatment effect as described above making it more difficult to show a difference 
(superiority). Time to event analysis as described above was used, with superiority 
tested using the stratified log rank test.   
 
All HR were adjusted apriori for randomisation strata and enrolment site. Similar 
methods were used for the secondary outcome measures; since these were not 
analysed as non-inferiority endpoints, the ITT population was used. 
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4.3 Results 
The results presented on the main trial outcomes including the figures and table below 
were from analyses performed by the COSTOP trial statistician. 2180 patients were 
enrolled at two sites in Uganda (Entebbe and Masaka); 74% were female. The median 
age was 41 years, the median CD4 count 518 cells/ul, and the median time on ART 
prior to enrolment was 48 months. In total 1875 participants completed follow up; 232 
(109 CTX) were lost to follow up/ withdrew, 36 participants (18 CTX) stopped trial drug 
and 37 participants (19 CTX) died. 
 
We documented 115 clinical events that were adjudicated to be CTX preventable; 46 of 
these occurred in the CTX arm and 69 in the placebo arm. Bronchopneumonia was the 
most common event with 53 cases (20 CTX arm). In the PP population, a total of 98 
adjudicated CTX preventable events occurred (39 CTX arm) (Table 3). The time to the 
first CTX preventable event was significantly shorter in the placebo arm compared to 
the CTX arm (P=0.03) (Figure 4). The HR, adjusted for site and CD4 stratum (aHR) was 
1.6 (90%CI=1.1-2.2). The number needed to treat with CTX for one year to prevent one 
event was 113. 
 
Participants experienced 551 grade 3 or 4 adverse events (318 CTX). Participants in 
the CTX arm were more likely to experience haematological grade 3 or 4 adverse 
events: the time to the first grade 3 or 4 haematological adverse event was significantly 
shorter in the CTX arm compared to placebo (P<0.001) (Fig.5). The incidence of the 
grade 3 or 4 haematological adverse events was lower in the placebo arm, aHR 0.7, 
(95%CI=0.6-0.8) (Table 3).  
 
We documented a total of 37 deaths ((19 CTX) log rank test P=0.9)). The ERC deemed 
6 of them as CTX preventable, of which 4 occurred in the placebo arm. 
 
4.4 Conclusion 
In this study population, the discontinuation of CTX led to a significant increase in CTX-
preventable clinical events, but is associated with a decrease in grade 3 or 4 
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haematological adverse events. There was no statistically significant difference in 
mortality between those that stopped CTX prophylaxis and those that continued. 
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 Figure 4: Time to CTX preventable event 
 
 
Figure 5: Time to first hematologic grade 3 or 4 adverse event 
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 Table 3: CTX preventable events and grade (3/4) adverse events by trial arm 
End point  Treatment 
arm 
Events  Person 
years 
Rate/100 pyrs 
(CI)1  
Rate 
ratio(CI)1 
P-value 
CTX preventable 
event2 
CTX 39 21.2 1.8 (1.3-2.5) 1 0.03 
 Placebo 59 20.1 2.9 (2.3-3.8) 1.6 (1.1-2.2)  
Grade 3 or 4 
adverse events3 
CTX 318 20.7 15.3 (13.7-17.1) 1 <0.001 
 Placebo 233 21.9 10.6 (9.4-12.1) 0.7 (0.6-0.8)  
1
Adjusted for CD4 stratum and site. 
2
CI=90%. 
3
CI=95%. 
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Chapter 5: Incidence of malaria by cotrimoxazole use in HIV 
infected Ugandan adults on antiretroviral therapy: a 
randomized placebo controlled study. 
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Incidence of malaria by cotrimoxazole use in
HIV-infected Ugandan adults on antiretroviral
therapy: a randomised, placebo-controlled study
Ronnie P. Kasiryea,b, Kathy Baisleyb, Paula Munderia, Jonathan Levina,c,
Zacchaeus Anywainea, Andrew Nunnd, Anatoli Kamalia
and Heiner Grosskurthb
Introduction: Previous unblinded trials have shown increased malaria among
HIV-infected adults on antiretroviral therapy (ART) who stop cotrimoxazole (CTX)
prophylaxis. We investigated the effect of stopping CTX on malaria in HIV-infected
adults on ART in a double-blind, placebo-controlled trial.
Methods: HIV-infected Ugandan adults stable on ART and CTX with CD4þ cell count
at least 250 cells/ml were randomized (1 : 1) to continue CTX or stop CTX and receive
matching placebo (COSTOP trial; ISRCTN44723643). Clinical malaria was defined as
fever and a positive blood slide, and considered severe if a participant had at least one
clinical or laboratory feature of severity or was admitted to hospital. Malaria incidence
and rate ratios were estimated using random effects Poisson regression, accounting for
multiple episodes.
Results: A total of 2180 participants were enrolled and followed for a median of
2.5 years; 453 malaria episodes were recorded. Malaria incidence was 9.1/100 person-
years (pyrs) [95% confidence interval (CI)¼8.2–10.1] and was higher on placebo
(rate ratio 3.47; CI¼2.74–4.39). Malaria in the placebo arm decreased over time;
although incidence remained higher than in the CTX arm, the difference between arms
reduced slightly (interaction P value¼0.10). Fifteen participants experienced severe
malaria (<1%); overall incidence was 0.30/100 pyrs (CI¼0.18–0.49). There was one
malaria-related death (CTX arm).
Conclusion: HIV-infected adults – who are stable on ART and stop prophylactic CTX –
experience more malaria than those that continue, but this difference is less than has
been reported in previous trials. Few participants had severe malaria. Further research
might be useful in identifying groups that can safely stop CTX prophylaxis.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
AIDS 2016, 30:635–643
Keywords: antiretroviral therapy, cotrimoxazole, HIV, malaria,
trimethoprim/sulfamethoxazole
Introduction
Adults with advanced HIV disease who are not on
antiretroviral therapy (ART) are at an increased risk of
opportunistic infections and malaria [1–3]. Cotrimoxazole
(CTX), an antimicrobial agent containing trimethoprim
and sulfamethoxazole, reduces the incidence of opportu-
nistic infections, mortality and malaria [4–9]. However,
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CTX use is associated with increases in cost of care [10],
risk of haematological toxicity [11], hypersensitivity skin
reactions [12] and pill burden. Once started on ART,
patients’ immune function improves and the risk of
opportunistic infections reduces. Based on studies from
developed countries it has been recommended to stop
CTX once patients’ immune function has been restored
[13,14]; however, this may not be advisable for sub-Saharan
Africa where the prevalence of malaria and bacterial
infections is often high. Of recent, WHO recommends
that CTX may be discontinued in patients who are
clinically stable with evidence of immune recovery and/or
viral suppression on ART, but should be continued in
countries with high endemicity of malaria and bacterial
infections [15]. A systematic literature review found that
patients who stop CTX prophylaxis experience an increase
in malaria episodes, with the strongest evidence provided
by randomized-controlled trials (RCTs); however, none of
the reported RCTs was blinded so observational or
reporting bias cannot be excluded [16]. We investigated the
effect of CTX in a blinded, placebo-controlled trial on
CTX cessation in HIV-infected adults who are stable on
ART (COSTOP; ISRCTN44723643). The main results
of this trial have been reported previously. In summary,
the trial found that stopping CTX prophylaxis leads
to a significant increase in CTX-preventable clinical
events [mainly bacterial pneumonias; adjusted hazard ratio
(aHR)¼ 1.57, 90% confidence interval (CI)¼ 1.12–2.21]
and a significant decrease in grade 3/4 haematological
adverse events (aHR¼ 0.70, 95%CI¼ 0.59–0.82), the co-
primary outcomes of the trial. There was no effect on
all-cause mortality. The estimated number needed to treat
(NNT) for 1 year to prevent one infection (excluding
malaria) was 113 [17]. In this article we provide a detailed
account on the effect of CTX prophylaxis on malaria, a
secondary outcome of the trial.
Methods
COSTOP was a randomized, double-blind, placebo-
controlled noninferiority trial conducted in Uganda to
determine whether long-term prophylaxis with CTX can
be safely discontinued among HIV-infected adults on
ART with sustained immune competence (defined as
CD4þ cell counts 250 cells/ml) [17,18]. The trial had
two co-primary outcomes: time to occurrence of the first
CTX-preventable clinical event (according to a pre-
defined list) or death, and time to the occurrence of the
first grade 3 or 4 haematological adverse event [17].
COSTOP was conducted by the MRC/UVRI Uganda
Research Unit on AIDS (MRC/UVRI) at its research
clinics in Masaka and Entebbe in Uganda.
Study procedures
Detailed procedures have been described previously [18].
Briefly, participants were eligible for enrolment if they
were HIV infected; aged 18–59 years; clinically
asymptomatic; had been taking CTX and ART for
at least 6 months; had two CD4þ cell counts not less
than 250 cells/ml, the most recent within 4 weeks of
enrolment; and were able to attend regular study
appointments. Exclusion criteria included pregnancy,
grade 3 or 4 anaemia, neutropenia or thrombocytopenia.
At an initial screening visit, information was recorded on
socio-demographics, medical history, current illness and
medication and a physical examination was performed.
Laboratory tests included a full blood count, malaria slide
and CD4þ cell count.
At enrolment (2–4 weeks after screening), participants
were randomized to receive either active CTX (960 mg)
or matching placebo once daily in place of their regular
CTX. Randomization was stratified by enrolment site
and CD4þ cell count (250–499 and 500 cells/ml).
Participants were provided with an insecticide-treated
bed net (ITN) and educated about the importance of
using it. Participants continued to receive ART from their
usual providers, but trial staff monitored ART availability
to ensure an uninterrupted supply. Enrolment started in
January 2011 and was completed in March 2013.
Participants were seen every month for the first 3 months
and three-monthly thereafter, and were followed for 12
months to 3.5 years, depending on date of enrolment. At
each visit, adherence to trial drug, ARTand ITN use was
assessed, using a structured questionnaire and returned pill
counts (trial drug only). Participants were seen by a doctor
who assessed their health, treated any concurrent
infections, and dispensed trial drug. Participants were
issued with a supply of trial drug to last until their next
scheduled visit, along with a 3 day/month buffer stock in
case they were late. Blood samples were drawn at
scheduled visits for a malaria slide, CD4þ cell count,
and full blood count. Participants were encouraged to
attend the study clinic if unwell. If the participant was
suspected to have malaria, based on a history of malaria
associated symptoms (reported fever, headache, chills and
rigors, joint aches, muscles aches, vomiting or diarrhoea),
a blood slide and other tests deemed necessary were done,
and confirmed malaria was treated with arthemeter-
lumefantrine according to national guidelines [19].
Participants who reported having been treated for malaria
elsewhere (e.g. during a journey) were asked to present
documentary evidence of diagnoses and test results.
Participants were withdrawn from trial medication and
started on open-label CTX if their CD4þ cell count fell
below 250 cells/ml at any point during the trial.
Laboratory methods
A blood sample was used to prepare thick and thin films
on a glass slide. Specimens were processed using
Leishman’s stain and examined by microscopy. Thick
film specimens were used to record the number of
636 AIDS 2016, Vol 30 No 4
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parasites per 200 white blood cells and thin films to
identify the plasmodium species.
For this study we considered two categories of malaria:
(1) clinical malaria, defined by the presence or history
(during the previous 2 weeks) of fever and microscopi-
cally confirmed malaria parasites;
(2) severe malaria (based on WHO guidelines [20]),
diagnosed if a patient had P. falciparum asexual
parasitemia, no other obvious cause of symptoms and
met any of the following criteria: convulsions, loss
of consciousness, hypotension (systolic blood pressure
<70 mmHg), admission to hospital due to malaria,
laboratory evidence of liver or kidney damage,
severe normocytic anaemia (haemoglobin <50 g/dl,
PCV<15%), or hyperparasitaemia on blood slide
(>5% or 250 000/ml).
Sample size
A total of 2180 participants were recruited and followed
for up to 3.5 years. The sample size for the main trial was
defined based on the power to demonstrate noninfer-
iority of placebo for the primary efficacy outcome of time
to the first CTX-preventable event or death [17,18]. For
this study, assuming an incidence of 1.4 clinical malaria
episodes/100 person-years (pyrs) in the control (CTX)
arm, as observed in a previous study among HIV positive
adults on ART in Uganda [21], and an average follow-up
of 2 years, we estimated that the COSTOP trial would
have more than 80% power to detect as significant (at the
5% level) a doubling of the incidence of clinical malaria in
participants who stopped CTX compared with those
who continued, assuming a 15% loss to follow-up at the
end of the study.
Statistical analysis
Data were double-entered and verified in MS Access and
analysed using Stata 12 (Stata Corp, College Station,
Texas, USA). All analyses used an intention-to-treat
(ITT) approach.
Baseline characteristics were compared between trial
arms. Socioeconomic status (SES) was measured by
combining data from all trial participants on housing
construction and ownership of household items into an
asset index score using principal component analysis [22].
Person years at risk were calculated from enrolment until
the date last seen or end of trial. After each malaria
episode, participants were considered to be not at risk for
another episode until the episode resolved (as evidenced
by resolution of symptoms and a negative repeat slide at
the 14-day follow-up visit), or for 28 days, if a resolution
date was not available. Time to first episode of clinical
malaria was examined using Kaplan–Meier plots, and
compared between trial arms using the log rank test. The
incidence of all clinical malaria episodes, the rate ratio for
the effect of trial arm, and 95%CI were estimated using
random effects Poisson regression to account for multiple
episodes within the same participant. The incidence of
severe malaria was calculated and compared between
arms.
In secondary analyses, follow-up time was divided into
12-month bands and analysis stratified by time to
investigate possible effect modification of trial arm with
time. Effect modification was assessed by comparing a
model with fixed effects for treatment arm and timeband
to one with treatment arm, timeband and their
interaction, using the likelihood ratio test. In addition,
effect modification by enrolment site was investigated.
The effect of trial drug adherence, and of ITN use, on
malaria was assessed. The proportion of expected doses of
trial drug taken, based on counts of returned pills at each
scheduled visit, was calculated as (tablets dispensed –
tablets returned)/(days elapsed since pills were dispensed).
We defined ‘good’ adherence as taking 80–105%
expected doses, allowing for adherence up to 105%
due to possible imprecision in tablet counts. Each
participant’s overall adherence was categorized as being
good at not less than 80% of visits or less than 80% of
visits. At each visit, participants were asked if they had
always slept under an ITN since their previous visit.
Overall ITN use was characterized as having always used
an ITN at not less than 90% of visits or less than 90%
of visits.
Ethical approval
Approval for the study was obtained from the Science and
Ethics Committee of the Uganda Virus Research
Institute, the Uganda National Council of Science and
Technology, the Ugandan National Drug Authority, and
the Ethics Committee of the London School of Hygiene
and Tropical Medicine.
Results
A total of 2180 participants were enrolled into the
COSTOP trial. Participants’ characteristics at baseline
were balanced by trial arm (Table 1). Baseline charac-
teristics have been described previously [17]. Overall,
mean (SD) age was 41 [8] years; 74% of participants were
female; 70% had primary education or less; and 52% had a
CD4þ cell count below 500 cells/ml.
Although balanced by trial arm within each site, there
were some differences in participant characteristics
between the enrolment sites. Participants in Masaka
were slightly older, had lower levels of education, and
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were of lower SES than those in Entebbe (Table 1). They
also had higher CD4þ cell counts at enrolment, and had
been on ART for longer.
Follow-up
Participants were followed for a median of 2.53 years
(interquartile range¼ 1.86–2.76), with no evidence of a
difference between arms (CTX median 2.53; interquar-
tile range 1.96–2.76 years vs. placebo 2.53; 1.84–2.76
years; P¼ 0.66 by Wilcoxon rank-sum test). In total 1875
participants (943 CTX) completed follow-up (Fig. 1); 36
participants were withdrawn from trial drug (18 CTX)
and started on open-label CTX; 232 participants were
lost to follow-up (109 CTX); and 37 participants died
(19 CTX). Only one death was malaria related (CTX)
and was due to quinine toxicity. Overall, 13 043
scheduled visits were attended by participants on CTX
and 12 913 by those on placebo (Fig. 1).
Effect of stopping cotrimoxazole
There were 453 episodes of clinical malaria experienced
by 362 participants (range 1–5) during follow-up; 9% of
participants in the CTX arm and 24% of those in the
placebo arm had at least one episode of clinical malaria.
Time to the first clinical malaria event was significantly
shorter in the placebo arm than in the CTX arm (log rank
test P< 0.001) (Fig. 2).
The overall incidence of clinical malaria was 9.1
(95%CI¼ 8.2–10.1) episodes/100 pyrs. The incidence
of malaria was 3.5 times higher in participants on placebo
than on CTX (95%CI¼ 2.7–4.4; P< 0.001; Table 2).
Malaria by CTX use in HIV-infected adults on ART Kasirye et al. 639
100%
80%
60%
40%
20%
0%
1091 967 873 751 608 484 37 0Placebo
1089 1042 989 890 757 601 48 0CTX
Number at risk
0 0.5 1 1.5 2 2.5 3 3.5
Time since enrolment (years)
CTX Placebo
Kaplan-Meier failure estimates
Fig. 2. Time to occurrence of first malaria event by treat-
ment arm.
2933 number screened
2180 enrolled 
Reason for non-enrolment
•   Low CD4+ count    382 (51%)
•   Neutropenia         89 (12%)
•   Never returned     93 (12%)
•   Other                   189 (25)
Randomized to CTX 1089 Randomized to placebo 1091
932 (85%) completed follow up 
12193 visits made
350 (32.1%) had at least one 
malaria episode                     
943 (87%) completed follow up 
13043 visits made
103 (9.5%) had at least one 
malaria episode
Lost to follow up 109 (10.0%)
Stopped trial drug
Died 19 (1.7%)
18 (1.7%)
Lost to follow up
Stopped trial drug
Died
123 (11.3%)
18 (1.7%)
18 (1.7%)
Fig. 1. COSTOP trial profile.
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There was some evidence that the effect of stopping CTX
on clinical malaria incidence decreased over time:
although incidence remained higher in the placebo
arm, the difference between arms was less in the third
year (rate ratio¼ 2.1; 95%CI¼ 1.3–3.5) than in the first
year (rate ratio¼ 3.6; 95%CI¼ 2.6–5.0; P for inter-
action¼ 0.10) (Table 2). In the placebo arm, clinical
malaria incidence decreased from 17.3/100 pyrs in the
first year to 9.0/100 pyrs after the second year (P for trend
<0.001; Supplementary Figure, http://links.lww.com/
QAD/A828). In the CTX arm, clinical malaria incidence
remained similar over time (rate ratio for linear trend in
incidence from one year to the next¼ 0.90, CI¼ 0.69–
1.16, P¼ 0.40).
The relative effect of stopping CTX on clinical malaria
was greater in Entebbe (rate ratio¼ 6.8; 95%CI¼ 4.1–
11.1) than in Masaka (rate ratio¼ 2.7; 95%CI¼ 2.1–3.6;
P for interaction <0.001) (Table 2). In both arms, the
incidence of clinical malaria was higher in Masaka than in
Entebbe (CTX: 6.3 vs. 1.6/100 pyrs, respectively;
placebo 17.2 vs. 10.6/100 pyrs, respectively).
Overall, 15 (2 CTX, 13 placebo) episodes of severe
malaria occurred among the 2180 participants (<1%)
(Table 2). None of the participants had more than one
episode of severe malaria. Reasons for classifying
malaria as severe were: high parasitemia [2], loss of
consciousness [1], mental confusion [1] and hospital
admission [11]. The overall incidence of severe malaria
was 0.30/100 pyrs (95%CI¼ 0.18–0.49); the incidence
of severe malaria was 6.5 (95%CI¼ 1.5–29.0) times
higher in the placebo arm than in the CTX arm. Only
one participant (CTX arm) died of a malaria-related
event.
The NNTwith CTX for one year to prevent one malaria
episode was 10, and was 233 for severe malaria.
640 AIDS 2016, Vol 30 No 4
Table 2. Incidence of malaria by trial arm, follow-up time, trial site, adherence to trial drug and ITN use.
Trial arm Episodes Person-years
Rate/100 person-
years (95% CI)a Rate ratioa
P value (CTX
vs. placebo)
P value (for
interaction)b
Clinical malaria
CTX 103 2540 4.1 (3.3–5.0) 1 <0.001
Placebo 350 2515 14.1 (12.5–15.0) 3.5 (2.5–4.4)
Severe malariac,d
CTX 2 2543 0.08 (0.02–0.31) 1 0.004
Placebo 13 2524 0.52 (0.30–0.89) 6.55 (1.48–29.01)
Stratified analyses
Stratum variable
Follow-up time
1st year CTX 51 1065 4.8 (3.6–6.3) 1 <0.001 0.097
Placebo 183 1062 17.3 (14.8–20.2) 3.6 (2.6–5.0)
2nd year CTX 29 939 3.1 (2.1–4.5) 1 <0.001
Placebo 120 924 13.1 (10.8–15.8) 4.2 (2.8–6.4)
After 2nd year CTX 23 536 4.3 (2.8–6.5) 1 0.004
Placebo 47 528 9.0 (6.7–12.1) 2.1 (1.3–3.5)
Site
Entebbe CTX 19 1215 1.6 (1.0–2.5) 1 <0.001 <0.001
Placebo 127 1209 10.6 (8.8–12.8) 6.8 (4.1–11.1)
Masaka CTX 84 1325 6.3 (5.1–7.9) 1 <0.001
Placebo 223 1306 17.2 (14.8–20.0) 2.7 (2.1–3.6)
Trial drug adherence
Good adherence at
80% of visitse,f CTX 57 1724 3.3 (2.5–4.4) 1 0.01 0.25
<80% of visitse,f CTX 46 816 5.6 (4.1–7.6) 1.7 (1.1–2.6)
80% of visitse,g Placebo 205 1617 12.8 (12.0–14.9) 1 0.05
<80% of visitse,g Placebo 145 897 16.4 (13.6–19.8) 1.3 (1.0–1.6)
ITN use
Reported always using ITN at
90% of visits CTX 86 2124 4.1 (3.3–5.1) 1 P¼0.98 0.39
<90% off visits CTX 17 416 4.1 (2.5–6.7) 1.0 (0.6–1.7)
90% of visits Placebo 267 2038 13.3 (11.6–15.2) 1 P¼0.06
<90% off visits Placebo 83 476 17.5 (13.6–22.5) 1.3 (1.0–1.8)
CTX, cotrimoxazole; ITN, insecticide-treated bed net.
arates and rate ratios adjusted for clustering of multiple episodes within participant using random effects Poisson regression.
bP value for interaction between stratum variable with treatment arm.
cP. falciparum malaria with clinical or laboratory features of severity.
dRates and rate ratios from Poisson regression without adjustment for clustering since no participant had more than one episode.
e‘Good’ adherence defined as 80–105% of expected tablets taken, based on pill counts.
fRate ratio and P value for comparison in CTX arm.
gRate ratio and P value for comparison in placebo arm.
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Effect of adherence to trial drug and insecticide-
treated bed net use on malaria
Among participants on CTX, the incidence of clinical
malaria in those with good adherence at less than 80% of
visits was 1.7 (95%CI¼ 1.1–2.6) times higher than in
those with good adherence at not less than 80% of visits
(P¼ 0.01) (Table 2). Among participants on placebo,
malaria incidence was 1.3 (95%CI¼ 1.0–1.6) times
higher in those with good adherence at less than 80% of
visits (P¼ 0.05). The relative outcome of effect of
stopping CTX was greater in participants with good
adherence than in those with lower adherence (rate
ratio¼ 3.9, 95%CI¼ 2.8–5.3 vs. rate ratio¼ 2.9,
95%CI¼ 2.0–4.2).
Malaria incidence did not differ by reported ITN
use among participants on CTX (rate ratio¼ 1.0;
95%CI¼ 0.6–1.7; P¼ 0.98). However, malaria inci-
dence was higher in participants on placebo who reported
using an ITN at less than 90% of visits than in those who
reported ITN use at not less than 90% of visits
(rate ratio¼ 1.3, 95%CI¼ 1.0–1.8; P¼ 0.06), although
there was no evidence of significant effect modification
by treatment arm (P¼ 0.39).
Discussion
In this trial, participants on ART who stopped
prophylactic CTX had a 3.5-fold higher probability to
experience clinical malaria than those who continued.
This is expected given the antimalarial properties of CTX
[23] and is consistent with other studies in adults on ART
who discontinued CTX [21,24–28]. However the rate
ratio in our study was much smaller than reported by
other randomized trials in adults. Campbell et al. [21]
conducted an open-label, cluster (household) RCT in
Uganda to investigate the effect of stopping CTX on the
incidence of malaria and diarrhoea among HIV-infected
adults on ART with CD4þ above 200 cells/ml. The trial
enrolled 836 participants with median time on ART of
3.7 years and found that participants stopping CTX had a
32.5-fold (8.6–275.0) higher malaria incidence than
those that continued. The trial was stopped after
4 months. Polyak et al. [28] conducted an open-label
RCT comparing stopping versus continuing CTX
prophylaxis among 500 HIV-infected adults in western
Kenya who had been on ART for more than 18 months.
After a year of follow-up participants stopping CTX had
a 33.2-fold (95%CI¼ 4.5–241.0) higher malaria inci-
dence than those who continued CTX.
The contrasting results between these trials and ours
could have resulted from the shorter follow-up times
(4 months and 1 year in the Campbell and Polyak studies,
respectively) and from the smaller number of malaria
episodes (55 and 34, respectively) compared with our
study, in which 453 episodes of clinical malaria were
documented over a median follow-up time of 2.5 years.
Another explanation could be that participants in our trial
may have used CTX from other sources outside the trial,
which may have accounted for the smaller differences
between arms. However, exit interviews conducted at the
end of our trial did not find any evidence that participants
had taken CTX from other sources. We used an ITT
approach to the analysis; however, only 18 participants in
the placebo arm were withdrawn from trial medication
and started on open-label CTX, so this is unlikely to have
had a large impact on our results. Importantly, the
Campbell and Polyak studies were not blinded, so that
investigators or participants might have been more likely
to investigate or seek treatment if they felt that stopping
CTX might be risky. This source of potential observer
bias may have resulted in diagnosing malaria more
frequently in participants who had stopped CTX.
Although the incidence of severe malaria was higher in
the placebo arm, there was very little severe malaria in our
trial (only 1.2% of participants in the placebo arm) and
there was no statistical difference in overall number of
deaths (due to any cause) between trial arms. This is
consistent with findings in the study by Campbell et al.
[21]. Only one malaria-related death was recorded, and
this occurred in the CTX arm.
We found a marked decrease in malaria incidence over
time in the placebo arm whereas the incidence in the
CTX arm remained stable. This initially higher incidence
among participants who had stopped CTX could be a
consequence of the detrimental effects that HIV had
caused on the innate immune response to malaria and
other infections [29]. Whilst participants with low
immunity were initially protected against malaria due
to CTX, it is possible that the incidence of malaria
increased when CTX was discontinued, until participants
re-acquired some immunity against malaria. This has
been described among children [30].
As expected, participants with good adherence to
trial drug in the CTX arm had less malaria than those
whose adherence was not as good. Unexpectedly, good
adherence was also associated with reduced malaria
incidence in the placebo arm. A possible explanation is
that participants with suboptimal adherence to trial drug
might also be less likely to adhere to other malaria
prevention measures like ITN use. There was no
association of reported ITN use with malaria in the
CTX arm. In contrast, participants on placebo with
high reported ITN use had less malaria than those with
lower reported ITN use, suggesting that people who
discontinue CTX would benefit from general malaria
prevention measures.
There were fewer malaria episodes observed in partici-
pants at Entebbe than Masaka, in both trial arms and over
Malaria by CTX use in HIV-infected adults on ART Kasirye et al. 641
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time. Participants at Entebbe were generally younger, and
had attained a higher education level and SES compared
with those in Masaka. If participants in Entebbe were
better able to take care of themselves, had better housing
or could access treatment more easily this may have
resulted in a lower incidence of malaria at the Entebbe
site. Another possible explanation is that malaria
endemicity and therefore exposure to malaria was higher
in Masaka compared with Entebbe. Data on malaria
endemicity by region in Uganda are limited; however,
both areas are considered to have very high malaria
endemicity [31]. Recent reports for the three quarters up
to June 2015 showed an incidence of 101, 59, and 106 per
1000 population in Masaka district, and 82, 86 and 56 in
Wakiso district, which includes Entebbe [32]. This seems
to suggest that background exposure to malaria may be
higher in Masaka.
Strengths and limitations
Strengths of our study include its design as a double-blind
placebo-controlled randomized trial, its large sample size,
and that participants were seen at frequent scheduled visits
and sick visits at which screening for malaria was routinely
performed and adherence to trial drug and ARTassessed.
Furthermore, participant retention was high, with more
than 85% completing follow-up.
Unfortunately we do not have data on malaria incidence
from HIV-negative individuals in our study area. We
can therefore not determine the extent to which the
incidence of malaria among HIV-infected participants on
ART and CTX may have been reduced below normal
levels.
Conclusion
In this blinded placebo-controlled trial in Uganda,
participants who were stable on ART and stopped taking
prophylactic CTX had malaria more frequently and
severely than those who continued, but the difference was
less than has been reported by earlier studies. Malaria
incidence reduced in participants on placebo over time.
Few participants experienced severe malaria. A potential
decision to stop or continue CTX will have to take into
account the main COSTOP trial results that have shown a
clear benefit of continued CTX prophylaxis in preventing
bacterial infections, but also showed an increase in
neutropenia incidence and no reduction in overall
mortality [17]. The NNT to prevent one CTX-
preventable event or malaria is also worth considering.
According to current WHO guidelines CTX may be
discontinued in some situations, but should be continued
in countries with high endemicity of malaria and bacterial
infections [15]. Given the costs and toxicity of CTX and
the potential development of wide spread of CTX
resistance, further research will be useful in identifying
groups and circumstances in which CTX prophylaxis
could be safely stopped.
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Abstract  
Introduction 
We investigated the effect of CD4 count on malaria incidence in HIV infected adults on 
antiretroviral therapy (ART) in the context of a randomized controlled trial on the effect 
of stopping cotrimoxazole (CTX). 
 
Methods 
This study presents a sub-analysis of the COSTOP trial (ISRCTN44723643) which was 
carried out among HIV-infected Ugandan adults stable on ART with CD4 counts ≥250 
cells/µl. Participants were randomized (1:1) to continue CTX or stop CTX and receive 
matching placebo, and were followed up for a minimum of one year (median 2.5 years). 
CD4 counts were measured at baseline, 3 months and then every 6 months. Clinical 
malaria was defined as fever and a positive blood slide and considered severe if a 
participant had one or more clinical or laboratory features of severity or was admitted to 
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hospital.  We assessed the effect of CD4 count (<350,350-499,>500) at enrolment, CD4 
count (<100, 100-249, >250) at ART initiation, and CD4 count at infection (<350,350-
499,>500) during follow-up on malaria using random effects Poisson regression to 
account for multiple episodes within participant.   
 
Results  
2180 participants were enrolled into the COSTOP trial. The incidence of clinical malaria 
was approximately 4 episodes/100pyrs in the CTX arm and 14 episodes/100pyrs in the 
placebo arm, and did not depend on CD4 count at ART initiation, enrolment or during 
follow up. When compared with participants in the lowest CD4 stratum, rate ratios within 
each trial arm were all close to 1, and P-values were all above P=0.30. There was no 
evidence that parasitemia levels differed by CD4 count at infection (P=0.24).  There was 
no effect of CD4 on severe malaria (P=0.14).   
 
 Conclusion  
The immune status of HIV infected participants who are stable on ART as measured by 
CD4 count was not associated with malaria incidence and did not modify the effect of 
stopping CTX on malaria. The decision of whether to stop or continue CTX prophylaxis 
for malaria in HIV infected individuals who are stable on ART should not be based on 
CD4 counts alone.  
 
Key words 
Malaria, CD4, antiretroviral therapy, cotrimoxazole, HIV 
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Introduction 
In many parts of sub-Saharan Africa (SSA), both malaria and HIV infection are highly 
endemic.  HIV infection enhances malaria acquisition and severity, similarly malaria 
enhances HIV viral replication (1-5).  The effect of HIV infection on malaria incidence 
seems to be a consequence of the immune suppression that is a characteristic of HIV 
infection (6). In clinical practice CD4+ cell counts are used to measure the degree of 
HIV induced immune suppression which guides decisions on antiretroviral therapy 
(ART) and the need for prophylaxis against opportunistic infections (7, 8).  
Decreasing CD4 counts have been associated with higher risk of acquiring malaria. In a 
study in rural Uganda, HIV infected adults with CD4 counts <200 cells/µl had 6.1 
(CI=2.1-17.5) times the risk of clinical malaria compared to those with CD4 counts ≥500 
(P=0.002) (9). A study among HIV infected adults in Entebbe, Uganda found that the 
incidence of clinical malaria due to Plasmodium falciparum increased with decreasing 
CD4 count; 57, 93, 140 cases per 1000 person years (pyrs) for CD4 counts >500, 200-
499, <200 and respectively (P<0.001).(10)   Both studies were in ART naïve individuals. 
Once viral replication is suppressed by ART, CD4 counts increase over time (11, 12).  
Consequently it may be expected that the risk of malaria will decrease as individuals’ 
CD4 counts increase. However, it is unclear whether this effect continues once the 
immune system has recovered under ART, or whether there is a CD4 threshold after 
which malaria incidence stabilizes.  
 
In order to address these research questions, we conducted a sub-analysis of data 
collected during the recently completed COSTOP trial in Uganda (13-15). These data 
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also provide an opportunity to investigate whether the effect of CD4 count on malaria 
incidence differs between individuals on ART who take prophylactic cotrimoxazole 
(CTX) medication and those who are not on CTX. It is well known that CTX is beneficial 
to HIV infected individuals as a prophylaxis against malaria and bacterial infections (16-
18)  even when individuals are on ART (19-21), and CTX is recommended for routine 
use in areas in which malaria is highly prevalent (8).   
 
Aim 
The study aimed to determine among HIV infected adults on ART with CD4 counts ≥250 
cells/µl:       
(i) the effect of CD4 count on malaria incidence  
(ii) whether this effect differs in the presence and absence of CTX medication 
 
Methods 
This study used data gathered during the COSTOP trial conducted from 2011 to 2014 in 
Uganda (ISRCTN44723643). Trial methods have been described previously (13, 15).  
Briefly, COSTOP was a randomized, double-blind, placebo controlled non-inferiority trial 
to determine whether long-term prophylaxis with CTX can be safely discontinued among 
HIV infected adults on ART with sustained immune competence (defined as a confirmed 
CD4 counts of ≥250 cells/µl). Individuals were eligible for enrolment if they were HIV-
infected; aged 18 years or older; clinically asymptomatic; had been taking CTX and ART 
for at least 6 months; and had 2 CD4 counts (not more than 6 months apart) ≥250 cells/ 
µl, the most recent no more than 4 weeks prior to enrolment. Exclusion criteria included 
Page 86
 
 
pregnancy, grade 3 or 4 anemia, neutropenia or thrombocytopenia. Participants were 
randomized to receive either active CTX (960 mg) or matching placebo once daily after 
stopping their regular CTX medication. Randomization was stratified by enrolment site 
(Entebbe or Masaka, both located in SW Uganda) and CD4 count (≥250-499 and ≥500 
cells/µl).   
 
Study procedures 
Informed consent for study procedures was obtained at screening and enrolment. 
At screening, data were documented on; disease history, duration of prior ART and CTX 
medication, and CD4 count at time of ART initiation. At enrolment, data were 
documented on socio-demographic characteristics and each participant was provided 
with an insecticide-treated bed net (ITN) and educated about the importance of using it. 
Participants were seen at scheduled follow-up visits every month for the first three 
months and three-monthly thereafter, and were followed for 12 months to 3.5 years, 
depending on date of enrolment. At these visits, participants were asked about their 
health, symptoms suggestive of malaria, adherence to medication and bednet use. 
Blood samples were drawn; at enrolment, monthly for three months and three monthly 
thereafter for a malaria slide; at 3 months, 6 months and 6 monthly thereafter for CD4 
count; and three monthly for the full blood count. Participants were asked to attend the 
study clinic at any time they felt unwell; if malaria was suspected, based on a history of 
malaria associated symptoms (fever, headache, chills and rigors, joint aches, muscles 
aches, vomiting or diarrhea), a blood slide and other tests deemed necessary were 
done. Participants who reported having been treated for malaria elsewhere (for example 
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during a journey) were asked to present documentary evidence of diagnoses and test 
results. 
 
Laboratory methods 
A sample of blood was taken either from the fingertip using a lancet or from a peripheral 
vein using a syringe, and used to prepare thick and thin films on a glass slide. The 
specimens were processed using Leishman’s stain and examined by microscopy. Thick 
film specimens were used to record the number of parasites per 200 white blood cells 
and thin films to identify the plasmodium species. Venous blood samples were taken for 
CD4 cell counts and measured using a FACS-count system (Becton-Dickinson San 
Jose) at the MRC/UVRI laboratories in Entebbe and Masaka. 
 
Statistical analysis  
Analyses were carried out using Stata 13.  Clinical malaria was defined as presence or 
history (during the previous 2 weeks) of fever and microscopically confirmed malaria 
parasites. Severe malaria (based on WHO guidelines) (15, 22) was diagnosed if a 
participant had P. falciparum asexual parasitemia, no other obvious cause of symptoms 
and met any of the following criteria: convulsions, loss of consciousness, hypotension 
(systolic blood pressure <70 mmHg), admission to hospital due to malaria, laboratory 
evidence of liver or kidney damage, severe normocytic anaemia (haemoglobin <50g/dl, 
PCV<15%), or hyperparasitemia on blood slide (>5% or 250,000/µl). 
 
The CD4 count at enrolment was calculated from the mean of the two most recent pre-
enrolment (screening) CD4 counts. Person years at risk were calculated from enrolment 
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until the date last seen or end of trial.  After each malaria episode, participants were 
considered to be not at risk for another episode until the episode resolved, or for 28 
days, if a resolution date was not available. Follow-up data were organized into intervals 
corresponding with the visit schedule.  For time-varying variables during follow-up (e.g. 
CD4 count at malaria infection, BMI) we used the most recent value measured at the 
start of each interval. CD4 count values were carried forward for the visits where CD4 
counts were not done, until the next recorded CD4 count.  
 
First, we assessed the effect of current (time of infection) CD4 count on clinical malaria 
incidence during follow up, using random effects Poisson regression to account for the 
clustering of multiple episodes within the same participant. The analysis was restricted 
to participants in the placebo arm in order to examine the effect of CD4 counts in the 
absence of the anti-malaria effects of CTX.  We examined the effect of CD4 adjusted for 
baseline covariates that were considered as potential confounders a priori (enrolment 
site, age, sex, socioeconomic status (SES) and baseline CD4 count), and then including 
time-varying variables (time since enrolment, current BMI).  SES was measured by 
combining baseline data from all trial participants on housing construction and 
ownership of household items into an asset index score using principal component 
analysis (23). In order to allow for non-linear effects, CD4 at infection, baseline CD4 and 
age were modelled using restricted cubic splines with 4 knots; this approach provides a 
flexible way to model the shape of the relationship of a continuous variable with the 
outcome (24).   
 
Page 89
 
 
Among participants with clinical malaria, we assessed the effect of CD4 count at 
infection on parasitemia during each malaria episode as the outcome, using random 
effects linear regression; parasitemia levels were log transformed for analysis.  The 
analysis was adjusted for baseline and time-varying potential confounders as described 
above.  In addition, we assessed whether CD4 count at infection had an effect on 
severe malaria; since there were only 15 episodes of severe malaria (13 placebo, 2 on 
CTX) (15), we did not attempt to adjust for potential confounders.   
 
Secondly, we assessed whether the effect of CD4 count at baseline, CD4 count at ART 
initiation, or CD4 count at infection on clinical malaria differed by treatment arm (CTX or 
placebo), using random effects Poisson regression. Regression models contained fixed 
effects for CD4 count group, treatment arm, enrolment site and year since enrolment, 
and an interaction term between CD4 count group and treatment arm.  
 
Ethical approval 
Approval for the COSTOP trial was obtained from the Science and Ethics Committee of 
the Uganda Virus Research Institute, the Uganda National Council of Science and 
Technology, and the Ugandan National Drug Authority. Approval for this sub-analysis 
was obtained from the COSTOP Trial Steering Committee and the Ethics Committee of 
the London School of Hygiene and Tropical Medicine. 
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Results  
2180 participants were enrolled into the COSTOP trial, 1002 (46%) at the Entebbe site, 
and 1091 (50%) were allocated to placebo (stopping CTX).  Baseline characteristics 
were well balanced between trial arms (Supplementary Table 1).  Mean age at 
enrolment was 41 years and 74% were female. The median (IQR) CD4 count at ART 
initiation was 155 (89-199) and 159 (83-214) for Entebbe and Masaka, respectively, and 
the median (IQR) CD4 count at enrolment was 446 (361-600) and 519 (397-655), 
respectively.  At the Entebbe site, 56 (5.7%) participants were on a protease inhibitor 
(PI)-containing regimen compared to 30 (2.6%) at Masaka.  239 (24%) participants in 
Entebbe and 220 (19%) in Masaka site had been on ART for <2years. 
 
Effect of CD4 on malaria 
Among participants in the placebo arm, overall clinical malaria incidence was 14.1/100 
person-years (95%CI=12.5-15.8). There was no evidence of an effect of CD4 count at 
infection on clinical malaria (P=0.56; Table 1; Figure 1).  Furthermore, there was no 
evidence that parasitemia levels differed by CD4 count at infection (P=0.24 from 
random effects linear regression model; Figure 2). 
 
There were 15 cases of severe malaria (13 placebo, 2 CTX). Severe malaria rates 
decreased with increasing CD4 counts among participants with CD4<400, then 
remained fairly similar in participants with higher CD4 counts.  (P=0.14; Supplementary 
figure 1).   
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Effect of CD4 count on malaria by trial arm 
The incidence of malaria did not differ significantly between CD4 count strata, neither 
for CD4 count at infection, CD4 count at ART initiation or CD4 count at enrolment into 
the study, and this was irrespective of whether participants were in the CTX arm or the 
placebo arm of the trial.  Although malaria incidence was significantly lower in the CTX 
arm than on placebo (15), compared to participants on the lowest CD4 stratum, rate 
ratios were all close to 1 and P-values were all above P=0.30 for each of the three CD4 
measures and within each arm.(Table 2).  
 
Discussion  
Previous studies in HIV-infected adults have reported an increase in malaria incidence 
with decreasing CD4 counts (9, 10) but these studies were in individuals who were not 
on ART.   
 
We have previously reported that the incidence of clinical malaria in our study 
population was lower in participants on CTX than on placebo, and reduced during follow 
up (15). This reduction over time was primarily driven by reduced incidence in the 
placebo arm while incidence in the CTX arm remained fairly constant. One possible 
explanation is that the immune system recovers in individuals on ART and is therefore 
able to more effectively control malaria infection. In the COSTOP trial, there was 
evidence of continued recovery of the immune system in HIV-infected participants who 
are stable on ART as shown by an increase in CD4 counts over time, particularly in 
participants on placebo (14). However we did not find evidence of the expected 
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association between CD4 count and the incidence of clinical malaria, or degree of 
parasitemia. This lack of an effect of CD4 count on malaria was observed for CD4 count 
at the time of starting ART (considered a measure of the extent of immune damage 
before starting ART), time of randomization (indicating the immune status at beginning 
of study) and time of malaria episode. These are surprising findings. One possible 
explanation is that all participants in the COSTOP trial had a CD4 count >250 cells/µl at 
enrolment, so participants may have been above the threshold below which CD4 count 
significantly influences the risk of malaria. An alternative explanation could be that an 
improvement of CD4 cell quality rather than quantity under ART may be important for 
malaria containment (25). We found no evidence of an effect of CD4 count on severe 
malaria; however, because there were so few cases of severe malaria, our power to 
detect significant associations was poor.  
 
Strengths and limitations of the study 
This study made use of a well-documented data set from a large trial of HIV-infected 
adults on ART. The large sample size and the regular collection of data on exposures 
(CD4 count), outcomes (clinical malaria and parasitemia) and a variety of potential 
confounders allowed us to investigate the research questions in great detail.  
 
Our study had some limitations. In spite of the large sample size only a small number of 
severe malaria episodes occurred which limited the power to detect a potential effect of 
CD4 count. Also, the study was not a priori designed to address detailed research 
questions related to malaria, but rather was conducted as a sub-analysis of data 
Page 93
 
 
gathered in the context of a randomized trial on the effect of stopping CTX. Although we 
adjusted for some potential confounders, we cannot rule out residual confounding as a 
result of imperfectly measured covariates for which we adjusted (e.g. SES) or 
covariates which we did not measure. Furthermore, we did not measure viral load, 
which may be a better indicator of immune competence than CD4 count: it has been 
shown that effective viral suppression reduces the incidence of opportunistic infections 
(26) and a similar effect might be expected for clinical malaria. Lastly, we were not able 
to investigate the immune responses to malaria which might have provided insight into 
why CD4 counts had no apparent effect on malaria incidence.  
 
Conclusion 
In this study of HIV-infected individuals on ART with baseline CD4 counts ≥250 cells/µl, 
the incidence of clinical malaria and the intensity of parasitaemia among patients with 
clinical malaria were not influenced by CD4 counts at ART initiation, enrolment into the 
study, or at the time of malaria infection. The finding of no association between malaria 
and CD4 count was similar among participants randomized to stop prophylactic CTX 
and those who continued CTX.  The decision of whether to stop or continue CTX 
prophylaxis for malaria in HIV infected patients who are stable on ART should not be 
based on a patient’s CD4 cell count alone. 
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Figure 1 a and b: 
Association of malaria incidence rate ratios (and 95% confidence intervals) with CD4 count at 
time of malaria episode as observed during follow up, modelled using restricted cubic splines 
with 4 knots in a random effects Poisson regression model, unadjusted (a), and adjusted for 
covariates during baseline and follow up (b).  A CD4 count of 200 was used as the reference to 
calculate the rate ratios.  
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Figure 2:  Parasite counts by CD4 count at infection among participants in the placebo arm 
with clinical malaria.  The central line represents the median; boxes represent 75th and 25th 
centiles; whiskers represent upper and lower adjacent values and dots represent outside 
values. 
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Table 1: Association of CD4 count (at infection) with malaria in the placebo arm  
 
Median 
value 
Rate/100 person yrs 
(95% CI) 1 
Crude rate 
ratio (95% CI)1 
Adjusted rate 
ratio (95% CI) 1,2 
Adjusted rate 
ratio (95% CI) 1,3 
CD4 count at infection4 
Clinical malaria 
  P=0.60 P=0.81 P=0.56 
<300 262 14.6 (11.2-19.0) 1 1 1 
300-399 355 13.4 (11.0-16.3) 0.9 (0.7-1.1) 0.9 (0.7-1.2) 0.9 (0.7-1.2) 
400-499 448 13.1 (11.1-15.5) 0.9 (0.7-1.2) 0.9 (0.7-1.2) 0.9 (0.6-1.3) 
500-599 547 13.5 (11.5-15.9) 0.9 (0.7-1.3) 0.9 (0.6-1.3) 0.9 (0.6-1.4) 
600-699 644 14.2 (11.7-17.1) 1.0 (0.7-1.4) 0.9 (0.6-1.5) 1.0 (0.6-1.6) 
≥700 836 15.5 (12.7-19.0) 1.1 (0.8-1.5) 1.0 (0.6-1.7) 1.2 (0.7-1.9) 
Baseline factors 
Site   P<0.001 P<0.001 P=0.002 
Entebbe  10.6 (8.8-12.8) 1 1 1 
Masaka  17.2 (14.9-19.9) 1.6 (1.3-2.1) 1.5 (1.2-1.9) 1.5 (1.1-1.9) 
Age4   P=0.07 P=0.04 P=0.04 
<35 years 31 12.4 (10.0-15.2) 1  1 1 
35-44 years 39 15.1 (12.8-17.9) 1.2 (1.0-1.5) 1.2 (1.0-1.5) 1.2 (1.0-1.5) 
≥45 years 50 14.0 (11.5-17.1) 1.1 (0.8-1.5) 1.1 (0.8-1.4) 1.1 (0.8-1.5) 
Sex   P=0.83 P=0.46 P=0.63 
Male  14.4 (11.4-18.1) 1 1 1 
Female  13.9 (12.2-16.0) 1.0 (0.7-1.3) 0.9 (0.7-1.2) 0.9 (0.7-1.2) 
SES   P<0.001 P=0.002 P=0.003 
Low  16.1 (13.6-19.0) 1.8 (1.3-2.4) 1.7 (1.3-2.4) 1.7 (1.2-2.3) 
Middle  15.7 (12.8-19.1) 1.7 (1.2-2.4) 1.6 (1.1-2.2) 1.6 (1.1-2.2) 
High  9.0 (6.9-11.8) 1 1 1 
Baseline CD4 count4  P=0.63 P=0.88 P=0.98 
<350 310 13.3 (10.4-16.9) 1 1 1 
350-499 422 13.1 (10.7-16.1) 1.0 (0.7-1.3) 1.0 (0.7-1.3) 1.0 (0.7-1.4) 
≥500 634 14.7 (12.1-18.0) 1.1 (0.8-1.5) 1.0 (0.8-1.4) 1.0 (0.6-1.5) 
Factors during follow-up 
Time since enrolment  P<0.001  P<0.001 
<1 year  17.3 (14.8-20.1) 1.9 (1.4-2.6)  1.9 (1.4-2.7) 
1-2 years  13.1 (10.8-15.7) 1.4 (1.0-2.0)  1.5 (1.0-2.1) 
≥2 years    9.0 (6.7-12.1) 1  1 
BMI (kg/m2)   P=0.01  P=0.02 
<18.5  10.0 (6.9-14.4) 0.6 (0.4-0.9)  0.6 (0.4-0.9) 
18-24.9  15.8 (13.8-18.1) 1  1 
≥25   11.6 (8.9-15.0) 0.7 (0.5-1.0)  0.8 (0.6-1.0) 
Bednet use   P=0.05  P=0.14 
≥90% of visits  13.2 (11.6-15.1) 1  1 
<90% of visits  17.5 (13.7-22.3) 1.3 (1.0-1.7)  1.2 (0.9-1.6) 
1Rates and rate ratios estimated from random effects Poisson regression.   2Adjusted for enrolment site, age at 
enrolment, sex, SES and baseline CD4 count. 3Adjusted for all covariates in footnote 2, and time since enrolment, 
current BMI and bednet use.  4Continuous covariates (CD4 count and age) were modelled by restricted cubic 
splines with 4 knots.  Rates are estimated at the median value in each range; the median value in the lowest 
range is used as the reference to estimate the rate ratios.  P-value is for overall association with covariate from 
likelihood ratio test. 
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Table 2: Effect of trial drug on malaria, by CD4 count at enrolment, ART initiation and at the 
time of malaria episode  
Trial arm Stratum  Episodes Person 
years 
Rate/100pyrs 
(95% CI) 1 
Rate ratio2 P-
value3 
CD4 count at ART initiation 
CTX <100 30 698 4.0 (2.8-5.9) 1 0.99 
 100-249 59 1461 3.9 (3.0-5.1) 1.0 (0.6-1.5)  
 250+ 10 229 3.9 (2.0-7.4) 1.0 (0.5-2.0)  
Placebo <100 92 709 12.4 (9.8-15.7) 1 0.73 
 100-249 196 1458 13.4 (11.4-15.7) 1.1 (0.8-1.4)  
 250+ 36 212 14.7 (10.1-21.5) 1.2 (0.8-1.9)  
CD4 count at enrolment 
CTX <350 14 416 3.5 (2.0-5.9) 1 0.51 
 350-499 32 900 3.4 (2.4-4.8) 1.0 (0.5-1.9)  
 500+ 57 1234 4.3 (3.3-5.7) 1.3 (0.7-2.3)  
Placebo <350 58 453 13.1 (9.8-17.5) 1 0.98 
 350-499 117 850 13.6 (11.1-16.7) 1.0 (0.7-1.5)  
 500+ 175 1211 13.4 (11.3-16.0) 1.0 (0.7-1.4)  
CD4 count at infection 
CTX <350 21 4618 4.4 (2.9-6.9) 1 0.52 
 350-499 30 8811 3.3 (2.3-4.7) 0.7 (0.4-1.3)  
 500+ 52 1197 4.0 (3.0-5.4) 0.9 (0.5-1.5)  
Placebo <350 60 390 14.6 (11.1-19.2) 1 0.32 
 350-499 98 807 11.8 (9.5-14.6) 0.8 (0.6-1.1)  
 500+ 192 1317 14.1 (12.0-16.5) 1.0 (0.7-1.3)  
1Marginal means from random effects Poisson regression model with fixed effects for CD4 
count stratum, treatment arm and their interaction, and site and year since enrolment.  
2rate ratio for effect of treatment arm in each CD4 count stratum, adjusted for site and 
year since enrolment, from random effects Poisson regression model.  3P-values for 
overall association of CD4 count with malaria incidence within each treatment arm.  P-
values for interaction between CD4 count and treatment arm:  CD4 count at ART initiation 
P=0.87; CD4 count at enrolment P= 0.60; CD4 count at infection P=0.96. 
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Supplementary figure 1: Rate ratio and 95% confidence interval for change in incidence of 
severe malaria with CD4 count at infection during follow-up modelled using restricted cubic 
splines with 3 knots in a Poisson regression model (Note: no participant had more than one 
event so random effects not included). 
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Supplementary Table 1:  Baseline characteristics by trial arm and site 
 
Overall (N=2180) 
Site 
 Entebbe  Masaka 
 CTX 
(N=1089) 
Placebo  
(N=1091) 
CTX 
(N=501) 
Placebo 
(N=501) 
Total  
(N=1002) 
CTX 
(N=588) 
Placebo 
(N=590) 
Total  
(N=1178) 
Age          
Mean (SD) 41.0 (8.0) 40.7 (8.3) 40.2 (7.9) 39.9 (8.1) 40.1 (8.0) 41.7 (8.1) 41.3 (8.5) 41.5 (8.3) 
Sex          
Male  286 (26.3) 283 (25.9) 130 (26.0) 125 (25.0) 255 (25.5) 156 (26.5) 158 (26.8) 314 (26.7) 
Female  803 (73.7) 808 (74.1) 371 (74.0) 376 (75.0) 747 (74.6) 432 (73.5) 432 (73.2) 864 (73.3) 
Socio-economic status        
Low  486 (44.6) 474 (43.4) 197(39.3) 213 (42.5) 410(40.9) 289 (49.1) 261 (44.2) 550 (46.7) 
Medium  318 (29.2) 329 (30.2) 117 (23.4) 113 (22.6) 230(23.0) 201 (34.2) 216 (36.6) 417 (35.4) 
High  285 (26.2) 288 (26.4) 187 (37.3) 175 (33.9) 362(36.1) 98 (16.7) 113 (19.2) 211 (17.9) 
CD4 count at enrolment        
<350 181 (16.6) 201 (18.4) 110 (22.0) 110 (22.0) 220 (22.0) 71 (12.1) 91 (15.4) 162 (13.8) 
350-499 394 (36.2) 371 (34.0) 182 (36.3) 189 (37.7) 371 (37.0) 212 (36.1) 182 (30.8) 394 (33.4) 
≥ 500 514 (47.2) 519 (47.6) 209 (41.7) 202 (40.3) 411 (41.0) 305 (51.9) 317 (53.7) 622 (52.8) 
ART regimen at enrolment1        
NNRTI 1021 (95.1) 1025 (94.9) 4532 (92.6) 449 (91.5) 902 (92.0) 568 (97.1) 576 (97.8) 1144 (97.4) 
NRTI  11 (1.0) 11 (1.0) 11 (2.3) 11 (2.2) 22 (2.2) 0 0 0 
PI 42 (3.9) 44 (4.1) 25 (5.1) 31 (6.3) 56 (5.7) 17 (2.9) 13 (2.2) 30 (2.6) 
Years on ART1         
< 1  73 (6.7) 82 (7.5) 46 (9.2) 43 (8.6) 89 (8.9) 27 (4.6) 39 (6.6) 66 (5.6) 
1 to 2 144 (13.2) 160 (14.7) 71 (14.2) 79 (15.8) 150 (15.0) 73 (12.4) 81 (13.7) 154 (13.1) 
2 to 5 508 (46.7) 480 (44.0) 261 (52.0) 255 (50.9) 516 (51.5) 247 (42.0) 225 (38.2) 472 (40.1) 
>5 364 (33.4) 369 (33.8) 123 (24.6) 124 (24.7) 247 (24.6) 241 (41.0) 245 (41.5) 486 (41.3) 
CD4 count at ART initiation2        
<100 292 (28.7) 310 (30.2) 135 (28.8) 139 (28.5) 274 (28.6) 157 (28.7) 171 (31.7) 328 (30.1) 
100-249 619 (60.9) 621 (60.4) 296 (63.1) 314 (64.3) 610 (63.7) 323 (58.9) 307 (56.8) 630 (57.9) 
≥ 250 106 (10.4) 97 (9.4) 38 (8.1) 35 (7.2) 73 (7.6) 68 (12.4) 62 (11.5) 130 (12.0) 
1Missing data on ART regimen at enrolment for 26 participants (15 on CTX and 11 on placebo). 2Missing data on CD4 count at ART initiation for 
135 participants, 72 on CTX and 63 on placebo.  
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2 London School of Hygiene and Tropical Medicine, London, UK 
3 School of Public Health, University of Witwatersrand, Johannesburg, South Africa 
4 MRC Clinical Trials Unit at University College London, UK 
 
Abstract 
Introduction 
Using the data of a trial on cotrimoxazole cessation (COSTOP), we investigated the 
effect of different ART regimens on the incidence of clinical malaria. 
 
Methods 
During the COSTOP trial (ISRCTN44723643), HIV-infected Ugandan adults who had 
a CD4 count of ≥250 cells/µl were randomised to receive either cotrimoxazole (CTX) 
prophylaxis or matching placebo and were followed for a median of 2.5 years. Blood 
slides for malaria microscopy were examined at enrolment, monthly for the first three 
months and three-monthly thereafter. Malaria was defined as fever with a positive 
blood slide. ART regimens were categorized as nucleoside reverse transcriptase 
inhibitor (NRTI)-only, non-nucleoside reverse transcriptase inhibitor (NNRTI)-
containing or protease inhibitor (PI)–containing. The incidence of malaria was 
calculated using random effects Poisson regression to account for clustering of 
events.  
 
Results 
Malaria incidence in the 3 ART regimen groups was 9.3 (8.3-10.4), 9.9 (3.6-27.4) 
and 3.5 (1.6-7.6) per 100 person-years (pyrs), respectively. Incidence in the PI group 
was significantly lower than that in the other groups (adjusted RR 0.4, 95%CI=0.2-
1.0, comparing with NNRTI-regimens). Stratification by CTX/placebo use gave 
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similar results, without evidence of an interaction between the effects of 
CTX/placebo use and ART regimen.  
 
Conclusion 
PI-containing ART regimens were associated with a lower incidence of clinical 
malaria compared to NNRTI-containing or NRTI-only regimens and this effect was 
not modified by cotrimoxazole use. This observation may be of importance when 
selecting ART regimens for patients from malaria endemic areas.  
 
Short title: Effect of ART regimen on malaria  
 
Key words: Malaria, HIV, antiretroviral therapy, cotrimoxazole 
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Introduction 
Antiretroviral therapy (ART) is used to control HIV replication in infected patients (1, 
2). In addition, some ART drugs, particularly protease inhibitors (PIs), have shown 
anti-malaria properties in vitro (3-5) and among children (6, 7). However, a study of 
HIV infected adult women found no beneficial effect of lopinavir/ritonavir compared to 
nevirapine (NVP) on the incidence of malaria (8). Other studies on PI use in the 
general adult population are lacking. 
 
Cotrimoxazole (CTX), a broad spectrum antimicrobial agent, is routinely used to 
prevent opportunistic infections and malaria in HIV infected patients (9). Its use in 
HIV infected patients who are stable on ART was recently evaluated in the 
(COSTOP trial; ISRCTN44723643), a placebo controlled trial to investigate the 
safety of stopping CTX among adults who are stable on ART (10, 11). In the study 
presented here, we used the COSTOP trial data set to assess whether malaria 
incidence differed between participants receiving different ART regimens and 
whether any such effects were modified by CTX use.  
 
Methods 
This study was conducted among participants enrolled in the COSTOP trial at two 
sites in Uganda (ISRCTN44723643). The trial has been described previously (10, 
11). In brief, this randomized, double-blind, placebo controlled non-inferiority trial 
was conducted between 2011 and 2014 to determine whether long-term prophylaxis 
with CTX can be safely discontinued among HIV infected adults on ART with CD4 
counts ≥250 cells/µl. Participants were randomised to receive either CTX or placebo. 
At enrolment, eligible participants were aged 18 years or older and clinically 
asymptomatic.   
 
Participants were followed-up every month for the first three months and three-
monthly thereafter, for 12 months to 3.5 years, depending on date of enrolment. 
Participants were encouraged to return also if they felt unwell. At enrolment 
participants were provided with an insecticide-treated bed net (ITN) and educated 
about the importance of using it. Blood samples were drawn at all visits for malaria 
microscopy, and for CD4 count, and full blood count at routine visits.  Participants 
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who had been treated for malaria elsewhere (for example, during a journey) were 
asked to present documentary evidence of diagnoses and test results.   
 
Information on participants’ ART regimens at ART initiation and at enrolment was 
obtained from the records of the 2 NGOs and 4 hospitals in the study area that 
provided ART and from where participants were recruited. During the trial, 
participants continued to receive ART from their usual providers, but trial staff 
ensured an uninterrupted supply of ART in case of unexpected shortages. Most 
participants were on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
containing regimen (the recommended first line regimen in Uganda) (12). Some 
participants were on a 1st line nucleoside reverse transcriptase inhibitor (NRTI)-only 
regimen of zidovudine/lamivudine/tenofovir (13). A few participants were on PI-
containing regimens, which is the recommended second-line therapy (12).  
.  
Blood samples were used to prepare thick and thin films on a glass slide. The 
specimens were processed using Leishman’s stain and examined by microscopy. 
Venous blood samples were taken for CD4 cell counts and measured using a FACS-
count system (Becton-Dickinson, San Jose, USA). 
 
Analysis 
Data were double-entered and verified in MS Access and analyzed using Stata 
statistical software (release 13, College Station, Texas StataCorp LP). 
Person years (pyrs) at risk were calculated from enrolment until the date last seen or 
end of trial.  After each malaria episode, participants were considered to be not at 
risk for another episode until the episode resolved, or for 28 days, if a resolution date 
was not available. The incidence of malaria and rate ratios comparing ART regimens 
were calculated using random effects Poisson regression to account for multiple 
episodes within the same participant.  Since we have previously shown that malaria 
incidence varied between enrolment sites and over time (10), models were adjusted 
for treatment arm (CTX or placebo), enrolment site, and time since enrolment as a-
priori confounders.  ART regimens were categorized as follows: NRTI only, if a 
regimen containing only NRTIs was used; NNRTI containing, if one of the drugs was 
an NNRTI and none was a PI; or PI containing, if at least one drug was a PI. ART 
regimen was analysed as a time-updated exposure, to take into account participants 
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who switched regimens during follow-up. The effect of ART regimen on malaria 
incidence was examined overall and separately for both treatment arms (CTX and 
placebo groups); stratified rate ratios were obtained from a model containing a term 
for interaction between treatment arm and ART regimen. 
 
Results 
Baseline characteristics have been described previously (10). Briefly; 2180 
participants were enrolled into the trial; with 1002 and 1178 at each site respectively. 
Half (1089) were randomised to CTX, 382 (18%) had a CD4 count between 250 and 
350 cells/µl, and 569 (26%) participants were male. 1721 (79%) participants had 
been on ART for 2 years or more. At the time of ART initiation, 2114 (97%) were 
started on an NNRTI-containing regimen, 58 (3%) on an NRTI-only regimen and 3 
on a PI-containing regimen; data were missing for 5 participants. At enrolment, 2046 
(94%) were on an NNRTI containing regimen, 22 (1%) on an NRTI-only regimen and 
86 (4%) were on a PI- containing regimen; for 26 participants (1%) enrolment ART 
information was missing. Of those on a PI-containing regimen; 75 (87%) were on 
lopinavir/ritonavir, 4 (5%) on atanazavir and 7 (8%) on another PI.  10 participants 
changed ART regimen during follow-up (9 NNRTI-containing, 1 NRTI-only); all 
changes were to a PI-containing regimen. Of the participants who changed to a PI 
during follow up; 6 changed to lopinavir/ritonavir, 3 to atanazavir and 1 to other PI.  
 
Effect of ART regimen 
2154 participants contributed data to the analysis; and 447 malaria episodes were 
observed in 4989 pyrs of follow up. 
 In the unadjusted analysis, malaria incidence was similar for participants on NRTI-
only compared to participants on the NNRTI-containing regimen, and was lower for 
participants on a PI regimen compared to participants on an NNRTI (Table). After 
adjustment for treatment arm, enrolment site and time since enrolment, malaria 
incidence among participants on an NRTI-only regimen was 1.6 (0.6-4.3) times 
higher than among those on an NNRTI-containing regimen, whilst that among 
participants on a PI-containing regimen was 0.4 (0.2-1.0) times lower (P=0.05; 
Table). 
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In the adjusted analysis stratified by treatment arm, malaria incidence among 
participants on an NRTI-only regimen was 1.5 (0.2-11.8) (CTX) and 1.6 (0.5-5.0) 
(placebo) times higher than those on an NNRTI-containing regimen, whilst that in 
participants on a PI-containing regimen was 0.5 (0.1-2.3) (CTX) and 0.4 (0.2-1.0) 
(placebo) times lower, respectively. There was no evidence of interaction between 
the effect of treatment arm and ART regimen (P=0.95; Table).  
 
Discussion 
PI- containing regimens are recommended as second line therapy in Uganda and 
elsewhere (12, 14) and were used by up to 4% of participants in this study. The most 
commonly used PI was lopinavir/ritonavir. 1% of participants were on an NRTI-only 
regimen, an alternative initial regimen recommended at the time (2, 15). 
 
We found that NRTI-only regimens provided the least protection against malaria 
followed by NNRTI-containing regimens. This is consistent with in vitro studies that 
showed no antimalarial activity from NRTIs and some activity from NNRTIs but at 
levels which were not achievable in-vivo  at standard dosing (3). A PI-containing 
regimen offered the strongest protection (RR 0.4; 95%CI=0.2-1.0, compared with 
NNRTI-containing regimens) and this is consistent with some of the previous studies 
(6, 7). The effect of PIs on malaria was not modified by CTX.  
 
These findings have potential public health implications. It has been suggested that 
the antimalarial prophylactic effect of PI-containing ART regimens could reduce the 
cost of care in malaria endemic countries due to  a potential reduction in malaria 
treatment costs (16), could help reduce the prevalence of malaria (17)  and could 
even contribute to malaria eradication because lopinavir  inhibits plasmodium 
falciparum liver stage parasites (18).  
 
Strength and Limitations 
Our study benefited from a well described study population that was followed for up 
to 3 years and routinely assessed for malaria.  However, whilst this offered an 
opportunity to investigate the effect of ART regimen on malaria, the COSTOP trial 
was not specifically designed to address this question. The number of patients in the 
different ART groups differed largely, limiting comparability between groups. Due to 
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the small number of participants on PIs, the observed protective effect just reached 
statistical significance, and therefore we cannot exclude the possibility that the 
effects might have occurred due to chance. Adherence to ART in our study 
population was high (10). However, as we did not determine viral load or serum 
levels of ART drugs during follow up, our findings may be subject to potential 
residual confounding resulting from differences in adherence between ART groups.  
 
Conclusion 
Among adult HIV infected individuals on ART medication, PI- containing ART 
regimens were associated with a reduced incidence of clinical malaria compared to 
NNRTI-containing or NRTI-only regimens. The anti-malarial properties of PIs may 
have clinical and public health importance.  
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Table: Incidence of malaria by ART regimen overall and stratified by treatment arm 
 ART regimen
1 Events  Person 
years 
Rate2  Rate ratio2  Rate ratio
2,3 
     P= 0.024 P=0.052,4 
 NNRTI containing 435 4737 9.3 (8.3-10.4) 1 1 
 NRTI only 5 50 9.9 (3.6-27.4) 1.1 (0.4-3.0) 1.6 (0.6-4.3) 
 PI containing 7 202 3.5 (1.6-7.6)  0.4 (0.2-0.8) 0.4 (0.2-1.0) 
Stratified 
analysis 
    P=0.925 P=0.955 
     P=0.626 P=0.646 
CTX NNRTI containing 97 2380 4.1 (3.3-5.0) 1 1 
 NRTI only 1 25 4.2 (0.5-32.1) 1.0 (0.1-8.0) 1.5 (0.2-11.8) 
 PI containing 2 100 2.0 (0.5-8.2) 0.5 (0.1-2.0) 0.5 (0.1-2.3) 
     P=0.076 P=0.116 
Placebo  NNRTI containing 338 2357 14.5 (12.9-16.4) 1 1 
 NRTI only 4 25 15.4 (4.9-48.0) 1.1 (0.3-3.3) 1.6 (0.5-5.0) 
 PI containing 5 102 5.0 (2.0-12.4) 0.3 (0.1-0.9) 0.4 (0.2-1.0) 
1
NNRTI containing was defined as a regimen that contained at least one NNRTI and no PI; NRTI only was defined as a regimen containing only NRTIs; 
PI containing was defined as a regimen in which at least one of the drugs was a PI.  
2
estimated from random effects Poisson regression. 
3
adjusted for 
treatment arm, site, and time since enrolment. 
4
P-value for effect of ART regimen, from likelihood ratio test (LRT). 
5
LRT for interaction between 
treatment arm and ART regimen.
6
P-value from the Wald test
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Chapter 8: Effect of cotrimoxazole on CD4 count (unpublished research result) 
 
8.1 Introduction 
CTX use is associated with haematological toxicity (1, 2). We assessed the effect of trial 
arm (active CTX versus placebo) on CD4 count. This analysis was done as part of the 
work in chapter 5.   However, it was not included in the submitted version of the paper 
because it was decided within the team of co-investigators to publish these findings in a 
separate future paper. I was encouraged though to include this analysis in the thesis. 
 
8.2 Methods 
The general methods have been described in chapter 2, but specifically for this 
analysis, the effect of trial arm on current CD4 count as the outcome was assessed 
using random effects linear regression. CD4 counts were log transformed for analysis. 
Models were adjusted for enrolment site, age, sex, baseline socioeconomic status 
(SES), time since enrolment, current BMI and current haemoglobin as a priori 
confounders. Continuous covariates were modelled using restricted cubic splines with 4 
knots.  
 
8.3 Results 
During follow up, CD4 count progressively increased from week 12 to week 144 
(P<0.001) (Figure 6; Table 4). This increase was significantly lower among participants 
allocated to continued CTX medication: the geometric mean CD4 during follow up in the 
CTX arm was 480 cells/µl vs.504 cells/µl on placebo (P<0.001). After adjusting for CD4 
count at baseline, participants in Masaka had a lower geometric mean CD4 count 
during follow up compared to those in Entebbe (P<0.001). There was strong evidence of 
interaction between enrolment site and treatment arm:  the increase in log CD4 counts 
on placebo was greater in Entebbe than in Masaka (0.07, 95%CI=0.05-0.09 vs 0.03, 
95%CI=0.01-0.05, respectively; P-value for interaction=0.004).  
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8.4 Discussion 
CTX has been shown to slow the rate of CD4 decline in individuals who are not on ART 
(3); however, in the COSTOP trial that enrolled individuals who were stable on ART, we 
found that participants on CTX had lower CD4 counts during follow up than those on 
placebo and that the further increase of CD4 counts over time (that continued as 
expected on ART) was lower in the CTX arm than in the placebo arm. This is consistent 
with observations made among HIV infected adults enrolled in the DART trial in Uganda 
and Zimbabwe (4). The most likely explanation for these observations is the known 
haematotoxic property of CTX (1, 2).  We also found a lower average CD4 count 
increase in participants on placebo at the Masaka site than in Entebbe. Participants at 
the Masaka site had lower social economic status (which could be associated with 
poorer nutrition) and a higher incidence of malaria compared to those at the Entebbe 
site, possibly as a result of increased environmental exposure (5), which may explain 
some of the difference in CD4 count response.  
 
The clinical implication of this observation at the individual level is not clear. At the 
population level, the negative effect of CTX seems to be outweighed by the benefits of 
CTX medication, at least in the COSTOP study population (6). 
 
In summary, prophylactic CTX medication in adults who are stable on ART is 
associated with lower CD4 counts and a reduced increase of CD4 counts over time, 
compared to individuals who do not take CTX. This is probably a result of the 
haematotoxic effects of CTX.  The overall benefits of CTX prophylaxis seem to justify 
CTX continuation.  Further research would be needed to determine whether there may 
be subgroups of HIV infected patients on ART who would fare better without CTX e.g. 
individuals with evidence of higher degrees of haematotoxic side effects due to ART. 
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Figure 6:  CD4 counts during follow-up, by treatment arm and enrolment site 
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Table 4:  Association between CD4 count and treatment arm, enrolment site and with 
time since enrolment 
 
Mean log CD4 
(95% CI) 1 
Geometric mean CD4 
(95% CI) 1 
Difference in log CD4  
(95% CI) 2 
Treatment arm 
   P<0.001 
CTX 6.17 (6.16, 6.19) 480 (475, 485) Reference 
Placebo 6.22 (6.21, 6.23) 504 (499, 509) 0.05 (0.03, 0.06) 
Enrolment site 
   P<0.001 
Entebbe 6.21 (6.20, 6.23) 500 (494, 506) Reference 
Masaka 6.18 (6.17, 6.19) 485 (480, 490) ‒0.03 (‒0.05, ‒0.01) 
Weeks since enrolment3 
   P<0.001 
0-12 6.17 (6.16, 6.18)  480 (475, 485) 0.005 (‒0.004, 0.01) 
12-24 6.17 (6.16, 6.18)  478 (473, 482) Reference 
24-48 6.18 (6.17, 6.19)  484 (479, 488) 0.01 (0.007, 0.02)  
48-96 6.23 (6.22, 6.24)  506 (502, 512) 0.06 (0.05, 0.07)  
96-144 6.26 (6.24, 6.28)  523 (515, 532) 0.09 (0.08, 0.11)  
1
marginal means from random effects linear regression model with fixed effects for treatment arm, 
enrolment site, baseline CD4 count, weeks since enrolment, age, sex, current BMI, current haemoglobin, 
and SES at enrolment.  Continuous covariates (baseline CD4 count, weeks since enrolment, age, and 
haemoglobin) modelled using restricted cubic splines with 4 knots.  
2
estimated from regression model in 
footnote 1.  
3
means are estimated at 12, 24, 48, 96 and 144 weeks, respectively; 24 weeks is used as the 
reference point for the calculation of the change in log CD4. 
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Chapter 9: Discussion  
 
9.1 Work that led to this PhD research 
Based on studies that showed a reduction in OI and malaria when CTX is used (1-5), 
CTX has been recommended and is routinely used for the prophylaxis of OI and malaria 
in ART naïve HIV-infected adults (6). Subsequently, it has also been widely used 
among patients receiving ART whether or not their health has improved. However, there 
has been inconclusive evidence as to whether, in patients whose immunity has 
recovered and are stable on ART, CTX could be stopped (7).  
 
The overall aim of this PhD was to investigate the effect of CTX on malaria incidence in 
HIV-infected adults who are stable on ART. To assess this association, I conducted a 
systematic review of the available literature and, using the opportunity provided by a 
randomised, placebo-controlled trial of CTX cessation (COSTOP); I examined the 
incidence of malaria and assessed the effect of CD4 count and of ART regimen on 
malaria by CTX use. 
 
The findings of the studies in this thesis should help improve our understanding of: 
 The effect of CTX on malaria in HIV-infected adults on ART; using a systematic 
review I found that there was limited literature on this effect, the majority of the 
reviewed studies found CTX use to be associated with reduced occurrence of 
malaria  
 The incidence of malaria in HIV-infected patients that are stable on ART once 
prophylactic CTX is stopped; using a placebo randomised controlled trial, I found 
that the incidence of malaria was higher in individuals who stopped CTX, 
however, the effect of stopping CTX was lower than reported by previous open-
label studies. 
 The antimalarial effect of ART regimen on malaria in adults and whether there is 
an interaction with CTX use; I found that malaria incidence was reduced among 
patients on a PI-containing regimen but this effect did not vary with CTX use 
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 The effect of CD4 count on malaria and whether it varies with CTX;  I found no 
evidence of an effect of CD4 count on malaria incidence irrespective of CTX use 
 
This chapter summarises the main findings, discusses the strengths and weaknesses of 
the work done, and provides an overview on on-going and future research and makes 
concluding remarks.  
 
9.2 Summary of results  
9.2.1 Systematic review 
I searched the literature using terms for HIV, malaria and CTX only (without a term for 
ART) to reduce the chances of missing relevant papers on the association between 
CTX and malaria in patients on ART. However I identified only 6 studies: 4 
observational studies and 2 randomised controlled trials (RCTs). Due to the diversity of 
the studies in the review, a meta-analysis to provide a point estimate of the effect of 
CTX on malaria in this population could not be done. Instead a qualitative synthesis of 
the selected studies was done, and the reviewed studies showed a trend towards a 
beneficial effect of CTX on malaria. The malaria in these studies was mostly mild. All 
reviewed studies were subject to bias and confounding. The RCTs were the only 
reviewed studies that were designed to investigate the association between CTX and 
malaria; however neither of them was blinded, and they were therefore prone to 
observer and reporting bias. I concluded that the current literature on the effect of CTX 
on malaria in patients on ART was limited in numbers, that the studies reviewed 
suffered from bias and confounding, and that their results were inconclusive. Also, the 
clinical relevance of malaria experienced by patients stable on ART who are not on CTX 
prophylaxis was not clear. 
 
9.2.2 Experimental work 
9.2.2.1 Incidence of malaria  
Analyses of data collected in the COSTOP trial showed that participants on ART who 
stopped prophylactic CTX experienced 3.5 (95%CI=2.7-4.4) times more clinical malaria 
episodes than those who continued and this is consistent with other studies that found 
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more malaria episodes in participants who are not on CTX prophylaxis (8-11). However 
the difference in our study was much smaller than that reported by other randomised 
trials in adults (Campbell et al. RR 32.5, 95%CI=8.6-275.0 (9) and Polyak et al. RR = 
33.0, 95%CI=4.5-241.0 (8)). It was similar to that reported by a study conducted in 
children (Bwakura-Dangarembizi et al. HR 2.2, 95%CI=1.5-3.3 (10)).  
 
The contrasting results between our trial and the other two trials among adults could 
have resulted from a difference in follow-up times. This would be the case if there was a 
higher incidence of malaria during the first few months after stopping CTX (rebound 
effect) followed by a reduction with time as patients' immune response to malaria 
improves with increased exposure to malaria after stopping CTX. The Campbell et al. 
study (9) had a follow-up of only 4 months and the authors hypothesized that the 
observed high incidence of malaria could have indeed been due to a rebound effect of 
malaria once CTX had been stopped. Our study had a median follow-up time of 2.5 
years and although clinical malaria incidence remained higher in the placebo arm, the 
difference between the arms was less in the third year (RR= 2.1, 95%CI=1.3-3.5) than 
in the first year (RR 3.6, 95%CI=2.6-5.0), P for interaction=0.10. Additionally, clinical 
malaria incidence in the placebo arm decreased from 17.3 per 100 pyrs in the first year 
to 9.0 per 100 pyrs after the second year (P for trend <0.001). In the Polyak et al. study 
(8) follow-up was for one year; malaria occurred throughout the study and authors did 
not find evidence of a rebound in the participants that discontinued CTX. It is, therefore, 
possible that some of the difference between our study and the others in adults was due 
to a difference in follow-up time although the evidence is inconclusive. 
 
Another possible explanation might be the smaller number of malaria episodes (55 and 
34, in the Campbell and Polyak studies respectively) compared to ours in which 453 
episodes were observed. The plausibility of this explanation follows from the fact that in 
our study, the site with fewer malaria episodes (146 in Entebbe versus 307 in Masaka), 
in both trial arms and over time, observed a larger effect of stopping CTX (RR=6.8, 
95%CI=4.1-11.1 versus RR=2.7, 95%CI=2.1-3.6, respectively), implying that the 
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number of episodes of malaria (which likely reflects the background prevalence of 
malaria) may play a role. 
 
Furthermore, the incidence of malaria among participants randomised to stop CTX in 
our study was similar to that in the Polyak study (14.1 versus 13.0 episodes/100pyrs, 
respectively), however the incidence among participants randomised to continue CTX 
was lower in the Polyak study (4.1 versus 0.4 episodes/100pyrs), suggesting that 
adherence to CTX might have been better in the open-label study. This would have 
been the case if being on open-label active drug acted as motivation for better 
adherence, as has been suggested elsewhere (12). Adherence in both trial arms of our 
study, as measured by pill counts and self-report, was very high. Therefore, differences 
in adherence to CTX are unlikely to explain the difference in the effect of stopping CTX 
between our study and the Polyak study. Ascertainment of CTX use is discussed further 
in subsection 9.3.1.3.  
 
Also, the observed differences in the effect of stopping CTX between our trial and the 
others in adults could have occurred if participants randomised to placebo took CTX 
from sources outside the study clinic. The results of exit interviews conducted at the end 
of the study suggest that this was not the case.  This is discussed in more detail in 
subsection 9.3.1.3.  
 
Importantly, our trial has been the only one so far that was double-blinded and placebo 
controlled.  Unblinded trials may have been subject to bias as the investigators may 
have diagnosed malaria less frequently in participants who continued CTX, and 
participants may have reported febrile episodes less often, if either felt that continuing 
CTX reduced the risk of malaria. This bias may further explain the greater effect 
reported in the Campbell and Polyak studies.  
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9.2.2.2 Effect of CD4 count  
We found evidence of continued recovery of the immune system in HIV-infected 
participants who are stable on ART as shown by an increase in CD4 counts over time, 
particularly in participants on placebo. However, we did not find evidence of the 
expected association between CD4 count and the incidence of clinical malaria, the 
degree of parasitaemia, or the incidence of severe malaria. This lack of an effect of CD4 
count on malaria was observed regardless of the timing of CD4 counts: we observed it 
for CD4 count examined at the time of starting ART (considered a measure of the 
immune damage before ART initiation), for CD4 count at time of randomisation 
(indicating the immune status at beginning of the study) and for CD4 count at time of 
malaria episode. One possible explanation is that since all participants in the COSTOP 
trial had a CD4 count >250 cells/µl at enrolment, they may have been above the 
threshold below which CD4 count may significantly influence the risk of malaria. An 
alternative explanation could be that an improvement of CD4 cell quality rather than 
quantity under ART may be important for malaria containment and that this 
improvement occurs early once patients are started on ART (13). The lack of an 
association between malaria incidence and CD4 count was similar among participants 
randomised to stop prophylactic CTX and those who continued CTX.  
 
 
9.2.2.3 Effect of ART regimen 
Another factor that could potentially affect the incidence of malaria in patients on ART 
and CTX is the ART regimen (7). PIs are reported to have antimalarial effects (14, 15). 
This class of drugs is mainly recommended for second-line therapy, in Uganda and 
elsewhere (16, 17). When comparing PI-containing regimens and NRTI-only regimens 
with NNRTI-containing regimens, we found that malaria incidence among participants 
on an NRTI-only regimen was 1.6 (95%CI=0.6-4.3) times higher than among those on 
an NNRTI-containing regimen, whilst that among participants on a PI-containing 
regimen was 0.4 (95%CI=0.2-1.0) times lower (P=0.05). This is consistent with previous 
studies (14, 18). The effect of PIs on malaria was not modified by CTX use (P=0.95). 
The observed protective effect just reached statistical significance, probably due to the 
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small number of participants on PIs (4% at enrolment, N=86), and therefore the 
possibility that the effects might have occurred due to chance cannot be excluded. 
Although trial arm allocation was adjusted for in the analysis, the comparison by ART 
regimen was not randomised and so the possibility of residual confounding cannot be 
ruled out. Furthermore, because most of the participants receiving a PI-containing 
regimen were on second-line therapy; the immunological condition of participants on 
such medication is likely to have been worse than that of participants who were not on a 
PI-containing regimen. It is, therefore, possible that the pharmacological effect of PIs on 
malaria is stronger than we observed.  
 
 
9.2.2.4 Non-malarial CTX preventable events and haematological adverse events 
In the main COSTOP analysis we found that stopping CTX was associated with a 
significant increase in CTX-preventable clinical events, but also with a decrease in 
grade 3 or 4 haematological adverse events (19). We also found that continued CTX 
use was associated with a slower rise in CD4 cell counts which is likely to be due to the 
haematological toxicity associated with CTX (20, 21). Other randomised studies 
investigating the effect of stopping CTX have reported 1.6 (1.1-2.4) times higher rate of 
hospitalization or death (10), 1.8 (95%=CI 1.3-2.4) higher incidence of diarrhoea (9), but 
one study found no statistically significant difference between trial arms with respect to 
the rates of diarrhoea and pneumonia IRR=1.4 (95%=CI 0.8-2.3) and IRR 1.4 (95%=CI 
0.5-3.8) respectively (8). Taken together, these results suggest that the advantages and 
disadvantages of continued CTX use have to be carefully weighed. 
 
The potential public health impact of stopping CTX should also be taken into account.by 
policy makers when developing guidelines for CTX use. When calculating the number of 
patients needed to treat (NNT) with CTX prophylaxis, we found that to prevent one CTX 
preventable infection, one clinical malaria episode and one episode of severe malaria 
the NNT was 113, 10, and 233 respectively. This suggests that, at least in areas of 
substantial malaria endemicity such as Southern Uganda, the main benefit of continued 
CTX prophylaxis is the prevention of mild malaria, whilst the prevention of more serious 
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outcomes is substantially more cost-intensive. Also, we did not have a comparison with 
HIV-uninfected individuals therefore it is not clear how malaria incidence in those who 
stopped CTX compares to that in HIV-uninfected immune competent people.  
 
9.2.2.5 Synthesis of results  
Our study findings suggest that the higher the malaria endemicity, the less effect 
stopping CTX prophylaxis has on malaria incidence. The reason for this is not clear, one 
possible explanation is that repeat exposure in areas of high malaria endemicity 
sharpens the immune response to malaria and therefore prophylaxis has less of an 
impact. The other possible explanation is that high malaria endemicity may lead to 
widespread CTX use, especially in areas with high HIV prevalence, leading to 
development of resistance to CTX (antifolate resistance) and hence reducing the impact 
of stopping CTX. We do not have data on antifolate resistance in our study areas; 
however, CTX has been shown to be effective even in areas where there is resistance 
(22).  
 
Another study finding is that among HIV-infected adults who are stable on ART, CD4 
count is not a good predictor of the risk of malaria and should not be used in deciding 
who should stop CTX prophylaxis. This finding also suggests that CD4 count might not 
be useful when deciding who to put on CTX prophylaxis among individuals who start 
ART with high CD4 counts as is the case with the new test and treat recommendations 
(23). Viral load has been shown to have predictive value for opportunistic infections (24, 
25). Therefore, viral load changes might give a better reflection of the immune status 
and better predict the risk of malaria among HIV-infected patients on ART. 
 
Also, our finding that PIs are associated with reduced malaria incidence may have 
implications for the treatment of HIV in adults. WHO recommends first-line regimens 
containing two NRTIs and one NNRTI. These regimens are generally less expensive 
than other regimens, have generic formulations, are often available as fixed-dose 
combinations, do not require a cold chain and preserve PIs for second-line (26). These 
benefits, in spite of the antimalarial benefits of PIs, should still make NNRTI-based 
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regimens the preferred choice for first-line, even in malaria endemic areas. However PI-
containing regimen should be considered for individuals, who might be particularly 
vulnerable for malaria for example non-immune migrants into a malaria endemic area, 
 
Finally, the effects of discontinuing CTX in HIV-infected patients on ART may be 
considered at individual and population level. At the individual level, as we found in our 
study, discontinuing CTX leads to a higher incidence of CTX preventable events, lower 
incidence haematological adverse events and higher rise in CD4 count, this should be 
useful in patient management, for example, CTX should be stopped in patients with 
poor CD4 count response or continued in individuals at high risk of malaria. At the 
population level, widespread use of CTX should result in lower prevalence of malaria 
due to its antimalarial properties and although CTX use is beneficial even in areas of 
widespread antifolate resistance (22), with continued large-scale use, the prevalence of 
antifolate resistance will most likely increase and eventually result in CTX losing most of 
its potency as an antimicrobial drug. 
 
9.3 Strengths and limitations 
 
9.3.1 Exposure ascertainment  
9.3.1.1 CD4 counts 
CD4 count at the time of starting ART was extracted from patients’ records that we 
obtained from their ART providers. Whilst we could not be sure that these records were 
accurate, they offered the best information possible to assess our patients’ immune 
status at that time. Of note, viral load is not measured in any routine HIV care 
programme in Uganda. CD4 count at enrolment was based on the average of two pre-
enrolment CD4 counts that had been done no more than 6 months apart, the most 
recent of which within 4 weeks of enrolment: this is likely to have been a good reflection 
of participants’ immune status at enrolment. During the course of the trial, participants’ 
CD4 counts were measured at 3 months and then 6-monthly. At the time of a malaria 
episode, the most recent CD4 count was used to reflect the immune status of a 
participant at that time with the assumption that this was still a good reflection of the 
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current situation. This assumption might not have been totally accurate. Any 
misclassification would have been non-differential, so would have biased the effect 
towards the null. However, analyses of the effect of CD4 count at enrolment and at ART 
start gave similar results, with RR very close to 1.  
 
 
9.3.1.2 ART regimen 
The ART regimen at start of treatment and any changes before joining the trial were 
recorded on case record forms from the ART providers’ records. Most of this information 
was readily available in their records and predictable because first-line ART was 
generally in line with the recommended national guidelines (17). Some participants had 
been involved in an earlier (completed) trial comparing antiretroviral therapy monitoring 
strategies (DART) at the Entebbe site and had been started on a triple nucleoside 
regimen (27), information on the history of these participants was easily accessible. Any 
ART changes either for toxicity or for treatment failure during follow-up were made by 
the ART provider and the ART provider and/or the patient informed the trial team of 
such changes.  Few participants (N=11, 0.5%) changed ART during follow-up and this is 
consistent with other studies (28). It is, therefore, unlikely that ART regimen was 
misclassified. There was also good adherence to ART as assessed by self-report. 
However, we did not monitor viral load during the trial or measure serum levels of ART 
drugs.  Assessment of the effect of ART regimen on malaria was not a randomised 
comparison; therefore our findings may be subject to potential residual confounding 
resulting from possible differences in adherence or other differences between ART 
groups. 
 
 
9.3.1.3 CTX 
There was a risk that any truly existing association between CTX use and malaria 
incidence might be diluted if patients allocated to active CTX did not take it or if those 
allocated to placebo took CTX from other sources. The placebo and active drug were 
similar in colour, size, and shape to reduce participant bias. Although some researchers 
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felt that there was a slight difference in taste between active drug and placebo, most 
participants were not aware of a difference, as suggested by the trial exit interviews 
described below. Through regular talks, participants were encouraged to adhere to the 
allocated trial drug. Adherence to trial drug was measured by pill count and self-report, 
both of which have limitations (29-31). Other ways of measuring adherence to trial drug 
were also explored: application of medication event monitoring system (MEMS) and a 
test to identify CTX metabolites in either blood or urine. Both methods proved to be too 
costly. However, at study exit, we retrospectively assessed drug adherence during the 
trial using two complementary approaches: a questionnaire was administered to all 
exiting participants (1993 respondents); and the MRC Unit’s social science team 
conducted individual qualitative (in-depth) interviews with a random selection of these 
participants. Both methods did not provide any evidence showing that adherence to trial 
medication had been seriously affected. For example, when asked about obtaining open 
label CTX from outside sources during the trial, only 92/1963 (4.7%) participants said 
they had done so (32). It is, therefore, unlikely that adherence problems had a 
significant effect on the results. 
 
All analyses were based on an intention to treat approach. However, only a few 
participants (1.6% in each arm) had stopped trial drug and switched to open label CTX; 
usually due to a participants’ CD4 count falling below 250 cells/µl, a level below which 
they were considered to be at an increased risk of OI. Also, for 79% and 76% of 
participants on CTX and placebo, respectively, adherence based on pill counts was 
>80% at each visit throughout the trial. Therefore, it is unlikely that an alternative on-
treatment analysis would have given substantially different results.  
 
 
9.3.2 Outcome ascertainment   
 
9.3.2.1 Clinical malaria  
Clinical malaria was defined as current fever or a recent history of fever combined with 
a positive malaria blood slide on microscopy, as is commonly used in other studies of 
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malaria (1, 22, 33). The personnel reading the slides comprised trained laboratory 
technicians working at the laboratories of the MRC/UVRI Uganda Research Unit on 
AIDS, located in Entebbe and Masaka. Microscopy is considered the gold standard for 
malaria diagnosis as it provides information on both the plasmodium species implicated 
and the level of parasitaemia (34), neither of which are available from serological tests. 
However, rapid diagnostic tests (RDTs) would have been of benefit as well because 
they are more sensitive at detecting plasmodium in blood than microscopy (35). 
However, doing both blood slides and RDTs would have significantly increased the 
costs of the study without much additional benefit, and was therefore not considered.  
 
When looking at malaria parasitaemia (with or without malaria-related symptoms), 
participants who had stopped prophylactic CTX were 2.8 (95%CI=2.3-3.4) times more 
likely to be diagnosed with malaria than those who continued. When any symptom 
(whether thought to be malaria-related or not) combined with a positive slide was used 
to suspect malaria, participants who stopped CTX had 3.2 (95%CI=2.6-4.0) times more 
malaria episodes than those who continued. So even with alternative definitions of 
malaria, participants that continued CTX had a lower disease incidence than those who 
stopped; and rate ratios were similar to those found for clinical malaria. 
 
9.3.2.2 Severe malaria 
A diagnosis of severe malaria was made if a patient had P. falciparum asexual 
parasitaemia, no other obvious cause of symptoms and met any of the following criteria: 
convulsions, loss of consciousness, hypotension (systolic blood pressure <70 mmHg), 
admission to hospital due to malaria, laboratory evidence of liver or kidney damage, 
severe normocytic anaemia (haemoglobin <50g/dl, PCV<15%), or hyperparasitaemia 
on blood slide (>5% or 250,000/µl). We did not proactively investigate all malaria 
episodes for severity by screening for end organ damage, as this would have been very 
costly, but participants with symptoms of severity were investigated further. In view of 
this approach it is possible that some cases of severe malaria were missed.  We also 
classified all malaria patients, irrespective of parasitaemia, that were admitted to 
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hospital as cases of severe malaria this may have led to misclassification of some 
cases of non-severe malaria.  
 
9.3.3 Blinding 
Our study was based on data from a double-blind placebo controlled trial: both the 
investigators and the participants were blinded to the allocated trial arm, which should 
have minimized reporter and observer bias. The intervention (CTX discontinuation) was 
individually randomised which resulted in a good balance of participants’ characteristics 
between trial arms at baseline with respect to likely confounders and also to unknown 
confounders.  
 
9.3.4 Sample size 
Our trial had a sample size of 2180 participants followed up for a median of 2.5 years; 
with this large sample size and long observation time it was sufficiently powered to 
detect any relevant differences in malaria incidence between the trial arms. 
 
9.3.5 Follow up 
Participants were seen every month for the first three months and three monthly 
thereafter and were also asked to come to the study clinics any time that they felt 
unwell. At scheduled visits participants were screened for malaria (and at sick visits 
when suspected to have malaria) and had their adherence to ART and trial drug 
assessed. This allowed us to capture any new malaria episodes and to regularly assess 
participant’s adherence to trial drug.  
 
9.3.6 Study retention 
Participant retention was high, with >85% completing follow-up and the loss to follow-up 
was balanced between trial arms: 10% versus 11% for CTX and placebo respectively. 
Our results are therefore unlikely to be biased due to differential loss to follow-up, which 
could have been the case if; for example, there were fewer events in the placebo arm 
because participants were lost due to illness, or fewer events in the CTX arm because 
participants on CTX were lost due to drug side effects. 
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 9.3.7 Generalisability 
Uganda has high to moderate levels of malaria endemicity (36). The results of this trial 
might not be generalizable to other parts of sub-Saharan Africa, especially with low 
intensity of malaria transmission.  
 
9.3.8 Malaria exposure 
Due to limited funding we were not able to use Global Positioning Systems to map 
participants’ residences in relation to ecological exposure to malaria, nor to use 
antibody or antigen tests to measure ecological exposure to malaria e.g. among 
residents of the surrounding communities. Therefore, differences in malaria incidence 
between sub-groups of trial participants could possibly have been due to differences in 
exposure. However, the randomized design of the trial that was stratified by enrolment 
site and its large sample size should have resulted in a balance in malaria exposure and 
other potential confounders across trial arms. This applies to the first objective of this 
study (incidence of malaria by trial arm), but the non-randomised comparisons (effect of 
CD4 count on malaria and effect of ART regimen on malaria) might have been subject 
to this limitation.  
 
9.3.9 Comparison with HIV-uninfected adults 
We do not have data on malaria incidence in HIV-uninfected individuals from our study 
area. Our study, like the other randomised trials on the effect of CTX on malaria in 
patients on ART, compared malaria incidence (most common infection in this population 
in malaria-endemic areas) in participants who stopped CTX to that in participants who 
continued CTX. CTX has antimalarial properties and it is expected that individuals on 
CTX prophylaxis will have fewer malaria episodes. Therefore, it is not clear how malaria 
incidence in those who stopped CTX compares to that in HIV-uninfected immune 
competent people. Malaria incidence may not genuinely differ between these two 
populations; and in that case the continued use of CTX for malaria prophylaxis in 
immune competent patients may be questionable.   
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9.4 On-going work and future research 
I am aware of only one on-going study in a malaria endemic setting that is investigating 
CTX discontinuation in HIV-infected adults that are stable on ART. In this trial 
(NCT01650558), the primary outcome is incidence of severe events (composite of 
death and WHO stage 3 and 4 illnesses), and secondary outcomes include incidence of 
detectable viral load, bacterial infections and malaria. The trial has three arms: i) 
continuing CTX, ii) discontinuing CTX (no placebo), and iii) discontinuing CTX and 
starting weekly chloroquine. The eligibility criteria include HIV-infected patients aged 18 
years and above, with CD4 count >250cells/µl and undetectable virus (<400 copies/ml).  
The purpose of this study is to determine if there is a benefit of taking CTX as 
prophylaxis among HIV positive adults with viral suppression and a good clinical 
response to ART. The study will enrol up to 1500 adults to be followed for 32 to 66 
months. This trial is an open-label trial and is, therefore, likely to be affected by 
reporting and observer bias. Nevertheless, it should shed light on the comparative 
effects of CTX and antimalarial drugs. In this context, the investigators state that they 
expect to determine whether among patients with successful viral suppression a 
classical anti-malarial prophylactic drug may be preferable over continued CTX 
medication (37). 
 
The trial will collect information on viral load every 6 months, and this will provide an 
opportunity to investigate whether the degree of viral suppression has an effect on 
malaria incidence and therefore might help interpret our own finding of a lack of effect of 
CD4 count level on malaria incidence. Results of this trial are expected in 2019.  
 
A number of questions remain unanswered and require further research: 
a) Do patients who stop CTX have a higher incidence of malaria than would be 
observed in HIV-uninfected people? 
b)  Are there groups which do not require CTX prophylaxis at all such as recently 
infected patients who start ART whilst their immune system is still undamaged? 
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c) As additional studies will be published, what is the point estimate (and its 95%-
confidence interval) of the effect of CTX prophylaxis on malaria in HIV-infected 
patients on ART in malaria endemic areas, based on a meta-analysis?  
 
9.5 Conclusion  
To date, the best approach to CTX use in HIV-infected adults living in areas that are 
endemic to malaria or that have a high bacterial disease burden is still not clear. One 
consideration is that HIV-infected patients may be regarded as a population that is 
particularly vulnerable to malaria as is the case with children, pregnant women or the 
elderly. The other is that continued CTX prophylaxis implies an additional pill burden, 
additional cost, an extra source of potential adverse drug events and a potentially 
unnecessary risk for the development of drug resistance in patients in whom CTX 
prophylaxis could possibly be stopped because their immune function has fully 
recovered, or who may not require CTX in the first place as their immune system may 
not have deteriorated. 
 
Our study (the first placebo controlled trial investigating this question) has shown that 
HIV-infected adults who are stable on ART and stop taking CTX experience malaria 
episodes (mostly uncomplicated) more frequently, that CD4 count has no effect on 
malaria incidence and that PI-based ART regimens reduce malaria. A potential decision 
to stop or continue CTX must of course take into account the main COSTOP trial results 
that have shown a clear benefit of continued CTX prophylaxis in reducing non-malarial 
CTX preventable infections, but on the other hand also showed a higher rate of 
haematological grade 3 or 4 adverse events among participants on continued CTX 
prophylaxis, as well as a slower increase of CD4 counts. Of note in this context is the 
fact that overall mortality among those who stopped and those who continued CTX 
medication was similar (19).  
 
Overall, our findings support the current WHO guidelines on CTX which state that CTX 
may be discontinued in some situations, but should be continued in countries with high 
endemicity of malaria and bacterial infections (38).  However, this decision is not 
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straightforward, as other factors such as cost at population level, and ART regimen and 
risk of toxicity at individual level should be considered. It should also be noted that 
because of the negative effect of CTX on CD4 count increase, an individual patient’s 
CD4 count alone might not be a sufficient criterion in guiding this decision. Further 
research might be useful in identifying groups that can safely stop CTX prophylaxis. 
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Appendix 1 
Events regarded as potentially preventable by cotrimoxazole medication 
WHO clinical stage 4 events of HIV infection 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Central nervous system toxoplasmosis 
Chronic isosporiasis 
Recurrent non-typhoidal salmonella bacteraemia 
 
WHO clinical stage 3 events of HIV infection 
Unexplained severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhoea for a duration of more than one month 
Unexplained persistent fever (above 37.6°C, intermittent or constant, for longer than 
one month) 
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis or bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
 
WHO clinical stage 2 events of HIV infection 
Moderate unexplained weight loss (<10% of presumed or measured body weight) 
Recurrent upper respiratory tract infections (sinusitis, tonsillitis, otitis media, laryngitis 
and pharyngitis) 
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Background 
Policy on Cotrimoxazole Preventive Therapy (CPT)  
adopted in resource limited settings  
follows WHO/UNAIDS recommendations  
 
Studies in Africa on ART naïve HIV +ve patients had  
demonstrated reduction in HIV-related mortality ranging from 
25-46%,  in hospitalization 21 – 53% and in malaria up to 72%. 
Other morbid events not characterized. 
 
Benefit for patients stable on ART remained to be determined 
Concerns: pill burden & haematological co-toxicity with ART 
 
In developed countries, primary CPT is not routinely practiced 
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Studies on CPT in ART treated populations 
Adults on ART for a mean of 3.7 years who discontinued CPT  
had a relative risk of malaria of 32.5 (95% CI 8.6–275.0)  
and of diarrhea of 1.8 (95% CI, 1.3–2.4)  
Campbell JD et al. CID 2012;54(8):1204-11 
 
Adults on ART who continued CPT had a reduction in Malaria IRR = 33.2 
no difference in pneumonia and diarrhea  
Polyak CS et al. CROI 2014. Oral Abstract 98 
 
ARROW trial, Children who stopped CPT after 96 weeks of ART had 
higher rates of hospitalisation/death HR=1.57, mainly due to malaria & 
bacterial RTI.  
Bwakura-Dangarembizi et al. NEJM 2014;370:41-53 
 
All of these were open-label trials 
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Objectives of COSTOP 
A placebo controlled trial to asses whether, 
in patients on ART with CD4 count  ≥250cells/mm³, 
discontinuation of CPT is 
 
•  not inferior to the control regimen in which CPT is continued  
•  superior with respect to the incidence of haematological 
adverse events 
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Study Design 
 
Minimum follow up 1 year - Maximum follow up 3 years 
                  
	  
2180 adults on ART for at least 6 months + daily CPT with confirmed sustained 
CD4 count ≥250 cells/mm3 and no contraindication to discontinuing CPT	  
	  
Randomised 1:1 
 
Active CTX 960 mg tablet daily 
Continue ART 
n = 1089 
 
 
Co-­‐	  Primary	  Endpoints	  
Time	  to	  ﬁrst	  CTX	  preventable	  event	  or	  Death	  -­‐	  Non	  inferiority	  if	  upper	  90%	  CI	  of	  HR<1.25	  
Grade	  3	  or	  4	  Haematological	  adverse	  event	  
 
Matching Placebo daily 
Continue ART 
n = 1091 
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Secondary endpoints 
 
•  Incidence of all CTX preventable events 
•  All cause mortality 
•  Incidence, severity & outcome of confirmed malaria episodes 
- asymptomatic & symptomatic 
•  Mean change in CD4 count & haematologic indices  
    - after 12 months on the trial 
 
•  Incidence of all hospitalisations & SAEs 
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Baseline Characteristics 
  
CTX  
(n=1089) 
Placebo 
(n=1091) 
Entebbe Site 46.0% 45.9% 
Masaka Site 54.0% 54.1% 
Females 73.7% 74.1% 
Age in years- Median (IQR) 41   (36-46) 40    (35-47) 
Months on ART - Median (IQR) 48   (27-66) 47    (26-65) 
CD4 cells/mm3 - Median IQR 518 (410-696) 519  (411-682) 
WHO Clinical Stage III 57.4% 57.6% 
WHO Clinical Stage IV 10.6% 9.7% 
Sleeps under an ITN  62.1% 63.6% 
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Results: ITT and PP populations 
ITT: all participants who took at least one dose of study medication  
and who had at least one follow-up assessment (no f/u in 5 participants) 
 
PP: participants whose  adherence assessed by pill count or self-report 
remained above 80% for each period between study visits 
Week	   CTX ITT  % retained	   Placebo ITT  % retained	   CTX PP  % retained	   Placebo PP  % retained	  
12	   98.3	   98.8	   90.4	   91.0	  
24	   97.5	   97.2	   88.2	   88.4	  
36	   96.0	   95.4	   85.6	   84.2	  
48	   94.4	   93.8	   82.1	   79.9	  
60	   91.3	   89.7	   77.8	   74.5	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Time to first CTX preventable event – PP population 
 
0.
85
0.
90
0.
95
1.
00
1091 929 830 695 567trtarm = Placebo
1089 948 871 756 631trtarm = Ctx
Number at risk
0 6 12 18 24
Months
trtarm = Ctx trtarm = Placebo
Pr
op
or
tio
n 
at
 r
is
k 
1089	   	  	  	  	  	  	  	  	  	  	  	  	  	  948	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  871	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  756	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  631	  1091	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  929	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  830	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  695	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  567	  	  	

Months from randomization    
CTX: 
Placebo: 
CTX arm 
39 events (1.84 / 100PY)  
59 events (2.94 / 100PY) 
Placebo arm 
   
aHR Placebo versus CTX = 1.57 [90% CI 1.12 -2.21]    
Number needed to treat for one year  to prevent 1 event = 113  
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CTX preventable events 
 
 
6 deaths were deemed CTX preventable 
Placebo arm   
1. Klebsiella pneumonia  
2. Septicaemic shock  
3. Diarrhoea of unknown cause 
4. KS with severe sepsis 
CTX arm  
1.  Malaria w quinine toxicity  
2. Pyogenic meningitis 
 
The most common CTX preventable events were:  
-  Bronchopneumonia (33 P ; 20 CTX) 
-  Recurrent Bacterial URTIs (4 P ; 5 CTX) 
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Months from randomisation 
1076        984        930         885        842        794       741         692        601      
1080        1043       988        945        904        837       765         723        643     	  CTX: Placebo: 
Placebo 
CTX 318 events ( 15.3 / 100 PY) 
233 events (10.6 / 100 PY) 
Time to first grade 3 / 4 haematological adverse event  
Log-rank chi-square = 18.1,  P<0.001 
aHR placebo vs CTX 0.70 [95% CI 0.59 ; 0.82] 
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Haematological adverse events 
 
•  Large number of grade 3 / 4 hematological adverse events  
Mainly grade 3 / 4 neutropenia 
•  Participants who experienced ≥ 1 grade 4 neutropenia  
      8.2 % in CTX arm vs 5% in the Placebo arm   
 
•  Number of participants with grade 4 anaemia  
    or grade 4 thrombocytopenia was very low & similar in two arms 
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Secondary endpoint: all cause mortality 
A total of 37 deaths, 6 were deemed CTX-preventable 
by ERC, while 31 not CTX-preventable 
 
 
 
 
CTX Placebo 
Number of deaths 19 18 
Stratified log-rank test  p = 0.91 
Page 156
Secondary endpoint: symptomatic malaria 
 
In total 362 (16.6%) participants experienced 453 episodes 
of symptomatic malaria (parasitaemia + fever) 
 
 
 
 
CTX Placebo 
Number of episodes  
of symptomatic malaria 
103 350 
Rate  4.1 / 100 PY 13.9 / 100 PY 
 
Log-rank chi-square = 137.3 ; P<0.001 
 
aHR placebo vs CTX 3.43 [95% CI 2.69 – 4.38] 
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Secondary endpoint: CD4 count at week 48 
 
    Adjusting for baseline CD4 count and study site,  
    CD4 count at week 48 was significantly higher  
    in placebo arm than in CTX arm (P<0.001) 
 
 
CTX Placebo 
Back-transformed adjusted  
mean CD4 count at 48 weeks 
469.5 cells/mm3 495 cells/mm3 
% participants with no increase 
in CD4 count at 48 weeks 
54.2% 45.7% 
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Secondary endpoint: hospitalisations 
146 participants had a total of 175 hospital admissions  
 
 
  CTX Placebo 
Number of 1st Hospital admissions 53 93 
Rate 2.1 / 100 PY 4 / 100 PY 
log rank chi-square = 12.36    P=0.0004 
aHR placebo versus CTX = 1.82  [ 95% CI  1.30 – 2.5 ] 
Reasons for admission 	   CTX Placebo 
Malaria	  related 13 34 
Anaemia 4 8 
Bacterial	  pneumonia 2 4 
Neutropenia 1 0 
Unknown	  cause	   9 5 
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Secondary endpoint: SAE’s 
155 SAE’s reported 
 
 
 
 
 
Time to 1st SAE: 122 participants had at least one SAE 
 
  CTX Placebo 
Total number of SAE’s reported  61 94 
Malaria related SAE’s 8 29 
Classified as “anaemia with clinical symptoms” 7 7 
  CTX Placebo 
Number with at least one SAE 47 75 
Rate 21.92 / 100 PY 3.18 / 100 PY 
log rank chi-square = 7.35    P=0.007 
aHR placebo versus CTX = 1.65  [ 95% CI  1.15 – 2.38 ] 
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Conclusion 
Discontinuing CPT: 
 
•  leads to a significant increase in CTX-preventable clinical 
events, mainly bacterial pneumonias 
•  significantly increases risk of Malaria and related 
hospitalisation 
•  is associated with a decrease in grade 3 / 4 haematological 
adverse events, mainly neutropenia 
•  has a small effect on change in CD4 counts on ART 
 
•  has no effect on all cause mortality 
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Implications 
 
•  Our results are in line with recently revised WHO 
guidelines on CPT in resource limited settings 
 
•  Number needed to treat with CPT (for one year)  
    is 113 to prevent one event  
 
    A cost effectiveness analysis is  pending  
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Introduction: Cotrimoxazole (CTX) prophylaxis is recommendedby theWorldHealthOrganisation for HIV infect-
ed persons. However, once HIV infected patients have commenced ART in resource limited settings, the beneﬁts
of continued CTX prophylaxis are not known. The few studies that investigated the safety of discontinuing CTX
prophylaxis in these settings had limitations due to their design.
Materials and methods: COSTOP is a randomised double blind placebo controlled non-inferiority trial among HIV
infected Ugandan adults stabilised on anti-retroviral treatment (ART). Participants with CD4 count of 250 or
more cells/mm3 are randomised to two arms: the intervention arm inwhich CTX is discontinued and the control
arm inwhich CTX prophylaxis is continued. The study aims to assesswhether the intervention regimen is not in-
ferior, with respect to the incidence of pre-deﬁned CTX-preventable events, to the control regimen and superior
with respect to the incidence of haematological adverse events.
Discussion: Studies that have previously evaluated the safety of discontinuing CTX prophylaxis amongHIV infect-
ed adults in resource limited settings have providedmoderate to low quality evidence owing in part to method-
ological limitations. COSTOP is designed and conductedwith sufﬁcient rigour to answer this question. The results
of the trial will assist in guiding policy recommendations.
Conclusion: This paper describes the design andmethodological considerations important for the conduct of CTX
cessation studies.
© 2015 Published by Elsevier Inc.
1. Introduction
The use of cotrimoxazole (CTX) as prophylaxis against opportunistic
infections among HIV-infected persons is part of the standard of care
recommended by the World Health Organisation (WHO) [1,2]. In re-
source limited settings, once HIV infected patients have commenced
ART, the beneﬁts of continued prophylactic CTX medication are not
known [1].
A fewstudies in resource limited settings [3–6] have investigated the
effect of providing prophylactic CTX versus no CTX among patients con-
currently takingART. All these studies had limitations in that either they
were observational [3], had small sample sizes [4,5] or followed partic-
ipants for short periods as reviewed by Suthar et al. [6]. This systematic
review also concluded that “cotrimoxazole signiﬁcantly increased sur-
vival in HIV infected adults on ART. Further research is needed to deter-
mine the optimum duration of CTX treatment in these patients”.
Campbell and colleagues carried out a trial in a home based care setting
in rural Eastern Uganda in which 836 patients who had been on ART for
a median time of 3.7 years and who had a CD4 count above 200 cells/μl
were randomised at household level to continue or discontinue CTX
prophylaxis in an open label design [7]. The trial was stopped at the rec-
ommendation of the DSMB following the occurrence of signiﬁcantly
higher rates of asymptomatic and symptomatic malaria in the group
which stopped CTX (RR = 27.7, 95% CI 6.8, 113.1, p b 0.001). There
was also a signiﬁcantly higher rate of self-reported diarrhoea, but no dif-
ference between the two arms in the incidence of AIDS-related opportu-
nistic infections and no deaths were reported. Recently, a study
conducted in Kisumu—Kenya compared the effect of CTX cessation ver-
sus continuation on a composite outcome of death, malaria, pneumonia
and diarrhoea among HIV infected adults stabilised on ART [8]. None of
these studies used a double-blind placebo controlled design.
A WHO Guideline Development Group on CTX Prophylaxis con-
vened in 2013 recommended the continuation of CTX prophylaxis
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amongpatients stable onART in settingswith severe bacterial infections
and high malaria prevalence; but that these guidelines should be
adapted to ‘national context’ [2]. There is still uncertainty within re-
source limited settings and further research is needed to provide evi-
dence based recommendations for or against stopping CTX. Garnering
high quality evidence requires studies with robust designs, methodo-
logical and ethical considerations.
In this paperwe present the design andmethods used in the conduct
of the CTX prophylaxis cessation trial amongHIV infected adults on ART
in Uganda (trial registration number: ISRCTN44723643).
2. Materials and methods
COSTOP is a randomised, double-blind, placebo controlled non-
inferiority trial amongHIV-infected adults inUganda that have been im-
munologically stabilised on ART. The objective of the study is to assess
whether, in patients with CD4 count of ≥250 cells/mm3, a regime in
which CTX prophylaxis is discontinued is:
(a) not inferior, with respect to the incidence of pre-deﬁned CTX-
preventable events to the control regimen in which prophylaxis
with CTX is continued and
(b) superior to continuing CTX prophylaxis with respect to reducing
the incidence of haematological adverse events.
The pre-deﬁnedCTX-preventable events (Table 1) are a subset of the
WHO-staging events, namely those that are deemed to be CTX-
preventable a priori.
2.1. Study setting and population
The study is being conducted in Uganda at theMRC/UVRI Unit clinics
in Entebbe andMasaka. Patients on long-term CTX and ART care are re-
cruited from local HIV treatment centres situated near-by.
The eligibility criteria used are as follows:
Inclusion criteria
❖ HIV-infected patientwith documented intake of CTX for at least
6 months;
❖ age of ≥18 years;
❖ documented intake of ART for at least 6 months;
❖ clinically asymptomatic;
❖ 2 CD4 counts (not more than 6 months apart) of ≥250 cells/
mm3, the most recent no more than 4 weeks prior to enrol-
ment; and
❖ able to attend study clinics at 3-monthly intervals and in
the event of intercurrent illness.
Exclusion criteria
❖ acute illness (opportunistic infection or other co-morbidity);
❖ ﬁrst trimester pregnancy;
❖ known hypersensitivity to cotrimoxazole; and
❖ grade 3/4 anaemia, neutropenia or thrombocytopenia.
2.2. Ethical approval
Ethical permissionwas obtained from theUganda Virus Research In-
stitute Research and Ethics Committee (UVRI REC), the Uganda National
Council for Science and Technology (UNCST) and the Ugandan National
Drug Regulatory Authority (NDA). The trial ismonitored by an Indepen-
dent Data Monitoring Committee (IDMC).
2.3. Intervention
All participants are required to stop their regular CTX after which
they are randomised to receive CTX tablets of 960mgor amatching pla-
cebo tablet. All participants continue to receive ART from their routine
providers. Trial medication is dispensed monthly for the ﬁrst three
months and three-monthly thereafter with a ﬁxed number of extra tab-
lets to allow for the possibility of late attendance. Participants are re-
quested to return their trial medication packs with any unused tablets
at scheduled clinic visits. Allocated trial treatment is discontinued in
the event of the following: conﬁrmed CD4 count drop to below
250 cells/mm3, participants' consent withdrawal and intercurrent
illness preventing further treatment with trial drug. No additional par-
ticipants are recruited to replace those withdrawn. Participants with-
drawn from trial treatment due to a conﬁrmed CD4 count drop to
below 250 cells/mm3 or due to consent withdrawal are prescribed
open label CTX. Follow-up of participants withdrawn from the study in-
tervention continue unless the participant explicitlywithdraws consent
for follow-up.
2.4. Study schedule
A summary of the study schedule of visits and procedures is shown
in Table 2. Participants are informed about the trial and provide in-
formed consent before screening by signing the informed consent
form. Illiterate participants sign by thumbprint in the presence of an in-
dependent literate witness.
At screening, potential participants are assessed for eligibility, socio-
demographic and behavioural characteristics, and for their medical his-
tory (including ART use and past WHO clinical stage events). A clinical
examination is conducted and Laboratory investigations include a full
blood count, malaria slide and CD4 count.
The enrolment visit takes place within 2 to 4 weeks of screening; el-
igibility is conﬁrmed and consent obtained for randomisation into the
trial. At enrolment and each follow-up visit, routine trial procedures
are performed as indicated in Table 2. Participants are seen monthly
for the ﬁrst three months and 3 monthly thereafter. All participants
are providedwith an insecticide treatedmosquito net (ITN) and educat-
ed about the importance of using it. Other medications and investiga-
tions are provided as required for the management of the participant's
reported disease condition. Participants are encouraged to report to
the study clinics whenever they fall sick. All adverse events (AE) are
Table 1
Cotrimoxazole preventable WHO staging events.
Cotrimoxazole preventable events
WHO clinical stage 4
Pneumocystis pneumonia
Recurrent severe bacterial pneumonia
Central nervous system toxoplasmosis
Chronic isosporiasis
Recurrent non-typhoidal salmonella bacteraemia
WHO clinical stage 3
Unexplained severe weight loss (N10% of presumed or measured body weight)
Unexplained chronic diarrhoea for longer than one month
Unexplained persistent fever (above 37.6 °C intermittent or constant, for longer
than one month)
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or
joint infection, meningitis or bacteraemia)
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
Unexplained anaemia (b8 g/dl), neutropaenia (b0.5 × 109 per litre)
or chronic thrombocytopaenia (b50 × 109 per litre)
WHO clinical stage 2
Moderate unexplained weight loss (b10% of presumed or measured body weight)
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media and
pharyngitis)
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assessed and appropriate management provided. Serious adverse
events (SAEs) are reported to the UVRI REC, UNCST and NDA.
2.5. Randomization and blinding
Participants are randomised in a ratio of 1:1 to stop or continue
CTX prophylaxis. The randomisation schedule was produced by an
independent statistician at the MRC/UVRI Unit using random per-
muted blocks of variable size with separate randomisations carried
out in four strata, deﬁned by the four possible combinations
of study site (Entebbe or Masaka) and baseline CD4 count
(250–499 cells/mm3 or ≥500 cells/mm3). Neither study staff nor
the endpoint review committee (ERC) members have access to the
randomisation schedule. Eligible participants details are entered by
the study clinician on the next available row of the enrolment regis-
ter in accordancewith their CD4 count. The trial number correspond-
ing to that row is used on all trial documents and to identify the pre-
labelled study medication.
2.6. Unblinding procedures
The randomisation codes are maintained by the independent trial
statistician and a copy is held by the trial pharmacist. Unblinding is dis-
couraged during treatment; if however, a trial clinician considers it nec-
essary for a participant's allocated treatment to be unblinded this is ﬁrst
discussed with the chief investigator. If unblinding is considered appro-
priate the reason for unblinding is recorded in the unblinding register
and an unblinding form is completed and sent to the independent stat-
istician, or in his absence to the pharmacist. The unblinding information
is disclosed to the attending clinician and is kept conﬁdential to other
study staff and is entered on the database.
2.7. Outcomes
There are two co-primary outcome measures: time to the ﬁrst CTX
preventable event (either one of the WHO staging events in Table 1 or
else a death adjudicated by the ERC to be CTX preventable), and time
to the ﬁrst grade 3 or 4 haematological adverse event. Secondary out-
come measures include the following: all-cause mortality; incidence
of all CTX preventable events, all clinical events and SAEs; incidence,
severity and outcome of all malaria episodes (asymptomatic and symp-
tomatic) conﬁrmed by positive parasitaemia on a blood slide; incidence
of grade 3 or 4 adverse events; mean change in CD4 and haematologic
indices after 12 months; adherence to use of ART, trial drug and ITN.
2.8. Assessment of adherence
Adherence to the use of trial drug, ART and ITN is assessed at every
scheduled and unscheduled visit using a standard adherence
questionnaire and by returned trial drug and ART pill counts. Adherence
counselling is given at every visit. An exit interview questionnaire will
be administered to capture the possible ingestion of CTX either from
supplies left over prior to enrolment or from sources outside the trial
during follow-up.
2.9. Sample size
Sample size calculations used the following assumptions: the rate of
CTX preventable events in the control arm would be 10 per 100 PYO,
based on an analysis of event rates from theDART trial [9] among partic-
ipants with conﬁrmed CD4 count above 250 cells/mm3; loss to follow-
up rate would be 4% per year; type I error of 0.05 (one-sided for non-
inferiority), the upper limit of the 95% conﬁdence interval for the hazard
ratio comparing the intervention armwith the control arm should be at
most 1.25 in order to demonstrate non-inferiority; power of 80% assum-
ing equal event rates in the two arms. Under these assumptions a total
of 2000 participants would be required, among whom a total of 494
CTX preventable events would be expected. For the co-primary safety
end-point a sample size of 1000 per arm would have over 80% power
to detect a halving in the rate of grade 3 or 4 haematological events at
the 5% level, assuming that at least 10% of those in the arm that con-
tinues to receive CTX prophylaxis experience such an event. The sample
size was estimated using the formula of Schoenfeld [10].
2.10. Trial oversight
The overall trial oversight is provided by the Trial Steering Commit-
tee (TSC). There is an unblinded Independent DataMonitoring Commit-
tee (IDMC) that meets six monthly and is responsible for reviewing
study recruitment targets, the safety and efﬁcacy endpoints and the
available external evidence from other related studies. The IDMC is
also responsible for advising the TSC onwhether to stop, amend or con-
tinue the trial as originally planned. The IDMC can recommend stopping
the trial if there is overwhelming evidence (as determined by the Peto–
Haybittle rule) [11,12] of a difference in the rate of CTX-preventable
events between the two arms.
2.11. Ascertainment of the primary endpoints
All potential primary endpoints are captured by the study clinicians
and adjudicated by the ERC. Haematological events (anaemia, neutro-
penia and thrombocytopenia) are assessed through scheduled laborato-
ry tests carried out in the MRC laboratories. Critical CD4 count
measurements (b250 cells/mm3) are conﬁrmed with a repeat test.
The DAIDS toxicity grading tables [13] are utilized to grade the severity
of the measured laboratory parameters.
Table 2
Summary of study schedule of visits and procedures.
Procedure Assessment time
Screening (weeks−2 to−4) Enrolment (week 0) Week 4 Week 8 Week 12 Week 24 Every 3 months after Every 6 months after
Consent for screening x
Consent for plasma storage x
Consent for enrolment x
History & physical examinationa x x x x x x x
CD4 countb x x x x x
Full blood count x x x x
Pregnancy testc x
Malaria slide x x x x x x
Adherence assessment x x x x x x
Study drug prescription/reﬁll x x x x x x
a Doctor assessment. Including a record of all clinical events and any adverse events since previous visit.
b CD4 counts at baseline, after ﬁrst three months, after 6 months and then 6 monthly thereafter.
c Pregnancy test in all women of reproductive age at screening. Thereafter, only in event of amenorrhea.
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2.12. Data management and quality assurance
Adatabase for the COSTOP trial is customdesigned inMSACCESS. All
CRFs are printed in duplicate and the data is double-entered and vali-
dated before being uploaded into the database. The data from the
Masaka site is transferred and merged with the main trial database in
Entebbe every two weeks. The monitoring of the trial to assess adher-
ence to the protocol, respect of participant rights and data quality is
done routinely by the MRC/UVRI Uganda Research Unit on AIDS moni-
tors and monitors from the East African Consortium for Clinical Re-
search (EACCR) and these are blinded to the treatment allocation.
2.13. Analysis plan
Two data sets will be used for analysis namely per protocol (PP) and
intention to treat (ITT) populations. The PP population will consist of all
subjectswhowere considered to have taken at least 80% of their blinded
study medication in each period between scheduled study visits. Study
participants will remain in the per protocol population as long as their
adherence as deﬁned above remains at 80% or higher, and will be
dropped from the PP data set at the visit at which their adherence dur-
ing that period drops to below 80%. Such patients will not re-enter the
PP data set. The ITT data set will consist of all subjects who took at
least one dose of blinded study medication and for whom there is at
least one follow-up assessment.
For the primary analysis of the ﬁrst co-primary endpoint, namely
time to ﬁrst CTX preventable event or death, the analysis will test for
non-inferiority (NI), hence the main analysis will be a per-protocol
(PP) analysis. An ITT analysis will also be done on this population as a
form of sensitivity analysis. For the primary analysis of the second co-
primary endpoint (time to ﬁrst haematological grade 3 or 4 adverse
event) and for all secondary endpoints, analysis will be carried out on
the ITT population.
For all time to event analyses, a subject will be considered to be part
of the trial until the subject experiences the event, or the trial ends, the
subject leaves the trial (due towithdrawal or loss to follow-up), the sub-
ject dies or in the case of the co-primary non-inferiority endpoint, the
subject no longer qualiﬁes for the per protocol population.
The comparative incidence of ﬁrst clinical events in the two study
arms will be illustrated graphically using Kaplan Meier plots. The inci-
dence rate in each arm will be estimated together with 95% conﬁdence
limits, since it is considered safe to stop CTX-prophylaxis if the event
rate in the experimental arm is sufﬁciently low (upper limit of 95%
conﬁdence interval is below 1 per 100 pyar), even if the formal non-
inferiority limit is not met. Non-inferiority will be tested by ﬁtting a
Cox proportional hazards regression model with terms for centre (En-
tebbe or Masaka), CD4 stratum (250–499 cells/mm3 vs. 500 or more
cells/mm3) and treatment arm and calculating the one sided 95% conﬁ-
dence limit for the hazard ratio for the experimental arm (stopping
CTX) relative to the control arm (continuing CTX). The experimental
arm will be deemed to be non-inferior to the control arm if the upper
limit of the conﬁdence interval is less than 1.25, that is, no more than
a 25% increased risk of an endpoint event on the placebo arm. In inves-
tigating whether stopping CTX prophylaxis is superior to continuing
CTX prophylaxis with respect to the safety endpoint of time to the
ﬁrst grade 3 or grade 4 haematological adverse events, an intention-
to-treat approach will be used.
The frequency of such events will be tabulated by treatment arm,
separately for neutropenia, anaemia and thrombocytopenia. Further
analyses will be carried out using survival analysis methods. The inci-
dence of grade 3 or grade 4 haematological adverse events will be illus-
trated graphically usingKaplanMeier plots. The primary analysiswill be
carried out bymeans of a log-rank test, stratiﬁed by the four randomiza-
tion strata deﬁned by the combinations of study site and CD4 stratum, to
compare the event rates between the two study arms. Further analysis
will be carried out by ﬁtting a Cox proportional hazard regression
model, with terms for site, CD4 stratum and treatment arm.
3. Discussion
The aim of COSTOP is to assesswhether CTXprophylaxis can be safe-
ly discontinued among HIV-infected African adults that have achieved
sustained immune reconstitution following initiation of ART in resource
limited settings. According to the recentWHOguidelines [2], completed
studies that have evaluated this concept have providedmoderate to low
quality evidence and the main reason for this is related in part to their
design.
Most clinical trials involving the use of drugs are ‘forward sighted’,
comparing a new drug to a standard, placebo or no treatment at all. In
a situation where stopping the standard treatment (intervention)
needs to be compared to the standard treatment itself (control), the
choice of study design and the methodological considerations to be
made can be quite challenging. A clear example in this case is the design
and conduct of CTX cessation studies.
In our study a non-inferiority designwas required since the goalwas
to determine whether withdrawing CTX would not disadvantage the
participant. The use of a matching placebo in the intervention arm in
which CTX is withdrawn is particularly important to avoid possible
biases associated with knowledge of whether the patient is receiving
prophylaxis. It would be very difﬁcult to maintain cessation of CTX pro-
phylaxis among patients randomised to do so in a setting where CTX is
readily and cheaply available and CTXwidely believed to be always ben-
eﬁcial. Adherence of participants to their allocated treatment arm is
clearly much easier if they are unaware of whether they are receiving
CTX or placebo. If either the investigators or the patients feel that
those allocated to placebo are disadvantaged, this may lead to differen-
tial reporting of events and even prematurewithdrawal of patients from
the trial. This could lead to failure to demonstrate non inferiority when
it actually exists (type II error). Without double blinding, both the pa-
tients and investigatorsmay perceive this to be true based on the previ-
ous evidence that HIV infected patients on ART who stop CTXmay be at
a higher risk of experiencing HIV-related mortality and morbidity [7]
while those continuing on CTXmay be at risk of adverse drug reactions.
The dose of CTX is maintained at 960mg daily as is the current prac-
tice since a reduction could result in increased event rates in the control
arm making it no longer a true control. Study drug and ART adherence
are strictly monitored as differential rates of adherence could lead to er-
roneous conclusions [14]. The primary outcome is a composite of mor-
bidity and mortality due to all CTX preventable WHO staging events.
The criteria developed by WHO for the diagnosis of these events is
based on both deﬁnitive and presumptive evidence by the clinician. In
this study, an Endpoint Review Committee is established to ensure pre-
cise ascertainment of endpoints based on the presumptive/deﬁnitive
WHO criteria [15]. Since some diagnoses based on this criterion involve
some degree of subjectivity, in the absence of the ERC, a high proportion
of incorrect diagnoses could add “noise” to the trial results and hence di-
minish the difference in the arms. All these design considerations are
necessary for the non-inferiority trial to be conducted with rigour and
avoid making false conclusions about the effectiveness of the interven-
tion [16].
We are aware of concerns that patients might have access to unused
supplies of CTX or be able to purchase CTX during the study. Ideally, ad-
herence to trial medicationwould be best assessed by serum level mea-
surements of CTX or its metabolites. However, there is no suitable
method that would only detect serum or urine levels of CTX or its me-
tabolites without being affected by other drugs that patients take. In
the absence of a suitable test it was decided to conduct end-of-trial in-
terviews by independent researchers in order to identify patients who
had possibly taken open label CTX at some time during the trial and
had correctly reported this to the trial team. If participants have such
access, non-inferiority might be inappropriately demonstrated.
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In conclusion, this paper describes the design and methods used in
the COSTOP trial highlighting some important aspects in designing
CTX cessation studies. It is expected that the design andmethodological
considerations will signiﬁcantly contribute to the quality of evidence
from this study.
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Incidence of malaria by cotrimoxazole use in HIV infected 
Ugandan adults on antiretroviral therapy: a randomized 
placebo controlled study 
 
         2180 participants enrolled; median follow-up 2.5 years.;453 malaria 
episodes recorded among 362 participants (range 1-5 episodes/participant).  
        Malaria incidence 9.1/100 person-years (pys) (95%CI=8.2-10.1); higher in 
participants on placebo RR=3.47 (CI=2.74-4.39).  
        Effect of stopping CTX similar by enrolment CD4 (≥250 to <500 versus 
≥500) (P=0.27 for interaction).  Malaria incidence in placebo arm reduced over 
time (from 17.3/100 pys in the first year to 9.0/100 pys after two years, 
P<0.001) ( Fig.2 and Table). Effect of stopping CTX reduced slightly with time 
(P=0.097 for interaction). Effect of stopping CTX greater in Entebbe compared 
to Masaka (P<0.001).  
       15 participants (13  on placebo) experienced severe malaria 
(<1%).;overall incidence of severe malaria 0.33/100 pys (CI=0.20-0.55). One 
malaria related death (CTX arm). 
Background 
Methods 
Results 
Discussion 
        Previous studies among HIV infected patients on antiretroviral therapy 
(ART) in Africa  have shown that malaria incidence increases when 
cotrimoxazole (CTX) prophylaxis is stopped1,2 ; however these trials were not 
blinded. Further research is needed on whether or not CTX should be continued 
long-term  in settings with high malaria endemicity. 
        Participants on ART who stopped  CTX had malaria 3.5 times more frequently than 
those who continued. The higher frequency is expected because of the antimalarial 
properties of CTX but has been significantly lower in this trial than in previous studies1,2.    
        The difference in malaria incidence between sites is probably due to higher 
exposure in Masaka where more rural residents were recruited than in Entebbe. The 
difference between sites in the effect of stopping CTX requires further investigation. Only 
1.2% of participants on placebo had severe malaria implying a need to review the 
necessity of continuous CTX prophylaxis to prevent malaria in ART treated individuals.  
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Study objective   
        To investigate the effect of stopping CTX on the  incidence and severity 
of malaria in HIV-infected  adults on ART in a placebo-controlled  trial 
(COSTOP-ISRCTN44723643). 
Figure 1: COSTOP trial site in Masaka 
Table: Malaria incidence by CD4 stratum, follow up time and site 
Figure 2: Malaria incidence during follow up by trial arm and site 
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          HIV-infected adults on ART and CTX with CD4 ≥250 cells/µl randomized 
(1:1) to continue CTX prophylaxis or receive matching placebo; randomisation 
stratified by CD4 count (<500 or 500+) and site (Entebbe & Masaka, Figure 1).  
        Participants followed monthly for the first 3 months and 3-monthly 
thereafter for 12-38 months.   
        Malaria defined as fever and positive blood slide; considered severe if 
participant had ≥1 clinical or laboratory feature of severity3, or were admitted to 
hospital for malaria.  
        Outcomes: overall rate of malaria, and rate ratios (RR) for the effect of 
treatment arm, estimated using random effects Poisson regression to account 
for correlation of repeated episodes within participant.  
  Trial arm Episodes Person-
years (pys) 
Rate/100 
pys 
Rate ratio 
(95% CI)  
 
Malaria incidence 
 
CTX 
 
103 
 
2540 
 
4.1 
 
1 
Placebo 350 2515 14.1 3.5 (2.5-4.4) 
Stratum specific            
 
CD4 count at 
enrolment 
          
<500 CTX 46 1322 3.5  1 
Placebo 178 1304 13.9 4.0 (2.8-5.6) 
≥500 CTX 57 1218 4.7  1 
Placebo 172 1210 14.3  3.1 (2.2-4.2) 
Follow up time           
1ST year  CTX 51 1065 4.8  1 
Placebo 183 1062 17.3 3.6 (2.6-5.0) 
2nd year   CTX 29 939 3.1  1 
Placebo 120 924 13.1 4.2 (2.8-6.4) 
After 2rd year   CTX 23 536 4.3  1 
Placebo 47 528 9.0  2.1 (1.3-3.5) 
Site            
Entebbe   CTX 19 1215 1.6  1 
Placebo 127 1209 10.6  6.8 (4.1-
11.1) 
Masaka   CTX 84 1325 6.3  1 
Placebo 223 1306 17.2  2.7 (2.1-3.6) 
Boundary adjustment was made when calculating the smoothed hazards for malaria incidence 
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Form 1
  COSTOPScreening questionnaire (part 1)
                                                           Centre: Entebbe  Masaka ❍
Date of screening D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
Has the patient been given an information sheet and has screening consent been obtained? Yes ❑   No ❑
If not please do so.
LABORATORY EVIDENCE OF HIV INFECTION
Date of positive HIV test D D M M M Y Y Y Y
If the patient does not have a positive HIV test on file take a serum sample for testing.
 ANTIRETROVIRAL HISTORY
Date of starting ART1. D D M M M Y Y Y Y
Regimen2.                                        /                                      /
Substitutions or switches3.  
Drug Dose Action Date of action Reason for action (see codes below )
Example Zidovudine 0 Stopped 15.01.10 Anaemia(08) 
1.  
2.
3.
4.
5.
6.
7.
8.
1= New or recurrent clinical 
WHO stage 3 or 4 event
2= CD4 count concerns
3= Intercurrent illness
4= Start of 2nd line regimen
5= Starting of salvage 
therapy
6= Restarting previous 
regimen after 
interruption
7= Pregnancy
8=Adverse event: 
name the event
9=Patient unable 
to attend ART 
clinic 
10=Voluntary patient decision (give 
details do not include adverse 
events)
11=Other (give details in table)
Current ART regimen:                      4.                                /                                    /  
Has the patient been on ART for at least 6 months? Yes 5. ❑   No ❑
(If no, patient will not be eligible for enrolment)
Where is the patient getting ART from? 6. 
Entebbe hospital   ❑ Masaka Hospital   ❑ TASO centre  ❑ Uganda Cares  ❑
Kitovu mobile       ❑ Other                   ❑ please specify  ……........…........……………..
Is the patient enrolled into any other antiretroviral therapy study? Yes 7. ❑   No ❑ 
(If yes, patient will not be eligible for enrolment)
COTRIMOXAZOLE USE
Does the patient have history of hypersensitivity to cotrimoxazole?                                              Yes 1. ❑   No ❑
(If yes, patient will not be eligible for enrolment into the study)
Has patient been on cotrimoxazole for at least 6 months?                                                            Yes 2. ❑   No ❑ 
(If not, patient will not be eligible for enrolment)
If yes, date started D D M M M 2 0 Y Y
CD4 COUNT HISTORY
What was the patient’s CD4 count at ART initiation?1.   ---------------------------  cells/mm3 not done ❑
Has the patient had CD4 count monitoring of their antiretroviral therapy?  Yes  2. ❑       No ❑
If yes, fill the table below
Date of most recent CD4 count Laboratory CD4 count
1.       D D   M M M     2 0 Y Y                       cells/mm3
2.       D D   M M M     2 0 Y Y                       cells/mm3
Please note; To be eligible for enrolment participant should have at least 2 CD4 counts > 250 cells/mm3. 
1st  CD4 count should not be more than 6 months prior to screening 
2nd (confirmatory) CD4 count must be done in MRC laboratory not > 4 weeks prior to enrolment.
CONCURRENT ILLNESSES /CONDITIONS
Does the patient have any other illnesses / conditions…….............................…. 1.  Yes  ❑       No ❑
If yes give summary below. (Details should be in the clinic notes)
Condition / illness Date of diagnosis (where available) Treatment 
1.
2.
3.
4.
(Patients with acute illness is ineligible for enrolment but may be considered after resolution of the illness)
 
Women only2. 
LNMPa. D D M M M 2 0 Y Y
Is the patient pregnant?b. Yes ❑ No ❑ post – menopausal ❑
Is the patient using any contraceptive method?c. Yes ❑ No ❑   (if the patient is pregnant mark no)
(Pregnant women in the 1st trimester are ineligible but may be re-evaluated after the 1st trimester) 
Doctor’s signature Print name Date
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Form 1
Screening questionnaire (part 2)
Date of screening D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
CLINICAL STAGING
WHO clinical staging (tick the events ever experienced by the patient)1. 
Stage 1
❑  Persistent generalised lymphadenopathy (PGL)
❑  Performance scale 1 (last month)
Stage 2
❑  Weight loss, less than 10% of body weight
❑ Minor mucocutaneous manifestations (seborrheic dermatitis, papular pruritic eruption)
❑ Fungal nail infections, recurrent oral ulcerations, angular cheilitis
❑ Herpes Zoster, within the last 5 years 
❑  Recurrent upper respiratory tract infections (e.g. bacterial sinusitis)
❑  Performance scale 2 (last month)
Stage 3
❑  Weight loss, greater than 10% of body weight                           
❑  Unexplained chronic diarrhoea, >1 month
❑  Unexplained prolonged fever (intermittent or constant), > 1 month
❑  Oral candidiasis (thrush)
❑  Oral hairy leukoplakia
❑  Pulmonary tuberculosis, within the past year
❑  Severe bacterial infections (e.g. pneumonia, pyomyositis)
❑  Unexplained anaemia (<8g/dl), neutropenia (<0.5 x 109 / l) or chronic (> 1 month thrombocytopenia (<50 x 109/l)
❑  Performance scale 3 (last month)
Stage 4
❑  HIV wasting syndrome
❑  Pneumocystis carinii pneumonia
❑  Recurrent bacterial pneumonia (this episode plus one or more episodes in last 6 months)
❑  Toxoplasmosis of the brain
❑  Cryptosporidiosis with diarrhoea, >1 month
❑  Chronic isosporiasis
❑  Cryptococcus, extra pulmonary
❑  Cytomegalovirus disease of an organ other than liver, spleen or lymph nodes
❑  Herpes Simplex Virus (HSV) infection, mucocutaneous >1 month, or visceral any duration
❑  Progressive multifocal leukoencephalopathy (PML)
❑  Any disseminated endemic mycosis (e.g. histoplasmosis, coccidioidomycosis)
❑  Candidiasis of the oesophagus, trachea, bronchi or lungs
❑  Atypical mycobacteriosis, disseminated
❑  Non-typhoid Salmonella septicaemia
❑  Extra Pulmonary tuberculosis
❑  Invasive cervical carcinoma
❑  Lymphoma
❑  Kaposi’s sarcoma (KS)
❑  HIV encephalopathy
❑  HIV- associated nephropathy
❑  HIV- associated cardiomyopathy
❑  Performance scale 4 (last month) 
Tick clinical stage as the maximum stage of events experienced by the patient: 
Clinical stage 1  ❑ 2  ❑ 3  ❑ 4  ❑
OTHER INCLUSION CRITERIA AT SCREENING
(For a patient to be eligible for enrolment, all answers must be in the shaded area)
a) Age 18 years and above………………………………………………………................……      Yes ❑          No ❑
b) Able to attend 3-monthly clinic follow-up visits………………...........….................………       Yes ❑         No ❑
c) Grade 3 or 4 anaemia, neutropenia or thrombocytopenia ……………….............…………        Yes ❑         No ❑
ELIGIBILTY  ASSESMENT
Is the patient potentially eligible for enrolment?                                                                       Yes ❑         No ❑
If yes, proceed with lab investigations and ask patient to return after 2 weeks
If no, inform the patient that they will not be eligible for enrolment at this time. Do not proceed with lab investigations.
LABORATORY INVESTIGATIONS
At this visit, a full blood count (hematology), CD4 count and if applicable a pregnancy test should be done. Also do 
any other tests required for detection and management of HIV related conditions. 
Trial scheduled investigations 
Hematology ……….................................… Yes ❑ No ❑
CD4 count ……….................................… Yes ❑  No ❑
Urine pregnancy test ……….................................… Yes ❑ No ❑ (For women)
Other investigations  
Blood slide for malaria ……….................................… Yes ❑ No ❑
Biochemistry ……….................................… Yes ❑ No ❑
Blood culture ……….................................… Yes ❑ No ❑
Sputum analysis ……….................................… Yes ❑ No ❑
Stool analysis ……….................................… Yes ❑ No ❑
Other microbiology ……….................................… Yes ❑ No ❑ (if yes, specify ….………….)
Chest X-ray ……….................................… Yes ❑ No ❑
Other tests (please specify) …………… ………………...……………………. 
        ………………………………....………………….
        …………………………………....……………….
Doctor’s signature Print name Date
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Form 3
  COSTOPEnrolment (nurse) questionnaire
COSTOP trial number
Date of enrolment D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
Has the patient been given an information sheet and has enrolment consent been obtained?  Yes ❑   No ❑
If not, please do so
SOCIO ECONOMIC STATUS
What is your religion?1. 
Protestant ❑ Catholic ❑ Muslim ❑ Seventh day Adventist ❑   
Pentecostal ❑ Traditional ❑	 No religion ❑ Other  ❑
What work do you usually spend most of your time doing?2. 
Farming ❑ Casual labour ❑	 House work ❑	 Fishing  ❑ Office job       ❑
Petty trading ❑		 Shop keeping ❑		 Student ❑
Other ❑	 	specify….....................................…………………
What is your typical monthly income from all sources (in Ugandan shillings)?3. 
Who contributes most for the regular house hold expenditures4. 
Self  ❑ Spouse ❑ Parent  ❑  Children  ❑  Brother / sister  ❑ Other  ❑
How many dependants do you support (include children and elderly)?5. 
Which of these items do you own or are found in your household? 6. 
(The item should be in working order)
House ❑ Car ❑ TV ❑ Radio ❑ Cooker ❑ Fridge ❑ 
Bicycle ❑ Motorcycle ❑ Phone ❑ Boat ❑ None of the above ❑
What is your house roof made of?7. 
Thatch ❑  Old iron sheets ❑ New iron sheets  ❑ Tiles   ❑
What is your highest level of education?8. 
None ❑ Primary  ❑	 Secondary   ❑	 University   ❑ Technical / vocational institution ❑
What is your marital status?9. 
Married monogamous  ❑  Married polygamous  ❑ Widowed   ❑ Divorced  ❑ Separated   ❑ 
Cohabiting  ❑  Single (never married)   ❑	 Other  ❑	          specify……....................………….
Do you have a casual or regular sexual partner? Yes  10. ❑   No  ❑
(If patient has a spouse or sexual partner, fill the table below, if not go to 11)
Partner
number 
Partner type 
1= Spouse
2= Regular
3= Casual 
Number of sexual 
encounters in the last 
month
1=None
2=4 or less
3=5 or more
Was a condom 
used at the 
last sexual 
encounter?
1=Yes
2=No 
Overall condom use 
with partner 
1 = Always
2 = Most times
3 = Sometimes
4 = Never
HIV status 
disclosure to 
partner
1 = yes
2 = No 
HIV status 
disclosure by 
partner
1 = yes
2 = No 
Have you disclosed your HIV status to anyone else other than spouse / sexual partner (where applicable)?11. 
Yes  ❑     No  ❑
If yes, to whom? (Mark all that apply)
Brother/Sister/Cousins ❑ Parents  ❑ Aunt/Uncle  ❑	 Own children  ❑ Employer  ❑ 
Friend / neighbor ❑	  Other; specify……….............…………………
How many biological children do you have? 12. 
Do you want to have more children? Yes  13. ❑    No  ❑ 
Are you using any family planning method? Yes  14. ❑    No  ❑
If yes, please specify (all methods you are using now). If no go to 15
Condom  ❑ Pill  ❑ IUD  ❑ Safe days  ❑ Injection  ❑ 
Implant   ❑ Vasectomy  ❑ BTL  ❑ Other  ❑ please specify………….....…….
Do you sleep under a mosquito net? Yes  15. ❑    No  ❑
 (If yes stop here)
If no, are you willing to sleep under an insecticide treated mosquito net once enrolled into the study and provided with 16. 
one?                        Yes  ❑   No  ❑
 (If yes stop here)
If the patient is not willing to sleep under an insecticide treated mosquito net, what is the reason? ...........................17. 
..............................................................................................................................................................
..............................................................................................................................................................
..............................................................................................................................................................
..............................................................................................................................................................
Nurse / Counselor’s signature Print name Date
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Form 4
  COSTOPEnrolment (doctor)
COSTOP trial number
Date of enrolment D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials    Male     Female 
HISTORY AND EXAMINATION
Weight . Kgs Height . cms
Blood pressure / mmhg Temperature . 0C
Performance status today (tick one box only)1. 
1 = asymptomatic, normal activity ❑
2 = symptomatic, normal activity ❑
3 = bedridden, <50% of the day during the last month ❑
4 = bedridden, >50% of the day during the last month ❑
Does the patient have any clinical symptoms? Yes 2. ❑    No ❑
(if yes please  fill the table below)
Symptom Yes No Symptom Yes No 
Eye itching / pain / discharge ❑ ❑ Cough ❑ ❑
Ear pain / discharge ❑ ❑ Difficulty in breathing ❑ ❑
Fatigue ❑ ❑ Muscle aches ❑ ❑
Fever or sweats ❑ ❑ Bone / joint aches ❑ ❑
Confusion ❑ ❑ Localized weakness of arms, legs or face ❑ ❑
Convulsions ❑ ❑ Numbness or tingling of hands and feet ❑ ❑
Severe headache ❑ ❑ Skin itching / new skin rash ❑ ❑
Nausea / vomiting ❑ ❑ Urinary symptoms ❑ ❑
Mouth sores / ulcers ❑ ❑ Genital itching / ulcers discharge ❑ ❑
Difficulty / pain on swallowing ❑ ❑ Possible pregnancy ❑ ❑
Diarrhea ❑ ❑ Other (specify below) ❑ ❑
Weight loss ❑ ❑ ……………….……………………
Please examine the patient and record any findings in the table below3. 
Any abnormal findings Yes No If yes, give details
Eyes ❑ ❑
Oral cavity ❑ ❑
Ear, nose, throat ❑ ❑
Skin, hair, nails ❑ ❑
Clinical anaemia  ❑ ❑
Lymph nodes ❑ ❑
Respiratory system ❑ ❑
Cardiovascular system ❑ ❑
Liver ❑ ❑
Spleen ❑ ❑
Rest of abdomen ❑ ❑
Nervous system ❑ ❑
Genital examination (if indicated) ❑ ❑
Other ❑ ❑
Is the patient on any long term medication?  Yes 4. ❑     No ❑
If so please record date started and indication (Should include primary and secondary prophylaxis and contraception).
Medication / drugs  Date started  Indication / reason 
i. D D M M M Y Y Y Y
ii. D D M M M Y Y Y Y
iii. D D M M M Y Y Y Y
ix. D D M M M Y Y Y Y
x. D D M M M Y Y Y Y
What was the patients WHO stage at screening?   WHO stage  (1 5. ❑ 2 ❑ 3 ❑ 4❑)
Does the patient have a new WHO clinical staging event at this visit?  Yes 6. ❑    No ❑ 
If so, give the name and stage of the event
Event name ………………………………………stage (1 ❑ 2 ❑ 3 ❑ 4❑)
Current clinical stage 1 7. ❑, 2 ❑, 3 ❑ or 4 ❑  (tick clinical stage as maximum stage patient has had)
Has any medication been prescribed today? If so give name and reason.8. 
Medication / Drug Reason Prescribed Date started
Trial drug  Enrolled onto study D D M M M 2 0 Y Y
D D M M M 2 0 Y Y
D D M M M 2 0 Y Y
D D M M M 2 0 Y Y
D D M M M 2 0 Y Y
LABORATORY INVESTIGATIONS (mark as appropriate)
(At this visit remember to take a blood sample for plasma storage – unless patient not consented)
Trial scheduled investigation
Plasma storage  ........................................ Yes ❑ No ❑
Blood slide for Malaria ........................................ Yes ❑ No ❑
Other investigations
Haematology ........................................ Yes ❑ No ❑
Biochemistry ........................................ Yes ❑ No ❑
CD4 count ........................................ Yes ❑  No ❑
Stool analysis ........................................ Yes ❑ No ❑
Sputum analysis ........................................ Yes ❑ No ❑
Blood culture ........................................ Yes ❑ No ❑
Other microbiology ........................................ Yes ❑ No ❑
Urine pregnancy test ........................................ Yes ❑ No ❑
X-ray ........................................ Yes ❑ No ❑
Other test (please specify)
Doctor’s signature Print name Date
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COSTOP
Enrolment consent
Centre: Entebbe   Masaka ❍
Date of consent D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
Please initial box if you agree
I have read/ been read the information sheet concerning the COSTOP Study and understand
what will be required of me if I take part in the study.
My questions concerning this study have been answered by:
.....................................................................................................
I understand that at any time, I may withdraw from this study without giving a reason and
without affecting my normal care and management.
I understand that I will have to continue taking my antiretroviral drugs plus either cotrimoxazole
(septrin) or placebo during the study.
I am willing to allow access to my medical notes to check that the trial is being carried out 
correctly but understand that strict confidentialitiy will be maintained.
I voluntarily agree to take part in the study.
Patient’s signature/ thumb print Name Date
Witness’ signature Name Date
Doctor’s signature Name Date
N.B: 3 copies: 1 for patient, 1 for researcher, 1 to be kept with clinic notes
CRF version 1.0. November. 2010 Page 1 of 1
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Form 5
               COSTOPRandomization
Date of 
randomization 
D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials    Male     Female 
ELIGIBILITY AND CONSENT
(The enrolment consent and enrolment nurse / doctor questionnaires should already have been filled)
Inclusion criteria
a) HIV-infected patient taking cotrimoxazole for at least 6 months…………….…………………… Yes ❑ No ❑ 
b) Age 18 years and above……………………………………………..............................………  Yes ❑  No ❑
c) Documented intake of ART for at least 6 months………………...............................………… Yes ❑  No ❑
d) Clinically asymptomatic…………………………………………….............................…………  Yes ❑ No ❑
e) 2 CD4 counts (not more than 6 months apart) ≥250 cells/mm3 the most recent no more than
 4 weeks prior to enrolment ……….................................................................................… Yes ❑ No ❑
(If so, specify the test dates and CD4 counts below)
Date of most recent CD4 test CD4 count (cells/mm3)
D D M M M 2 0 Y Y
D D M M M 2 0 Y Y
Exclusion criteria
a) Acute illness (opportunistic infection or other co- morbidity). Patients will be considered for inclusion into the 
trial after resolution of the illness……………………….....................................................…  Yes ❑  No ❑
b) Enrolled in other ART trial……………………………………………….............................……  Yes ❑  No ❑
c) First trimester pregnancy (when pregnant women reach their second trimester of pregnancy,
 they could then be re-evaluated for inclusion into the trial)…………...............................…… Yes ❑  No ❑
d) Unable to attend 3-monthly clinic follow-up visits………..............................………………… Yes ❑	 No ❑
e) Hypersensitivity to Cotrimoxazole…………………………………….................................…… Yes ❑  No ❑
f) Grade 3 or 4 anemia, neutropenia or thrombocytopenia…............................................……  Yes ❑  No ❑
If any answer is in the shaded area, patient is not eligible for enrolment.
Is the patient eligible for randomization? Yes ❑	 No ❑	
If patient is eligible, obtain the COSTOP trial number by entering the patient’s name on the next line of the 
appropriate enrolment register
RANDOMIZATION
COSTOP trial number
Randomized by (signature) Print name Date
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Form 6
  COSTOPAdherence
COSTOP trial number
Assessment date D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
This week’s visit number 
Visit type: Scheduled (on time) ❑ scheduled (early / late) ❑ Sick ❑	 Missed ❑ Unannounced home visit ❑
TRIAL DRUG ADHERENCE
(If patient is missing pills or has taken an overdose inform the doctor)
How many pills of trial drug has the patient returned?1. 
Has the patient taken trial drug more than once a day? Yes 2. ❑   No ❑
(If no, go to 3)
If yes, what was the reason ……………………………
Fill table below
Number of days excess pills were taken Excess number of pills taken
Has the patient missed any of the trial drug doses since the last scheduled visit? Yes 3. ❑  No ❑ 
If yes, fill the table below
Reason for missing trial drug Yes No How many days
a) Was away from home? ❑ ❑
b) Was too busy with other things? ❑ ❑
c) Simply forgot? ❑ ❑
d) Had too many pills to take? ❑ ❑
e) Wanted to avoid side-effects? ❑ ❑
f) Did not want other people to notice you taking pills? ❑ ❑
g) Was following the doctor’s advice? ❑ ❑
h) Felt sick or ill? ❑ ❑
i) Ran out of pills? ❑ ❑
j) Felt good? ❑ ❑
k)  Other, specify……………………………………..............................................……
Total number of days missed
ART ADHERENCE
Since the last scheduled visit has the patient missed any of their Antiretroviral drug doses? Yes 1. ❑ No ❑
If yes fill table below
Drug Number of days missed Reason (see codes below)
Reasons for missing ART:
1=Forgot, 2=Was ill, 3=Doctors advice, 4=Was tired of taking pills, 5= Did not want other people to notice, 
6=Was away from home, 7=Ran out of pills, 8=Drugs out of stock, 9= Feeling well, 10=Other
BEDNET USE
Since the last visit has the patient been sleeping under an insecticide treated mosquito net (ITN)? Yes 1. ❑	 No ❑
If not, fill the table below           
Reason for not using ITN Yes No How many days
a) Was away from home? ❑ ❑
b) ITN got damaged / stolen ❑ ❑
c)   It was uncomfortable to sleep under the ITN ❑ ❑
d) Gave the ITN to child / spouse / other ❑ ❑
e) Partner was opposed to using ITN ❑ ❑
f) Was using other net (non treated) ❑ ❑
g) Have no bed where to put it ❑ ❑
h) Fears side effects of impregnated medication ❑ ❑
i)  Other, specify……………………………………..................................………………
Nurse / counselor’s signature Print name Date
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Form 7               COSTOP
Nurse follow-up form
COSTOP Trial  number
Assessment 
date
D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male  Female  
This week’s visit number 
Visit type: Scheduled (on time) ❑  Schedules (early / late) ❑ Sick ❑ Missed ❑ 
HISTORY AT THIS VISIT
Has the patient changed contact details since the last nurse visit? Yes 1. ❑   No ❑
If yes, please update the contact form.
Has the adherence questionnaire been filled?  Yes 2. ❑   No  ❑
If not please do so.
SYMPTOM CHECK LIST, HISTORY AND EXAMINATION
Weight(kgs) . Temp.(0c) . BP (mmhg) /
Is the patient ill today?........................................................................................................  Yes 1. ❑    No ❑
If yes what are the main symptoms
Symptom Duration(days) 
(i)
(ii)
(iii)
(iv)
(a) Has the patient taken any new medication since the last visit? Yes 2. ❑ No ❑
  If yes, give reason below
Medication Code Reason Code Dose (mg) / day Duration (days)
(i)
(ii)
(iii)
(iv)
(b) Has the patient taken any open label cotrimoxazole (Septrin)?  Yes ❑ No ❑
  If yes, check that this was documented in 2(a) above.
 Has the patient been admitted to hospital since the last nurse visit? Yes 3. ❑ No ❑
 If yes notify the doctor 
Nurse’s signature Print name Date
CRF version 1.1, October. 2011 Page 1 of 1
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Form 8
  COSTOPDoctor follow-up (part 1)
COSTOP trial number
Assessment date D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
This week’s visit number 
Visit type: Scheduled (on time)  ❑ scheduled (early/ Late)  ❑ Sick  ❑	 Missed  ❑ 
SYMPTOMS AND SIGNS
Performance status today (tick one box only)1. 
1 = asymptomatic, normal activity   ❑  3 = bedridden, <50% of the day during the last month  ❑
2 = symptomatic, normal activity    ❑ 4 = bedridden, >50% of the day during the last month  ❑
Are there any new symptoms and signs since the last doctor visit? Yes 2. ❑     No ❑
If so, please fill the table below:
Symptom Yes No Symptom Yes No 
Eye itching / pain / discharge ❑ ❑ Cough ❑ ❑
Ear pain / discharge ❑ ❑ Difficulty in breathing ❑ ❑
Fatigue ❑ ❑ Muscle aches ❑ ❑
Fever ❑ ❑ Bone / joint aches ❑ ❑
Confusion ❑ ❑ Localized weakness of arms, legs or face ❑ ❑
Convulsions ❑ ❑ Numbness or tingling of hands and feet ❑ ❑
Headache ❑ ❑ Skin itching / new skin rash ❑ ❑
Nausea / vomiting ❑ ❑ Urinary symptoms ❑ ❑
Mouth sores / ulcers ❑ ❑ Genital itching / ulcers / discharge ❑ ❑
Difficulty / pain on swallowing ❑ ❑ Possible pregnancy ❑ ❑Abdominal pain ❑ ❑
Diarrhea ❑ ❑ Other (specify below) ❑ ❑
Weight loss ❑ ❑
……………….…………………................................…
Sweats ❑ ❑
Please examine the patient and record any findings below3. 
Any abnormal findings Yes No If yes, give details
Eyes ❑ ❑
Oral cavity ❑ ❑
Ear, nose, throat ❑ ❑
Skin, hair, nails ❑ ❑
Clinical anaemia  ❑ ❑
Lymph nodes ❑ ❑
Respiratory system ❑ ❑
Cardiovascular system ❑ ❑
Liver ❑ ❑
Spleen ❑ ❑
Rest of abdomen ❑ ❑
Nervous system ❑ ❑
Genital examination (if indicated) ❑ ❑
Other ❑ ❑
Does the patient have a fever or is the patient suspected to have malaria? Yes  4. ❑     No  ❑
(If yes please do a blood slide and any other necessary investigation)
Does the patient have diarrhea today? Yes  5. ❑     No  ❑
(If yes obtain a stool sample)
Does the patient have a cough today? Yes  6. ❑     No  ❑
(If so, take a sputum sample)
DIAGNOSES
Have any diagnoses been made at this visit?  Yes ❑     No ❑
If yes, record diagnosis and the respective code below.
Diagnosis Event code 
i)
ii)
iii)
iv)
v)
TREATMENT AT THIS VISIT 
TREATMENT (Other than ART / Trial drug)
Has any treatment other than ART / Trial drug been prescribed at this visit? Yes ❑    No ❑
If yes, record the treatment below.
Treatment (non ART / Trial drug) Drug code Duration  (days)
i)
ii)
iii)
iv)
v)
vi)
TRIAL DRUG
Has trial drug been stopped or restarted today? Yes ❑    No ❑
If yes, fill the log below
Action (stopped/restarted) Date Reason / comment
Trial drug D D / M M M / Y Y Y Y
1=Adverse event: name the event 
(record on Form 11 if serious or 
on Form 8 if grade 3/4)
2=Patient is being 
switched to open label 
cotrimoxazole.
3=Voluntary patient 
decision (give details,        
do not include adverse 
events)
4=Other (give details 
in table)
5=Restarting trial drug 
after interruption 
Doctor’s signature Print name Date
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Form 8
Doctor follow-up (part 2)
COSTOP trial number
Assessment date D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
ANTIRETROVIRAL THERAPY
Has there been a change in antiretroviral therapy since last visit? Yes ❑    No ❑
If yes, please fill the log below.
Drug name Action (started or stopped) Date of action Reason / comment
1=New or recurrent clinical 5=Starting of salvage 8=Adverse event: name the 10=Voluntary patient
     WHO stage 3 or 4 event therapy event (record on Form 8 if decision (give details do
2 = CD4 count concerns 6=Restarting previous grade 3/4 or form 11 if serious)  not include adverse events)
3= Intercurrent illness 
regimen after interruption
 9=Patient unable to attend ART 11=Other (give details
4=Start of 2nd line regimen 7 = Pregnancy 
clinic should be on a new line  in table)
INVESTIGATIONS
Are there any investigations to be done at this visit?  Yes ❑    No ❑
If so, please indicate those to be done in the table below;
Scheduled investigations 
Hematology………………………………….......................................…………….. 1. Yes  ❑  No  ❑
CD4 count …………………………………………………….................…………….2. Yes  ❑  No  ❑
Blood slide for malaria……………………………………...............………………….3. Yes  ❑  No  ❑
Plasma storage ……………………………………………...........…………………….4. Yes  ❑  No  ❑
Non scheduled investigations
Biochemistry ……………………………………………………..............…………….1. Yes  ❑ No  ❑
Viral load…………………………………………………………...............……………2. Yes  ❑ No  ❑
Blood culture………………………………………………………...............………….3. Yes  ❑ No  ❑
Sputum ……………………………………………………………...............………….4. Yes  ❑ No  ❑
Stool analysis……………………………………………………................……………5. Yes  ❑ No  ❑
Other microbiology………………………………………………...............……………6. Yes  ❑ No  ❑
Urine  pregnancy……………………………………………….....................………….7. Yes  ❑ No  ❑
X-ray……………………………………………………….....................………………8. Yes  ❑ No  ❑
Other investigation (please specify)……………………………......................………………………………….9. 
CLINICAL EVENTS / MALARIA / ADVERSE EVENTS / HOSPITALISATION
1. Has the patient had a new WHO staging event since the last visit? Yes ❑   No ❑
 If yes, fill a WHO staging form (form 10)
2. Does the patient have malaria or has a previous malaria episode resolved? Yes ❑   No ❑
 If yes, fill a malaria form (form 9)
3. Does the patient have a new serious adverse event (SAE) or has a previously recorded adverse event resolved since 
the last visit? Yes ❑     No ❑
 If yes, fill an SAE form (form 11)
4. Has the patient experienced a new adverse (AE) event or has a previously recorded adverse event resolved since
 the last visit? Yes ❑   No ❑ 
 If yes, fill the table below.
Event Grade Date of onset Resolved (y/n) Date resolved
In the table below list all the drugs including trial drug and zidovine that the patient was on at the time of the event 
and state the relationship of the adverse event to the drugs.
Drug 
Date drug started Relationship of adverse event  to drug 
D D M M M Y E A R Unrelated Unlikely Possible Probable Definitely 
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
❑ ❑ ❑ ❑ ❑
5. Has the patient been admitted to hospital or discharged since the last doctor visit? Yes ❑   No ❑
 If so, please fill a hospital admission form (form 14) and SAE form
6. Has the patient experienced a febrile / acute illness? .................................................................Yes ❑    No ❑
 If so, please fill form 24 and any other appropriate forms
Doctor’s signature Print name Date
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Form 9
  COSTOPMalaria form
COSTOP trial number
Date of form D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male     Female 
Date of malaria diagnosis D D M M M 2 0 Y Y
What type of malaria report is this?               Initial   ❑	 follow up   ❑ Resolution  ❑
What type of malaria diagnosis was made?  Definitive   ❑ Presumptive   ❑
What was the highest recorded temperature . 0 c
SYMPTOMS AND SIGNS
Symptom 
Fever Yes  ❑ No  ❑
headache Yes  ❑ No  ❑
loss of consciousness Yes  ❑ No  ❑
Convulsions Yes  ❑ No  ❑
Chills and rigors Yes  ❑ No  ❑
Joint pains / muscle aches Yes  ❑ No  ❑
Diarrhea Yes  ❑ No  ❑
Vomiting Yes  ❑ No  ❑
Yellowing of eyes Yes  ❑ No  ❑
Whitening of eyes / palms Yes  ❑ No  ❑
Other ❑. please specify
Signs 
Pallor ❑ Jaundice  ❑ Hepatomegally    ❑ 
Splenomegally     ❑															None    ❑																		Other   ❑   specify…………...................................………….. 
LABORATORY INVESTIGATIONS
If patient was treated at the study clinic fill the table below, if not go to 2; 1. 
Initial malaria blood slide result 
Positive           ❑  Negative     ❑
Parasite count / 200 wbc’s (thick film) % (thin film)
Species 
P. Falciparum            ❑  P. Malariae      ❑ P. Vivax            ❑
P. Ovale                    ❑  Other              ❑, please specify
For patients getting treatment outside the study clinic, give the blood slide result?2. 
 Positive ❑ Negative ❑ Not done ❑
TREATMENT
Source of treatment? Study clinic 1. ❑ Other Health worker ❑ self medication ❑	 None ❑
Treatment given (tick all that apply)2. 
Drug  Drug  
Chloroquine ❑ Tab quinine ❑
Sulphadoxine / pyrimethamine ❑ I.V quinine ❑
Artemether / lumfantrine ❑ Herbs ❑
Other artemesin derivatives ❑
Other drug  ❑,  specify
Amodiaquine (Kamaquin) ❑
Is the patient on any malaria chemoprophylaxis ?  Yes  3. ❑ No  ❑
If yes, what anti malarial are they on? (fill table below)
Chloroquine  ❑ Doxycycline  ❑ Fansidar  ❑ mefloquine  ❑ Primaquin  ❑
Proguanil      ❑, Other  ❑ please specify
OUT COME
(Remind the patient to come back for review within 2weeks of a malaria episode)
Have the malaria symptoms completely resolved?  Yes 1. ❑  No ❑
If yes, give date?
Date of resolution D D M M M 2 0 Y Y
Was a repeat slide done after treatment?   Yes 2. ❑  No ❑
a)   For a patient reviewed in the study clinic fill the table below, if not go to b
Repeat malaria blood slide result
Positive                  ❑   Negative        ❑
Parasite count / 200 wbc’s (thick film) % thin film
Species 
P. Falciparum         ❑ P. Malariae     ❑  P. Vivax            ❑
P. Ovale                 ❑ Other             ❑,  please specify
b)   For patients reviewed outside the study clinic. Give the blood slide result
Positive  ❑ Negative  ❑ Not done  ❑
Doctor’s signature Print name Date
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 COSTOP
Consent withdrawal form
COSTOP study number
Date of form D D M M M 2 0 Y Y
Clinic/hospital 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male  Female  
I no longer wish to (or cannot) take trial drugs but I am willing to attend follow up visits.
Encourage the patient to continue with all, or at least some, scheduled visits. 
I no longer wish to (or cannot) take trial drugs and do not wish to (or cannot) attend further visits. I agree 
to my medical records being consulted in future to obtain clinical information
Set in place procedure to follow the patient up through medical records alone and report any trial outcomes on the 
appropriate form. Inform the patient that s/he may still return for follow-up visits only 
I no longer wish to (or cannot) take trial drugs and do not wish to (or cannot) attend further visits.  I do 
not agree to my medical records being consulted in future to obtain clinical information for the study
Discontinue all follow up through medical records. 
I no longer wish to (or cannot) take trial drugs and do not wish to (or cannot) attend further visits.  I do 
not agree to my medical records being consulted in future to obtain clinical information and also withdraw 
consent for information already collected to be used in any analysis
Discontinue all follow up through medical records. Consult the Trial Centre for advice on removing records from 
the trial database. 
Patient’s signature (or thumbprint) Print name Date
Witness’s signature Print name Date
Study Team Member’s  signature Print name Date
Study Doctor’s signature Print name Date
One signed copy to be given to patient, One signed copy (original) to be kept by the researcher,
One signed copy to be kept in the patient file.
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Form 17
               COSTOPUnblinding form
COSTOP trial number
Date of form D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials   Male  Female  
This week’s visit number 
Visit type: Scheduled (on time) ❑  scheduled (late) ❑ Sick ❑ Missed ❑ 
ReqUeST TO Unblind PaTienTS in The COSTOP STUdy
Name and phone number of clinician requesting for Unblinding1. 
Reason for Unblinding2. 
Has the patient experienced a hypersensitivity reaction? Yes 3. ❑   No ❑
(If, so please fill a hypersensitivity form)
Has this been discussed with the principal investigator or clinical deputy Yes   4. ❑   No  ❑
(if not please do so)
As the clinician responsible for this patient, remember that the unblinding information given to you is confidential 
and should not be shared with anyone else.
Doctor’s signature Name Date
Unblinding
Date patient unblinded D D M M M 2 0 Y Y
Has the doctor caring for the patient been informed?  Yes ❑   No ❑      (if not, please do so)
Statisticians’ signature Name Date
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Form 14
  COSTOPHospital Admission
COSTOP trial number
Date of form D D M M M 2 0 Y Y
Clinic/ hosp. 
number 
Date of birth D D M M M Y Y Y Y   Patient initials    Male     Female 
Admission summary
Date of admission D D M M M 2 0 Y Y
Date of discharge D D M M M 2 0 Y Y
Date of death (if patient died in hospital) D D M M M 2 0 Y Y
Hospital admitted to
Entebbe ❑ Kisubi ❑ Mulago  (referral) ❑ 
Masaka ❑ Villa Maria ❑ Kitovu ❑ 
Other ❑, please specify…………….........…………………………………………..
Main diagnoses at discharge or death
1.               
2.                
3.                
4.                
5.                
Admission details
History 
Findings on Clinical Examination
Investigations and results
Treatment / procedures 
Condition at discharge
Has  Malaria, WHO clinical event,  Adverse event or Death  occurred ? Yes ❑     No ❑
If Yes, please fill relevant COSTOP study event report form
Doctor’s signature Print name Date
CRF version 1.0. October. 2010   Page 1 of 2 CRF version 1.0. October. 2010   Page 2 of 2
Appendix 16 Page 183
                                             Observational / Interventions Research Ethics Committee
Ronnie Kasirye 
Research Degree Student
IDE / EPH
LSHTM
7 January 2014 
Dear Dr. Kasirye,
Submission Title:      Effect of cotrimoxazole on malaria in HIV infected patients on antiretroviral therapy 
LSHTM Ethics Ref:    7022 
Thank you for your response of 6 January 2013, responding to the Observational and Interventions Committees' request for further information on the above research and
submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval for the amendment having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Information Sheet Information Sheet.PDF 22/11/2010 1.0
Information Sheet luganda information sheet.PDF 22/11/2010 1.0
Information Sheet Screening consent.pdf 22/11/2010 1.0
Information Sheet Enrolment Consent.pdf 22/11/2010 1.0
Protocol / Proposal Appendix 2­COSTOP Screening Questionnaire.pdf 15/3/2012 1.2
Protocol / Proposal Appendix 3­COSTOP Enrolment quest. Nurse.pdf 15/10/2011 1.1
Protocol / Proposal Appendix 4­COSTOP Enrolment quest. Doc.pdf 15/10/2010 1.0
Protocol / Proposal Appendix 5­COSTOP Adherence questionnaire.pdf 15/3/2012 1.1
Protocol / Proposal Appendix 6­COSTOP Nurse fup.pdf 15/10/2011 1.1
Protocol / Proposal Appendix 7­COSTOP Doctor's fup.pdf 15/3/2012 1.3
Protocol / Proposal Appendix 8­ COSTOP Unblinding form.pdf 15/10/2010 1.0
Protocol / Proposal Appendix 9­COSTOP Malaria form.pdf 15/7/2012 1.3
Protocol / Proposal COSTOP Protocol ­ Version 5 2.doc 15/5/2013 5.2
Protocol / Proposal Effect of CTX on malaria in pts on ART 0.7.doc 15/6/2013 0.7
Protocol / Proposal Appendix 10­COSTOP Hospital Admissions.pdf 15/10/2010 1.0
Page 1 of 2
Appendix 17 Page 184
 After ethical review
Any subsequent changes to the application must be submitted to the Committee via an Amendment form onthe online application website. The Principal Investigator is
reminded that all studies are also required to notify the ethics committee of any serious adverse events which occur during the project via anAdverse Event form on the online
application website. An annual report form is required on the anniversary of the approval of the study and should be submitted during the lifetime of the study onthe online
application website. At the end of the study, please notify the committee via anEnd of Study form onthe online application website.     
Yours sincerely,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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